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There is increasing evidence that societal inequities and cultural differences in 
attitudes toward cancer and its treatment drive health outcomes. Therapeutic clinical trials 
represent a promising treatment option for cancer patients, yet the percentage of African 
American patients who enroll in clinical trials is lower than the national average. This 
creates a racial imbalance that limits the extent to which research results from clinical 
trials can be generalized. Studies of African Americans report some attitudes toward trial 
participation are based on trust and fear.  Enrollment of minority patients is nece sary to 
collect group specific data, and adapt treatments as may be necessary.  To that end, 
interventions aimed at shifting attitudes hol promise, but hinge upon a better 
understanding of the interplay between attitudes toward trial participation, cultural 
constructs, and enrollment.   
The purpose of this dissertation was to examine interrelationships between two 
socio-cultural constructs, and four attitudinal barriers to clinical trial participation among 
African American cancer patients.  Specifically, the study sought to (1) understand the 
relationship between attitudinal barriers to clinical trial participation and the subsequent 
 
intention to enroll; (2) understand the contribution of racial identity (racial centrality) and 
religious belief (specifically a belief in ‘God as healer’) to intention to enroll. The study 
was guided by elements of the Theory of Planned Behavior and theories of racial identity 
and religiosity.  Interviews were conducted with 111 African American cancer patients in 
a purposive sample from an urban, community-based teaching hospital in Washington, 
D.C.   
Logistic regression analyses explored the predictive value of four attitudinal 
constructs in patients’ intention to enroll. Three of the four attitudinal barriers were 
significant predictors of intention for this sample.  The concern about ethical conduct of 
investigators was the only attitudinal barrier that remained statisticlly significant in the 
unadjusted model (OR =0.85, p=0.04).  Racial identity and a belief in God as healer were 
not significant predictors of intention to enroll.  Finally, a moderation analysis explored 
the effect of levels of racial centrality and religious belief on attitudes and on intention.  
A belief in God as healer significantly moderated the association between the concern 
about ethical conduct of investigators and intention to enroll in a therapeutic clinical trial.  
Among participants with a low belief in God as a healer, a lower level of concern about 
the ethical conduct of investigators predicted a greater intention to enroll than those with 
a higher level of concern about ethics.  Racial centrality did not significantly moderate 
any of the attitudinal barriers. 
The extant literature is scant in terms of addressing the role that socio-cultural 
constructs play in clinical trial decision-making for African American patients. In 
particular, implications of this study suggest that the historical legacy of research abuse 
and unethical treatment of African Americans in research continues to color attitudes 
 
towards clinical trials. This study provides a basis for further exploration of socio-cultural 
moderators among African Americans, an understanding of which may enable tailoring 











THE ROLE OF RACIAL IDENTITY AND RELIGIOUS BELIEFS IN 
THE ATTITUDES OF AFRICAN AMERICAN CANCER PATIENTS 












Dissertation submitted to the Faculty of the Graduate School of the 
 University of Maryland, College Park in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 







Advisory Committee  
 
Assistant Professor Kerry M. Green, Chair 
Associate Professor Cheryl L. Holt 
Dr. Jessica M. Rath 
Professor Min Qi Wang 


















© Copyright by 
 


































This dissertation is dedicated first and foremost to the patients who shared tei  
experiences, candid thoughts, and true feelings with me. Thank you for helping me to 
better understand your reality and for making this research possible.  Also, to my parents, 
who have always cultivated my thirst for knowledge, and sacrificed all they could to give 
me boundless opportunities.  Thank you for raising me to expect that no dream was ever 
too big or beyond my reach.  I could not have reached this point without your 






There is no way I could have finished my doctoral program or written this 
dissertation without the help of so many.  To the faculty members, friends and family 
who helped me in so many ways, a heartfelt thank you.   
 To my advisor, faculty mentor and committee chair, Dr. Kerry Green. You 
challenged me gently and inspired me greatly.  From the beginning of the program you 
made yourself available to me in any capacity you could and I am so thankful to you for 
that critical presence through every stage.  I will forever be grateful for the opportunity to 
work with you on your research and for giving me the exposure I needed to begin 
developing my research skills.  Working with you undoubtedly made me a better student 
and has helped me become a much better writer.  Thank you for taking on my interests as 
your own and for all you did to help me complete this dissertation in record time. 
 To Dr. Sandra Swain, who in so many ways made this study possible.  Thank you 
for providing me the incredible opportunity to be a part of such an important undertaking.   
Thank you for trusting me with your project and for giving me the latitude and flexibility 
to make this the springboard for my future research.  Working with you and sharing your 
passion created a situation where coming to work everyday was fun.  For that and for the 
incredible amount I have learned from you, I thank you.  
 I am truly grateful to each of my dissertation committee members for your time, 
your interest and guidance at each stage of this project.  Dr. Smith Bynum, yo r 
enthusiasm for my project is unbridled and your passion and depth of knowledge inspired 
me from our first meeting.  I also appreciate that you are the only person I know who 
writes emails as long and as animated as I do.  Dr. Holt, thank you for sharing your 
expertise with me, helping me to constantly flesh out my ideas and to focus my thoughts. 
Dr. Wang, thank you for always being available and for helping me to understand less is 
more.  Dr. Rath, your willingness to help me reason through each stage of this 
dissertation was key.  Thank you for showing me that there are few problems in life that 
cannot be addressed with a good conceptual model. 
 To all of my friends, who put up with years of my constantly being unavailable, 
except for when it worked with my school schedule.  Thank you all for sticking it out.  To 
Vivian Cabral, my biggest supporter and the one responsible for starting me on this path - 
I would not have made it without you.  You picked me out of a resume lineup and ended 
up one of my nearest and dearest.  Thanks for always keeping me honest and for being 
there through ALL of it, to laugh and to learn.  Your mentorship, guidance, ‘come-to-
Jesus’ talks, and irreplaceable friendship are the best gifts you ever gave me.  Thank you 
for always believing in me and of course for willingly reading this entire dissertation 
through.  Bless your heart. 
To Cathia (Cat- dawg) Moise, for hanging in there with me like a true sister.  
From our GW days, through all the ups and downs of life in the subsequent years.  Thank 
you for sharing in all of the laughter and tears and thank you for loving me in spite of 
myself.  
Katrina Debnam. You already know - I would have never imagined that our “geek 
talk” could evolve into such an amazing friendship.  Thank you for helping to keep me 
motivated, for minimizing the extent of my procrastination, and for setting such a good 
example with your drive, determination and discipline.  
 iv
Dr. Nneka Mokwunye. Yet another angel sent just in time.  Thank you for taking 
me under your wing, feeding me caffeine and talking me off that ledge.  You took the 
time to get to know me and my research and reminded me why I was doing this in a way 
no one else could have.  When I grow up, I want to be just like you. 
Luda Brener, thank you for being there when I needed you most and for always 
being in my corner and willing to listen and share. You will never truly understand what 
a difference you have made in this journey. 
 Thank you to the ‘PhD crew’.  Dr Lindsey Hoskins for paving the way, helping 
me focus on the goal and for loving sushi.  Chandria, Denise, Eva, Shaki, Brian, Sylvette, 
Iris, Eric and Jordana for always being on my side, constantly cheering me on and not 
humoring my threats to quit.  And to Ramona Jackson, for becoming an all important and 
honorable member of the crew, thank you for the constant affirmation. 
 To the coworkers who helped to keep me sane with all the juggling I was 
constantly doing, I appreciate your patience.  My NIH colleagues: all of the members of 
the Clinical Genetics Branch and the phenomenal women who showed me how it should 
be done - thank you Dr. Larissa Korde, Dr. Christine Mueller and Dr. Phuong Mai.  To 
my Washington Hospital Center colleagues for helping me get through each day 
especially during the recruitment phase (Dr. Rita Kapoor- you’re my ace!) nd to all the 
wonderful nurses and doctors who “fed me patients” and took the task on as if it were 
their own.  You put the fun in research. 
  Last but in no way the least, thank you to my wonderful family, for whom no 
words will ever suffice.  For putting up with me when I was tired, cranky, and 
overwhelmed.  For understanding when I was unable to be there, physically or 
emotionally.  Despite the challenges throughout this process you were always there to 
support, uplift and encourage me; ever ready to share in my excitements, and understand 




* Acknowledgement of funding: This research was made possible by funding from the 
















Table of Contents 
ABSTRACT ....................................................................................................................  
Dedication .................................................................................................................. ii 
Acknowledgements ................................................................................................... iii 
Table of Contents ....................................................................................................... v 
CHAPTER ONE: INTRODUCTION .................................................................................. 1 
1.0 Background ..................................................................................................................1 
1.1 Cancer and Clinical Trials ..............................................................................................2 
1.1.2 African Americans, Cancer and Clinical Trials ..............................................................2 
1.1.3 Addressing the Disparity: Culturally Sensitive Interventions ........................................4 
1.1.4 Relevance of Culturally Sensitive Interventions ..........................................................5 
1.1.5 Barriers to Trial Participation .....................................................................................7 
1.1.6 Attitudes Toward Clinical Trials and Related Cultural Factors ......................................8 
1.2. Conceptual Underpinnings of the Study ..................................................................... 13 
1.3 Statement of the Problem .......................................................................................... 15 
1.4 Purpose of the Study .................................................................................................. 16 
1.6 Significance of the Project .......................................................................................... 17 
1.7 Research Aims and Hypotheses................................................................................... 17 
1.8 Summary ................................................................................................................... 18 
1.9 Definition of Terms ..................................................................................................... 19 
CHAPTER TWO: REVIEW OF THE LITERATURE ............................................................ 21 
2.1 Introduction ............................................................................................................... 21 
2.2 Barriers to African American Trial Participation ........................................................... 22 
2.3 Attitudinal Barriers to African American Trial Participation .......................................... 29 
2.4 Racial Identity and Trial Participation .......................................................................... 35 
2.5 Religion and Trial Participation ................................................................................... 41 
2.6 Theoretical Considerations ......................................................................................... 44 
2.7 Summary ................................................................................................................... 48 
CHAPTER THREE: METHODS ...................................................................................... 49 
3.1 Study Overview .......................................................................................................... 49 
3.2 Study Site ................................................................................................................... 49 
3.3 Study Sample ............................................................................................................. 50 
3.4 Study Design .............................................................................................................. 54 
3.4 Conceptual Framework/Model ................................................................................... 56 
3.5 Data Collection ........................................................................................................... 58 
3.6 Data Analysis Plan ...................................................................................................... 66 
3.7 Human Subjects Concerns ........................................................................................... 69 
CHAPTER FOUR: RESULTS ......................................................................................... 71 
4.1 Introduction ............................................................................................................... 71 
4.2 Independent Variables: Attitudinal Barrier .................................................................. 71 
4.3 Moderator Variables .................................................................................................. 78 
4.7 Correlation Analysis.................................................................................................... 79 
4.8 Binary Dependent Variable Analyses ........................................................................... 82 
 vi
4.10 Regression Analysis .................................................................................................. 84 
4.12 Summary Findings .................................................................................................. 107 
CHAPTER FIVE: DISCUSSION .................................................................................... 109 
5.1 Introduction ............................................................................................................. 109 
5.2 Study Findings .......................................................................................................... 109 
5.3 Implications of Findings ............................................................................................ 116 
5.5 Implications for theory ............................................................................................. 119 
5.6 Limitations ............................................................................................................... 120 
5.7 Threats to Validity .................................................................................................... 122 
5.8 Future Research Directions ....................................................................................... 123 
5.9 Summary ................................................................................................................. 125 
Appendix A Flow Chart of Study Activities: Patient Recruitment for Parent Study and 
Dissertation Study .................................................................................................. 126 
Appendix B WCI IRB Approval ................................................................................. 127 
Appendix C Quantitative Study Consent ................................................................. 128 
Appendix D Qualitative Study Consent ................................................................... 138 
Appendix E Participant Demographic Information .................................................. 143 
Appendix F Survey of attitudes about clinical trial participation .............................. 146 
Appendix G Qualitative Study Interview Guide ....................................................... 151 
Appendix H: Contact notification recruitment letter ............................................... 153 
APPENDIX I: Exploratory Factor Analysis Results ..................................................... 154 
APPENDIX J:  ANOVA Results .................................................................................. 158 
REFERENCES ........................................................................................................... 165 
 
 vii
List of Figures and Tables 
Figure 1: Conceptual Model ......................................................................................................... 57 
 
Table 1: Summary Statistics: Socio-Demographic Variables ....................................................... 53 
Table 2: Dependent Variable Item Responses .............................................................................. 59 
Table 3: Distribution of Responses on Fear and Distrust of the Medical Establishment Scale: 
Frequencies and Percents ............................................................................................................... 60 
Table 4: Distribution of Responses on Concern about the ethical conduct of investigators scale: 
Frequencies and Percents ............................................................................................................... 61 
Table 5: Distribution of Responses on Fear of losing one’s rights by signing a research informed 
consent document scale: Frequencies and Percents ....................................................................... 61 
Table 6: Distribution of Responses Worry That Investigators will treat poor or Black patients      
Unfairly Scale: Frequencies and Percents ...................................................................................... 62 
Table 7: Distribution of Responses on Seller’s Centrality scale: Frequencies and Percents ........ 63 
Table 8: Distribution of Responses on Belief in God as Healer scale: Frequencies a d Percents 64 
Table 9: Reliability and Descriptives for Study Variables ............................................................ 73 
Table 10: Pearsons Correlation of Individual Items on Attitudes Scale and Intention Item ......... 76 
Table 11: Factor Loadings for Centrality Scale ............................................................................ 78 
Table 12: Factor Loadings for God as Healer Scale ..................................................................... 79 
Table 13:  Pearson Correlations of Attitudes, Moderators and Intention Variables ..................... 81 
Table 14: Proportion of Intention to enroll by Demographic Variable ......................................... 83 
Table 15: Unadjusted Regression Model: Racial Centrality ......................................................... 84 
Table 16: Unadjusted Regression Model: God as Healer ............................................................. 85 
Table 17: Unadjusted Regression Models by Individual Attitude ................................................ 86 
Table 18: Unadjusted Regression Models With all Four Attitudes .............................................. 86 
Table 19: Adjusted Regression Model for All Four Attitudes ...................................................... 88 
Table 20: Adjusted Regression Models for Individual Attitudes .................................................. 88 
Table 21: Centrality Interaction Models with All Four Attitudes ................................................. 90 
Table 22: Centrality Interaction Model for Ethics ........................................................................ 91 
Table 23: Centrality Interaction Models by Individual Attitudes ................................................. 92 
Table 24:  God as Healer Interaction Model with all Four Attitudes ............................................ 93 
Table 25: God as Healer Interaction Models for Ethics and Distrust ........................................... 94 
Table 26: God as Healer Interaction Models for Worry and Rights ............................................. 95 
Table 27: Stratified Analysis Low Centrality- Full Model ........................................................... 96 
Table 28: Stratified Analysis Low Centrality- Ethics and Distrust ............................................... 97 
Table 29: Stratified Analysis Low Centrality- Worry and Rights ................................................ 98 
Table 30: Stratified Analysis High Centrality- Full  Model.......................................................... 99 
Table 31: Stratified Analysis High Centrality- Ethics, Distrust, Rights, Worry ......................... 100 
Table 32: Stratified Analysis Low Belief in God as Healer- Full Model ................................... 101 
Table 33: Stratified Analysis Low Belief in God as Healer- Ethics ........................................... 102 
Table 34: Stratified Analysis Low Belief in God as Healer- Distrust ......................................... 103 
Table 35: Stratified Analysis Low Belief in God as Healer- Worry and Rights ......................... 104 
Table 36: Stratified Analysis High Belief in God as Healer- Full Model, Ethics and Distrust... 105 
Table 37: Stratified Analysis High Belief in God as Healer- Worry and Rights ........................ 106 







CHAPTER ONE: INTRODUCTION  
“…..And if I was going to die [from my cancer] today, or that day, or two years from 
now, I still say it’s in God’s hands, and they can’t tell me anything about it.”   ‘Vanessa’ 
- Breast cancer survivor 
 
“…..The fact that you believe in God don’t mean that you don’t use your mind. You use 
your mind in conjunction with your faith in God.”  ‘James’- Prostate cancer survivo  
 
“…Well, I’ve never known anyone who participated in a clinical trial, first of all. And 
then the average Black person, we tend to stay away from it because the things that I’ve heard 
from older Black people” ‘Rebecca’ – Osteosarcoma survivor 
 
“….All the faith I have; I’m a missionary in my church; very active in my church. But all 
that went out the window. I didn’t think about God, or nobody. I just knew my life was over, y u 
know, because of cancer.”  - ‘Diane’- Kidney cancer survivor 
 
Source:  African American Cancer survivors and clini al trial participants interviewed for the patient 
education video development.  
1.0 Background 
There is an underrepresentation of minorities in cancer clinical trials.  As we 
continue to struggle to find cancer treatments that show efficacy in all subgroups of the 
population, this lack of representation presents a significant problem.  Cancer is the 
second leading cause of mortality in the United States, with differential outcomes by 
race/ethnic group (American Cancer Society, 2010). Clinical trials repres nt a promising 
treatment option for cancer patients; however, the underrepresentation of minority groups 
in these clinical trials likely plays a role in health disparities. Health disparities in cancer 
outcomes, in part, may be driven by biological differences (Stark et al., 2010); however, 
there is increasing evidence that societal inequities and cultural differences in attitudes 
toward the disease and its treatment drive health outcomes (Moore et al., 2010; Smith et 
al., 2009; Morris et al., 2010).  Culturally appropriate behavioral interventions could 
potentially impact the differential rates of participation in clinical tri ls; however, our 
understanding of patient factors contributing to decisions to participate is limited.  This 
dissertation, focusing on African American cancer patients, seeks to (1) understa  the 
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relationship between attitudinal factors that present barriers to clinical trial participation 
and the subsequent intention to enroll in therapeutic clinical trials; (2) understand the 
contribution of racial identity and religious belief to the intention to enroll in therapeutic 
clinical trials.  
1.1 Cancer and Clinical Trials 
The current standard of care for cancer treatment is based on data from 
therapeutic clinical trials.  Since 1990, cancer mortality rates have declined by 15% and 
over 65% of all patients now survive at least 5 years beyond diagnosis (Petrelli et al., 
2009).  To continue to improve outcomes, the development of better therapeutic options 
for cancer patients is contingent on their voluntary participation in therapeutic clinical 
trials.  Trial participation also represents an opportunity for cancer patients to receive 
state-of-the-art care, close monitoring of their disease, and careful att ntion to their 
quality of life (Joffe, 2010).  
Studies find that patients who enroll in clinical trials have longer survival and 
overall better prognosis than patients who do not participate in clinical trials (Joffe, 
2010).  Despite this evidence, of all US adults diagnosed with cancer, fewer than 3% will
participate in a therapeutic clinical trial (Du et al., 2009; Baquet et al., 2008). The accrual 
of diverse patients to clinical trials remains one of the biggest challenges to advancing 
treatment and improving cancer outcomes, especially for underrepresented racial 
minorities (Park et al., 2007). 
1.1.2 African Americans, Cancer and Clinical Trials 
Despite a lower overall incidence for most cancers, African Americans suffer
from a disproportionately higher cancer mortality and worse five-year survival than other 
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racial/ethnic groups (American Cancer Society, 2010).  The percentage of African 
Americans who enroll in clinical trials is also lower than the overall national average for 
all other racial groups (Du et al., 2009; Baquet et al., 2008; Ford et al., 2008).  Enrolling 
African American patients is necessary to collect group specific data, evaluate the 
effectiveness of existing treatments for different races/ethnic groups, and adapt 
treatments as may be necessary by race/ethnic group (Park et al., 2007).  Such an 
imbalance in enrollment limits the extent to which research results from clinical trials can 
be generalized.  
One of the National Cancer Institute’s strategies towards overcoming cancer 
health disparities is to characterize and understand the factors that cause hem.  In 1993, 
the National Institutes of Health (NIH) Revitalization Act was intend d to encourage 
representation of minorities and women in research funded by the NIH including clinical 
trials (Tejeda et al., 1996; Stewart et al., 2007). Despite the allocation of a considerable 
amount of federal budget towards this end, cancer disparities have not changed 
drastically since this act was passed (Morris et al., 2010). 
 Studies show that equitable racial representation on clinical studies in the USis 
possible (Hutchins et al., 1999; Hutchins et al., 1999; Stewart et al., 2007; Tejeda et al., 
1996).  This suggests a need to not only identify the factors preventing this from being 
the norm, but also to identify, to test and to implement effective interventions that ensure 
equitable representation is achieved. Given the documented benefits of trial participation, 
it follows that the inclusion of African-Americans in clinical trials is an integral part of 
addressing disparities in cancer outcomes. It may also improve the delivery of healthcare 
services to minority populations (Stewart et al., 2007).  
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1.1.3 Addressing the Disparity: Culturally Sensitive Interventions 
African American populations in particular have deep-rooted historical reasons 
that need to be accounted for in the development of any intervention, educational or 
otherwise (Gamble, 1997; Heintzelman, 2003).  There is a gap in the literature when it
comes to describing and testing strategies to overcome the barriers of minority 
recruitment in clinical trials.  A major issue confronting medical practitioners and public 
health researchers is how to effectively design interventions so that they are culturally 
relevant and salient for populations for whom specific and attitudinal barriers may exist 
(Kagawa-Singer et al., 2010). With increasing diversity in the United States, there is a 
growing need to determine how culturally specific attitudes can be addressed to improve 
health behavior.  
Specific to improving cancer outcomes, Moore and colleagues (2010) suggest 
establishing a framework that incorporates culture and identifies promising strategies 
using culturally sensitive communication.  Cultural beliefs and values are becoming 
increasingly recognized as integral to decision-making about the prevention ad control 
of cancer, begging further inquiry in this arena.  Recent recommendations to addressing 
health disparities specifically suggest exploration of an individual’s attitudes toward 
disease (Moore et al., 2010).  They acknowledge the role of poor quality of care and 
limited access to treatment in many cases but implore researchers to further study 
attitudes to disease and treatment and target interventions accordingly (Moore et al., 
2010).   
A variety of intervention approaches have already attempted to increase clinical 
trial participation by addressing cultural issues (e.g.,Wang et al., 2008; Outlaw et al., 
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2000).  Du and colleagues (2009) concluded that an educational video is a cost effective 
way to educate patients about clinical trials and address specific cultural and ttitudinal 
barriers.  Several patient education videos have been created about cancer clinical trials 
(Du et al., 2008; Du et al., 2009; Hutchison et al., 2007; Zapka et al., 2004); however, 
there are currently no known patient education videos that address the particular attit des 
and cultural barriers faced by African Americans with cancer.  Further there has been no 
known intervention specifically targeting African Americans to attempt to address their 
attitudes toward clinical trials.  
1.1.4 Relevance of Culturally Sensitive Interventions 
Du and colleagues state that to increase participation and diversity in clinical trials, 
new strategies are needed to have an impact on barriers experienced by a wide spectrum 
of the population (Du et al., 2009).  Health education programs for minority groups need 
to be culturally targeted in terms of content and presentation format (Mishra et al., 2007).  
There are arguments to the contrary suggesting such interventions lack utility (Kotkin & 
Tseng, 2003); however, these arguments state that youth in particular benefit the l as  
from racially targeted interventions.  Since children are typically not included in clinical 
trials, tailoring is likely still beneficial for interventions for the many cancer patients 
potentially eligible for a trial.  
The efficacy of videos as a means to address health issues has been well 
demonstrated (Gagliano, 1988; Zapka et al., 2004; Taylor et al., 2006; Williams et al., 
2008).  Simple, practical, effective, theory-driven patient-level interventions hat can be 
rapidly and widely disseminated, utilized and implemented at a relatively low cost offer 
promise in increasing African American participation in clinical trials. Video-based 
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interventions offer a pragmatic mechanism for delivering health information due to their 
relatively low cost to reproduce and implement and their likely acceptability for clinical 
use (Warner et al., 2008). They also represent an ideal format to present information 
regardless of literacy level. Given the current healthcare climate, simple low-cost video-
based interventions may facilitate much needed patient education within the context of 
time-restricted clinics, hospital settings and physician’s offices.  What is first needed, 
however, is a thorough understanding of how the uptake of such interventions may be 
affected by individual attitudes and specific socio-cultural factors.  
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1.1.5 Barriers to Trial Participation 
African Americans have poorer access to quality cancer treatment (Siminoff & 
Ross, 2005) and the literature identifies a multitude of barriers found to relate to clinical 
trial participation.  These encompass socio-cultural barriers, research bar iers, economic 
barriers, and individual level barriers (Swanson & Ward, 1995).  Systematic and 
structural factors, such as socioeconomic conditions, insurance status and questions of 
eligibility, are well documented for their relationship to unequal trial participation 
(Adams-Campbell et al., 2004; Branson et al., 2007).  One aspect requiring particular 
focus is cultural differences that may breed particular attitudes and create and propagate 
further disparity.  The role of culture in the causal pathway of disparities and the potential 
impact of culturally competent cancer care on improving cancer outcomes in ethnic 
minorities has been underestimated (Kagawa-Singer et al., 2010).  A person’s cultural
context or lived experience may significantly influence their attitudes towards clinical 
trials ultimately preventing or promoting their participation in spite of the seemingly 
more tangible barriers, such as access to treatment.  For African Americans, this may be 
even more salient given the history of exploitation and abuse by the US government a d 
healthcare system (McCaskill-Stevens et al., 1999).  
This dissertation will consider four particular attitudinal barriers that are the 
leading individual barriers to trial participation for African Americans cited in the 
literature. These are 1) fear and distrust of the medical establishment (doctors, s ientists 
and the government); 2) concern about the ethical conduct of investigators in general; 3) 
fear of losing one’s rights by signing a research informed consent; and 4) worry that 
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investigators will treat poor Black patients unfairly (e.g. the patient becomes a guinea pig 
because of their race or SES). 
Since there is no consensus on the relative influence or interrelationship of these 
barriers, designing culturally relevant and targeted interventions can prove to be a poorly 
guided undertaking.  To understand the decision-making process of a person enrolling in 
a clinical trial, a consideration of how barriers interact to impact attitudes will prove 
valuable. Further, very little research has investigated other cultural factors such as 
religion and racial identity (both important in the context of African American 
populations), and how these influence the intention to participate in clinical trials.  
1.1.6 Attitudes Toward Clinical Trials and Related Cultural Factors 
  Both qualitative and quantitative studies of African Americans and clinical trials
report some attitudes towards clinical trial participation are based on trust and fear 
(Advani et al., 2003; Ford et al., 2008; Branson et al., 2007). Current behavioral research 
points out that ethnic group identification operates as a type of reference group and exerts 
both normative and informational influence on an individual’s behavior and attitudes 
(Simpson et al., 2000).  It therefore seems reasonable to explore group identification as 
an influence on health behavior. Racial identity could therefore be a key influence on 
individual attitudes including those that may impact clinical trial participation. This 
however has rarely been studied. It could be that the extent to which an individual 
identifies with their race or ethnicity is related to the types of attitudes they form about 
participation in a clinical trial, particularly since the historical exp rience with research in 
the US varies for different races/ethnicities. 
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An altruistic attitude has been cited as a factor influencing clinical trial 
participation independently of other socio-demographic, psychosocial, and clinical 
factors (Rosenbaum et al., 2005; Aby et al., 1996).  The argument can be made that for 
minority participants, this extends to a feeling of “helping one’s community” (Hussain-
Gambles, 2004) and acting for the sake of helping others like themselves.  Thus, strong 
identification as a part of a specific racial/ethnic group, or an individual’s possession of a 
healthy racial identity, may impact their attitudes toward clinical tri ls.  Further, the fact 
that the experiences of African Americans are not heterogeneous yield  a variability in 
the significance and qualitative meaning they attribute to Black racial group membership 
(Sellers et al., 1998b). Therefore, it is necessary to examine the influence of ra ial 
identity on the intention to participate in clinical trials. A better understanding of the 




The United States Office of Management and Budget (OMB) defines race and 
ethnicity based on five race categories and two ethnicity categories. Race categories 
include American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, and White.   Ethnicity includes Hispanic or Latino 
and Non-Hispanic or Latino.  There is a growing recognition that each of the established 
categories in reality has multiple, diverse subgroups with different cancer risk and 
responses (Kagawa-Singer et al., 2010).  The aggregated categorization could lead to 
misleading assumptions about individuals and may obscure the true differences between 
 10 
them. This may be even more so when considering how health behaviors and attitudes 
may vary between people belonging to the same category.  
There is considerable diversity within African descent populations (Agyemang et 
al., 2005), and the category ‘Black or African American’ does not account for the 
heterogeneity within the group. Waters (1994) explored the racial and ethnic ident ties 
adopted by a sample of second-generation West Indian and Haitian Americans in New 
York City and their subjective understanding of being Black, in contrast with those of 
first-generation immigrants from the same countries. She reported three types of 
identities: a Black American identity, an ethnic or hyphenated national origin identity, 
and an immigrant identity, each of which relate to different perceptions and 
understandings of race relations in the United States (Waters, 1994).  Ponterotto and 
Park-Taylor (2007) recommend disaggregating data from African Americans, Caribbean 
Americans, and African internationals, all of whom may share the “Black” designation 
but vary on the socially constructed nature of their racial identity experience in North 
America. 
Racial Identity and Clinical Trials 
 
In the context of this dissertation, it is important to investigate how attitudes 
towards clinical trial participation may vary within the group, especially considering that 
not all individuals who are otherwise categorized as “Black or African American” have 
experienced the same history in the United States.  The US Public Health Service Study 
(more colloquially known as the Tuskegee Syphilis Study) begun in 1932 has a 
continuing impact on African-Americans’ trust of medical research studies (Shavers et 
al., 2000).  However, it is conceivable that many African Americans may not identify 
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with a history of Tuskegee, for example, if they are recent African or Caribbean 
immigrants, and therefore their attitudes towards research and clinical trials may stem 
from a different perspective.  For instance, individuals in the US self-identifying as 
Black, may have just arrived from Ethiopia, recently immigrated from Haiti, or been 
raised in the rural South or the urban North and have very different cultures especially 
with regard to health-related practices (Jones, 2001).  Foreign-born Blacks may or y 
not feel a sense of connectedness to or identify with Black people in the United States or 
native-born Blacks.  As a result it is possible that they may or may not feel connected to 
the same historical abuses or struggles of native-born Blacks. Accordingly, their at itudes 
towards research and clinical trials may vary.  It is thus informative to dis inguish 
between subgroups as self-identified within the African American population to 
contextualize any existing differences in attitudes that may exist. 
Religious Beliefs 
 
 Religion and spirituality are an integral part of all socio-cultural system , 
particularly in African American cultures (Carter, 2002) . Various religious factors have 
been associated with physical and mental health, citing improved outcomes and even 
decreased mortality (Brown & Gary, 2010; Brown & Gary, 2010; Levin et al., 2005; 
Levin et al., 2010; Holt et al., 2005; Strawbridge WJ et al., 2010).  Evidence supports an 
overall protective effect of religion on morbidity and mortality (Levin et al., 2005; Holt et 
al., 2009) and the exact mechanisms responsible for this effect have yet to be elucidated. 
The literature posits behavioral modification based on religious beliefs as individuals 
who are involved with religion tend to engage in lifestyles that are healthier.  They tend 
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to not include as an example excessive alcohol consumption, illicit drug use or tobacco 
use (Koenig et al., 1999; Holt et al., 2005; Ellison & Levin, 1998a). 
Religious beliefs may influence specific aspects of an individual’s attitudes 
toward disease and treatment (Ellison & Levin, 1998b; Smitherman, 2009).  For example, 
research in some older African Americans show they have faith-based explanatory 
models of illnesses and their ability to heal or be cured from them (Wittink et al., 2009).   
A 2005 review of recurrent themes describing how spirituality or religiosity ma  
influence treatment preferences among African Americans found that some see God as 
responsible for their physical and spiritual health and that only God has the power to 
decide life and death (Johnson et al., 2005c).  
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Religious Beliefs and Clinical Trials 
 
Research shows a tendency for African Americans to use religion as a coping 
mechanism when diagnosed with cancer (Holt et al., 2009; Smitherman, 2009); however, 
little research has considered religion in the decision-making process for enrolling in a 
clinical trial.  What warrants further exploration is how certain religious beliefs may 
influence the consideration of a clinical trial for cancer treatment.  Specifically how 
might the intention to enroll in a clinical trial be impacted given evidence that some 
African Americans believe that God acts through doctors to cure illness and that God’s 
will is the most important factor in recovering from illness (Johnson et al., 2005b).  The 
belief of God’s role in healing may have particularly important implications fr one’s 
perceived potential utility of a clinical trial, and subsequently, their intention to enroll.  
Holt and colleagues (2009) developed a measure for the religious construct ‘God as 
healer’, found to be one of several identified as important in cancer coping for African 
Americans.  The construct assesses an individual’s perception of God’s dual role as a 
direct healer, or a healer through doctors.  How this construct relates to the intention to 
enroll in a clinical trial, and how it impacts the four attitudinal barriers to participa ion is 
worthy of exploration.  
1.2. Conceptual Underpinnings of the Study 
A review of the literature on African American participation in cancer clinical 
trials reveals a limited theoretical influence.  Theory driven work is critical to 
understanding health behavior.  A few existing studies have used elements of the Theory 
of Planned Behavior and the Health Belief Model (HBM) (e.g. Yang et al., 2010) but 
have done so in an inconsistent manner (Yang et al., 2010; Moore et al., 2010). 
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This dissertation draws elements from multiple theoretical models including those 
of health behavior, racial identity and religiosity.  The Theory of Reasoned Action (TRA) 
(Fishbein & Azjen, 1975) is a health behavior theory to which attitudes and intentions are 
central.  The dissertation utilizes aspects of TRA by focusing on how an individual’s 
experience with two constructs (i.e., racial identity and religious belief) relates to their 
attitudes towards clinical trials and the manner in which they affect the intention to enroll 
in a clinical trial (See Conceptual Model. Figure 1).  It is through the TRA also, that a 
sense of directionality in the proposed relationships between the constructs is inferred 
such that attitudes precede the intention, which ultimately leads to engaging in the desired 
behavior, enrolling in a therapeutic trial.   Further, Fishbein and Azjen (1975) suggest a 
mediating role for intention. However, given the inability to ascertain actual enro lment 
in the patients studied, exploring the extent to which constructs specific to African 
Americans vary with established attitudes could be particularly informative. 
The experience of African Americans in the United States differs significa tly 
from those of all other racial/ethnic groups (Sellers et al., 1998b). A consideration of 
race, racism and racial identity thus seems central to any theoretical consideration of 
attitudes of African Americans towards clinical trials. There are sev ral theories and 
models of racial identity development, most of which were developed primarily for 
African Americans to understand the black experience in the United States (Chavez & 
Guido-DiBrito, 1999).  For this study, the focus will be on the role, significance and 
meaning African Americans place on race in defining themselves.  Thus, this study will 
focus on racial identity as conceptualized by Sellers and colleagues’ Multidimensional 
Model of Racial Identity (MMRI) (Sellers et al., 1998). Specifically, the construct of 
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racial centrality and how this construct may moderate attitudes towards clinical trials and 
impact intention to enroll in clinical trials. 
The literature on the connection between religion and health proposes several 
explanatory mechanisms rather than established models or theories (Ellison, 1998).  The 
mechanisms propose ways in which religious involvement may yield positive health 
outcomes (Ellison, 1998). This study focuses more on the actual religious belief one 
holds.  Specifically a belief in the role God may play in healing cancer and how that 
relates to the intention to participate in a clinical trial.   
1.3 Statement of the Problem 
African Americans suffer a disproportionately greater morbidity and mortality 
from cancer than Whites (American Cancer Society, 2010).  When compared with white 
cancer patients, African American patients are significantly less likely to participate in 
trials (Stewart et al., 2007).  A 2007 study of enrollment in National Cancer Institute 
(NCI) cooperative group surgical oncology trials showed conclusively that overall 
enrollment was extremely low across the general population in the US (Stewart et al., 
2007), however African Americans had much lower enrollment fractions compared with 
whites, Hispanic and Asian/Pacific Islanders (Stewart et al., 2007). When the four most 
common causes of cancer mortality and the proportion of all new diagnoses who went on 
to participate in a clinical trial were considered between 2000 and 2002, the enrollment 
fraction for African Americans cancer patients was 1.3% (Stewart et al., 2007; Murthy et 
al., 2004).  
The low participation rates of African Americans on clinical trials limits the 
generalizeability of study findings about the effectiveness of cancer treatment (Du et al., 
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2009).  Further, the absence of adequate racial/ethnic subgroup data prevents the 
detection of possible interactions of treatment effect by race/ethnicity based on 
biological, social or cultural factors related to race.   
One of the most defining socio-demographic changes in the United States is the 
marked increase in the proportion of minorities; the number of which is expected to 
increase from an estimated 83 million in the year 2000, to 157 million projected by 2030 
(Smith et al., 2009). Moreover, there is an anticipated 99% increase in cancer incidence 
for minorities, compared with a 31% corresponding increase for whites (Smith et al., 
2009). It is therefore imperative that the inherent selection bias and objectivity of clinical 
trial design be addressed (Adams-Campbell et al., 2004).  Interventions aimed at shifting 
attitudes towards clinical trials hold promise but first there needs to be a better 
understanding of the interplay of cultural constructs with specific attitudes towards trial 
participation.   
1.4 Purpose of the Study 
The purpose of this study is therefore to examine interrelationships between two 
socio-cultural constructs, religious beliefs (specifically a belief in ‘God as healer’) and 
racial identity, with four attitudinal barriers to clinical trial enrollment and the overall 
intention to enroll among African American cancer patients.  Direct associations between 
religious belief and racial identity with intention to enroll will be tested as will the 
interaction of these constructs with the four attitudinal barriers. A cross-sectional 
quantitative approach will be employed to better understand the problem by surveying a 
sample of cancer patients. 
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This research will focus on the experience of African American cancer patints in 
an urban, community-based teaching hospital in a city with the nation’s largest disparity 
in cancer outcomes for Blacks compared with all other groups. By better understanding 
the barriers to participation and how they interact with one another, interventions can be
better targeted for African Americans and improve their rates of particiption in 
therapeutic clinical trials. 
1.6 Significance of the Project 
An appreciation of the beliefs, values, attitudes, and preferences of individuals is 
essential to understanding barriers to participation (Branson et al., 2007). This 
dissertation makes a contribution to addressing the Healthy People 2010 goal of 
improving cancer survival by understanding racial/ethnic health disparities.  The paucity 
of literature on religious beliefs, racial identity and their impact on attitudes and intention 
to enroll in clinical trials hinders progress in what Brown and Topcu (2003) term the 
“emerging science of recruitment”. 
1.7 Research Aims and Hypotheses 
This dissertation has four main research aims and four accompanying hypotheses: 
 
Aim 1: To examine the effects of racial identity on the intention to enroll in a therapeutic 
clinical trial among African American cancer patients. 
H1: Participants with higher levels of racial identity will be more likely to express 
intention to enroll in a therapeutic clinical trial.  
Aim 2: To examine the effects of religious beliefs on the intention to enroll in a 
therapeutic clinical trial among African American cancer patients. 
 18 
 H2: Participants with stronger belief in the notion of God as healer will be less 
likely  to express an intention to enroll in a therapeutic clinical trial.
Aim 3: To determine how the relationship between four attitudinal barriers (distrust of 
doctors, the healthcare system, fear of losing one’s rights, concern about the ethical 
conduct of researchers, and the fear of being treated poorly as a minority) is impacted by 
racial identity. 
H3: The attitudinal barriers will be moderated by racial identity, such that 
negative attitudes will have less influence on the intention to enroll among those 
with higher levels of racial identity. 
Aim 4: To determine how the relationship between four attitudinal barriers (distrust of 
doctors, the healthcare system, fear of losing one’s rights, concern about the ethical 
conduct of researchers, and the fear of being treated poorly as a minority) is impacted by 
religious beliefs (belief in ‘God as healer’).  
H4: The attitudinal barriers will be moderated by belief in God as healer, such 
that negative attitudes will have less influence on the intention to enroll for those 
with higher levels of the belief in God as healer. 
1.8 Summary 
Using a sample of African American cancer patients recruited as part of a 
culturally relevant narrative-based video intervention, four attitudinal barriers will be 
examined for the degree to which they affect overall intention to participate in a clinic l 
trial.  This study will focus on how these barriers are moderated by two important cultural 
constructs for African Americans – racial identity and the specific religious belief of God 
as healer.   
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 The dissertation research employs a cross-sectional, quantitative methodology 
based on a pretest in which data will be collected immediately prior to a video 
intervention.  
1.9 Definition of Terms 
African American: The terms Black or African American are used interchangeably 
throughout this study to refer to individuals of African, Caribbean or West-Indian 
descent, or otherwise self identifying as Black. 
Culture: Culture is the core, fundamental, dynamic, responsive, adaptive, and relatively 
coherent organizing system of life designed to ensure the survival and well-being of its 
members. A system which comprises beliefs, values, and lifestyles (Kagawa-Singer et al., 
2010). 
Cancer Health Disparity: The National Cancer Institute defines a ‘cancer health 
disparity’ as any difference in the incidence, prevalence, mortality, and burden of ca cer 
and related adverse health conditions that exist among specific population groups in the 
United States.  
Enrollment Fraction:  The number of individuals enrolled in a clinical trial divided by 
the number of patients diagnosed with cancer 
Ethnicity:  Ethnicity is one’s sense of identity as a member of a cultural group within a 
power structure of a multicultural society and as identified by others as a member of that 
group on the basis of socio-historical context (Kagawa-Singer et al., 2010). For this study 
ethnicity will refer to the individual’s shared history, ancestry, language and geographic 
origin. 
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Race: Race has been said to refer to biological differences between groups of people 
(Dein, 2004). Race as a construct, developed from the belief that races represent 
subspecies of Homo sapiens, and, therefore, one’s phenotype was believed to be 
indicative of one’s genotype and potential for moral character (Kagawa-Singer et al., 
2010).  Thus, in this study, race refers to the original biological categories, derived from 
physical characteristics, recognizing that there are more similarities than differences 
between racial groups and more differences than similarities within these groups 
(Littlefield, Lieberman and Reynolds, 1982). 
Racial Identity: As defined by Sellers (1998), racial identity is the part of the person's 
self-concept that is related to her/his membership within a race. It is concerned with both 
the significance the individual places on race in defining him/herself and the individual's 
interpretations of what it means to be Black. For this study this is a social constru tion, 
which refers to a sense of group or collective identity based on an individual’s perception 
that they share a common heritage or experience with a particular racial group (Helms, 
1993). 
Religion: Definitions of religion and spirituality are used inconsistently throughout the 
literature. For this study, they will be used synonymously to refer all factors related to an 
organized system of beliefs, practices, rituals, and symbols (Thoreson, 1998). 
Therapeutic Clinical Trials :  Therapeutic clinical trials are rigorously controlled 
research studies designed to test new treatments or new ways of using exist treatments 
and how well they work in people. These are done to answer questions about the safety 





CHAPTER TWO: REVIEW OF THE LITERATURE 
 
This chapter presents a summary of the literature about factors affecting clinical 
trial participation among African Americans.  It describes common attitudinal barriers to 
participation and presents an overview of literature on the proposed role of the cultural 
and psychological constructs of religious beliefs and racial identity.   
2.1 Introduction 
When compared with non-participants, clinical trial participants are more likely to 
be younger, have higher education, be of higher socioeconomic status and are 
overwhelmingly more likely to be white and male (Adams-Campbell et al., 2004; 
McCaskill-Stevens et al., 1999). The current literature is replete with established barriers 
to trial enrollment for Black patients and tangible factors that impede even a willing 
patient’s participation in clinical trials (Adams-Campbell et al., 2004; Baquet et al., 2008; 
Corbie-Smith, 1999; Mouton et al., 1997; Ford et al., 2008).  Factors that frequently 
prevent African American cancer patients from enrolling in clinical trials include 
personal beliefs, attitudes and socio-cultural factors.  They also encompass factor  
outside of the individual’s locus of control such as trial design and eligibility criteria 
(Advani et al., 2003; Townsley et al., 2005; Branson et al., 2007).  Despite the 
identification of some barriers, there needs to be a better understanding of modifiable 
factors that contribute to differences that exist in the participation of Blacks compared 
with all other groups in order to address health disparities in clinical trial enol ment.  
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2.2 Barriers to African American Trial Participation  
Eligibility 
 
Eligibility for therapeutic clinical trials is based on relatively stringent entry 
criteria.  The presence of co-morbid conditions is often a major exclusion criterion built 
into trial designs (Adams-Campbell et al., 2004).  Comorbidity alone accounts for the 
design factor most frequently responsible for the exclusion of minorities, regardl ss of 
their attitudes or willingness to participate (Adams-Campbell et al., 2004; Stewart et al., 
2007).  Specifically, the existence of comorbid cardiovascular, cerebrovascular dise ses 
and diabetes tend to be the most common exclusion criteria for cancer clinical tr als (Van 
Spall et al., 2007; Morris et al., 2010).  These very diseases are also most prevalent 
among African Americans (Adams-Campbell et al., 2004; Adams-Campbell et al., 2004; 
American Cancer Society, 2010).   
A large study of breast cancer patients at a National Cancer Institute (NCI) 
comprehensive cancer center reported that eligibility was a more important factor for 
Black patients than white patients (Simon et al., 2004).  Black patients were more likely 
to be ineligible than white patients because of poor disease performance status and 
inadequate organ function. According to this study, unwillingness was much more 
important than ineligibility; 12% of the failed enrollment was attributed to ineligibility, 
while 88% was due to patient refusal.   
In an examination of rate-limiting factors for cancer patients being served by a 
historically Black medical institution, another study determined overall eligibility for 
clinical trials to be at only 8.5% (Adams-Campbell et al., 2004).  Approximately 17% of 
participants were deemed ineligible to enroll in a clinical trial due to the pres nc  of co-
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morbid conditions¸ another 25% were unable to enroll because no suitable trials were 
open, and 10% were ineligible due to advanced disease stage. The remaining participants 
were ineligible due to disease specific factors.  Despite the low proportion ultimately 
eligible, almost two thirds of those who were eligible actually enrolled in a trial (Adams-
Campbell et al., 2004). This is much higher than the proportion suggested by national 
statistics, which ranges from 3% to 20% for eligible minorities (Stewart et al., 2007; 
Adams-Campbell et al., 2004).  Despite the obvious benefits of changing eligibility 
requirements, a relaxation of stringent eligibility criteria may comprise the integrity of 
any findings on therapeutic trials and reduce the usefulness of the results (Comi et al., 
2003). It is therefore not considered as a useful intervention strategy.  For African 
American cancer patients, the issue of eligibility may be as important as a willingness to 
participate; however, understanding willingness to enroll among those eligible may offer 
the greater avenue for decreasing disparities in participation.  
Lack of Knowledge and Awareness of Clinical Trials 
 
 A basic knowledge about clinical trials and general awareness of their purpose, 
expected risks and benefits is often necessary before a patient considers one as a cancer 
treatment option.  Several studies report that lack of knowledge and general 
misperceptions about clinical trials remains one of the major barriers to intentio  to enroll 
among African Americans (Shavers-Hornaday et al., 1997; Braunstein et al., 2008; 
Fenton et al., 2009). Patients faced with this decision-making might obtain information 
about trials and how to participate, from a variety of sources including their physcian, 
friends, the internet or other media sources (Freimuth et al., 2001; Braunstein et al., 
2008).  The source of information is shown to have a direct impact on a patient’s 
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likelihood to participate as certain sources are deemed more trustworthy than others; 
Fenton et al., 2009).  
 A 2006 study investigated the differences in attitudes of female cancer clinical 
trials participants and non-participants (Madsen et al., 2007). Madsen and colleagues 
found that most of the patients they studied stated the media was a major source of their 
knowledge about and attitudes toward trials, however, they also judged the media to be 
untrustworthy(Madsen et al., 2007). Since this was a Dutch study, the attitudes may not 
be representative of African Americans. It did suggest that media representation and 
normative beliefs may be an important consideration.   
 A 2009 US-based study of the role of the physician in health-decision making 
relative to cancer clinical trials reported that the majority of patients are made aware of a 
clinical trial by their physician (Comis et al., 2003). The study showed that cancer 
survivors and the public alike depend primarily on their physicians as their most 
important source of health information, including clinical trials.  Advani’s 2003 study 
found that the influence of a physician’s advice on the likelihood of participating was 
ranked lower for African American patients than white patients relative to all other 
factors influencing the decision to participate.  Communication between a patient, their 
physician and their families is an important factor in awareness and knowledge about 
clinical trials and influences their intention to participate (Albrecht et al., 2008). 
In a study of racial differences among cancer patients in a radiation oncology 
clinic, Wood and colleagues (2006) found no difference between white and non-white 
patients in their interest in learning about clinical trials or the rate of previous or current 
enrollment.  They did, however, find differences in expectations of clinical trals. 
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Compared with white patients, more non-white cancer patients reported they would likely 
enroll in a clinical trial only if there was a greater than 50% chance of them benefiting 
from the trial (Wood et al., 2006).  Freimuth and colleagues (2001) established, through 
qualitative inquiry that there was a lack of accurate knowledge about clinical research 
among African Americans including adequate knowledge of the informed consent 
process (Freimuth et al., 2001).Given that knowledge and awareness are known to be 
necessary, but not sufficient for behavior change, improving knowledge, alone does not 
present an effective intervention strategy.  
Provider Level Barriers 
 
 Low enrollment of African Americans has also been attributed to provider-level 
factors. These center around the fact that eligible patients may not be referr d to clinical 
trials by their physician (McCaskill-Stevens et al., 1999). In 2008 Albrecht and 
colleagues confirmed that when offered a trial, most eligible patients do in fact enroll.  
Simon and colleagues (2004) showed that over two thirds of women in their study were 
not even offered participation in a clinical trial (Simon et al., 2004). Sub-optimal patient-
physician interactions seem to contribute to low clinical trial participation for African 
Americans (Stewart et al., 2007; Hutchins et al., 1999). This includes the inability of 
physicians to adequately explain clinical trials to the level at which a patient fully 
understands. It also includes the inability of some physicians to make the patient feel 
comfortable, respected and not pressured nor intimidated. The underrepresentation of 
African American oncologists may also have a negative impact on African American 
patient accrual to clinical trials (Stewart et al., 2007; Cohen et al., 2002).  
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Non-Changeable Individual Factors: SES, Race, Gender 
 
Brown and Topcu (2003) focused on African Americans aged 50 years and older.  
In their study sample of 222 whites and 216 African Americans, gender and age were 
significant predictors of intention to enroll.  They were unable to show any race-based 
difference in willingness to participate and intention to enroll; however, willingness to 
participate was significantly higher among males than females and persons of younger 
age compared to older individuals (Brown & Topcu, 2003). 
Similarly, in their study of enrollment in NCI-sponsored cooperative group trials, 
Murphy and colleagues (2004) also found age to predict enrollment, with younger 
patients much more likely to enroll than those over 65. Although the majority of incident 
cancers are diagnosed in older adults (Comis et al., 2003), the more aggressive tend to be 
diagnosed in younger populations (Cancer Facts and Figures, 2010). Therefore, since 
these studies did not control for the aggressiveness of the cancer, it is unclear exactly why 
younger participants are more likely to enroll.   
A 2003 study reported significant interactions between race and age, as well as 
race and income, in predicting enrollment (Brown & Topcu, 2003). Factors such as 
knowledge about Tuskegee and fatalistic attitudes did not result in a decreased likelihood 
to participate when African Americans were compared with whites, for this older 
population. This study concludes a view that intervention strategies would be best 
targeted to racial differences in factors related to age and income level, rath r than 
attitudes and knowledge (Brown & Topcu, 2003).   
BeLue and colleagues (2006) examined gender differences in both the perceptions 
of risks and benefits of trial participation, and the perceived barriers and motivators to 
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participation through a series of focus groups. They found that men and women 
expressed different beliefs and expressed different barriers. For exampl , being treated 
respectfully as an individual and not as a study subject was more important to women 
than men. Knowing the source of research funding was more important to men than 
women. Their findings suggested that there were different factors that ul imately 
contributed to intention to enroll in clinical research for males compared with females 
(BeLue et al., 2006).  
When African American cancer trial participants are compared with white 
participants, education and income emerge as two factors that differ significantly between 
them (Advani et al., 2003).  African American patients who were not willing to 
participate were more likely to be lower income and have less education than those who 
did participate (Advani et al., 2003).  Race is often confounded with socioeconomic 
status (SES), and racial differences in willingness to participate in clinical trials may be 
more attributable to SES than race, though few investigators have studied this.  Advani
and colleagues (2003) found that being African American versus White was not as strong 
a predictor of willingness to enroll, as being poor and lacking education.  In comparing 
African-American with white patients’ beliefs about cancer, clinical tri ls and their 
overall willingness to participate, Advani and colleagues (2003) found no differences by 
race in the percentage of patients who had heard of a clinical trial, knew what a clinical 
trial was, or had been asked to participate in one (Advani et al., 2003).  
In Wei Du and colleagues’ 2009 follow-up study of breast cancer patients the 
racial difference in enrollment rate found were thought to in part be explained by the
race-driven differences in perceptions of clinical trials. They recommended this should 
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guide educational interventions such that specific barriers pertinent to populati n 
subgroups are addressed. They also stated since their study was done in breastcanc r 
patients, the generalization to other types of cancer should be done with caution. 
 Thus, addressing individual level barriers to African American participation may 
help increase accrual to clinical trials (Advani et al., 2003; Wood et al., 2006).  However, 
since factors such as gender, age and race are not amenable to change, focusing on 




It is unclear whether the disparities in enrollment would still exist in an equal-
access system (Stewart et al., 2007). The US Department of Veteran’s affirs (VA) is one 
such system, and the findings of a study (Shavers et al., 2001a) of VA patients show no 
racial differences in decision to enroll in a clinical trial. They suggest that systemic 
factors, such as access and cost, are responsible for the apparent underrepresentation and 
not patient-centered factors.  
An Australian study similarly concluded that the underlying issues leading to 
disparities in cancer outcome are complex and multi-factorial. The authors agreed that 
timely access to high-quality care for all would decrease the disparity in cancer outcome; 
however, when they compared public and private patients, where ready access to a 
comparable level of medical care was available, differences in outcome were still 
apparent. Factors including differential stage at diagnoses, mode of presentation, 
completion of care, acceptance of treatment recommendations and co-morbidities, also 
seemed to contribute to disparities (Moore et al., 2010). 
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Other Factors Affecting Trial Participation 
 
The reasons a cancer patient may refuse to participate in a clinical trial re 
complex. It is challenging to fully assess the contribution of each factor.  In a qualitative 
study of African Americans recruited from churches, Linden and colleagues (2007) 
showed that 80% of their participants reported being willing to enroll in a clinical tr al. In 
particular, they were more likely to participate if they felt the cause was personally 
meaningful to them. Similarly, in attempting to understand the decision to enroll in a 
clinical trial, prior experience with a research study or clinical tri l may be influential.  
There is also evidence to suggest that associations between clinical trial 
participation differ by types of cancer. In the Du et al. study (2009) a multivariable 
logistic model found race and stage of disease to be significantly related to trial 
enrollment where African American patients were less likely to enroll compared with 
white patients.  Thus cancer type and stage of disease should be considered in any 
explanatory model of clinical trial participation. 
2.3 Attitudinal Barriers to African American Trial Participation  
An appreciation of the beliefs, values, attitudes, and preferences of the African 
American community is essential to understanding their fears and barriers (Branson et al., 
2007).  This requires an awareness of the root of these attitudes as African Americans 
have a particularly strained relationship with scientific research in the Unit d States 
(Gamble, 1997). Studies show significant differences in attitudes towards clinical trials 
between white patients and non-white patients (Wood et al., 2006). Many of the specific 
cultural and attitudinal factors which exist are the legacy of a sordid past of slavery and 
unfair/unethical treatment (Gamble, 1997).   
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A randomized study in a large urban Comprehensive Cancer Center tested a 
patient education video as a tool to increase clinical trials enrollment among breast cancer 
patients (Du et al., 2009).  They aimed to determine if there were race-based differences 
in attitudes towards clinical trials and to show a change in these individual attitudes.  Th  
sample of almost 200 breast cancer patients showed a small increase in enrollment in 
therapeutic trials for the group randomized to the educational intervention.  This change 
was not statistically significant but it offered preliminary evidence that changing attitudes 
may increase enrollment.  The study clearly showed not only a lower enrollment rat  
among African American patients, but also significantly more negative scores on three 
out five attitudinal scales (Du et al., 2009) 
 Corbie-Smith and colleagues (1999) documented the most commonly cited 
reasons for the attitudes African Americans have towards participation in cli ical trials. 
These included: 1) mistrust of doctors, scientists, and the government; 2) concern about 
the ethical conduct of investigators; and 3) believing that investigators would treat poor 
or minority patients unfairly. Others have confirmed these, as well as the fear of loss of 
autonomy after signing a research informed consent (Sood et al., 2009; Verheggen et al., 
1998).  They are considered here in more detail as the main attitudes under study for this 
dissertation. 
Fear and Distrust of the Medical Establishment 
 
A fear and distrust of doctors, scientists and the government is frequently cited as 
one of the most pervasive attitudinal barriers to clinical trial participaton for African 
Americans, linked to both individual experiences with discrimination, as well as a 
cultural memory of victimization and exploitation (Rajakumar et al., 2009; Boulware et 
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al., 2003; Shavers et al., 2001b; Swanson & Ward, 1995; Mouton et al., 1997; Sood et al., 
2009; Gamble, 1997). 
A 2008 study of 717 patients from Maryland outpatient cardiology and general 
medicine clinics found African Americans expressed a significantly lower willingness to 
participate in a cardiovascular drug trial, compared with white participants (Braunstein et 
al., 2008). African Americans scored significantly higher than whites on mean distrust 
scales, and believed that doctors had previously experimented on them without their 
consent.  Significantly more African American patients than whites reported that their 
physicians would not fully explain participating in research to them, and they beli ved 
doctors would prescribe medication as a way of experimenting on them. They also more 
frequently reported that they believed their doctors would ask them to participate n 
research even if it may harm them (Braunstein et al., 2008).  
A series of focus groups held in Los Angeles, Chicago, Washington DC, and 
Atlanta in 1997 found that accurate knowledge about clinical research was limited and 
that a general understanding and trust of informed consent procedures was pervasive.  
Participants expressed a distrust of researchers as a significant barrier to recruitment to 
clinical trials (Freimuth et al., 2001).  Rajakumar and colleagues (2009) also found that 
distrust of medicine and research was significantly greater among African Americans 
even when education was controlled for, as education was associated with having 
significantly greater distrust (Rajakumar et al., 2009). 
While numerous others have found distrust to be an important predictor of 
enrollment in clinical trials (Corbie-Smith, 1999; Corbie-Smith et al., 2002; Rajakum r et 
al., 2009; Gamble, 1997; Katz et al., 2008a; McCallum et al., 2006),  Advani and 
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colleagues (2003) did not find distrust of the medical profession or medical research to be 
a significant barrier to participation in their study (Advani et al., 2003).  Thus more
research is necessary to understand the role of distrust in decisions about clinical trial 
participation.  
It is suspected that the trust issues stem from the historical treatment of African 
Americans in research. The critically low participation of African Americans in clinical 
trials and other medical procedures, such as organ donation, has been linked to this 
legacy (Gamble, 1997; Swanson & Ward, 1995). The Tuskegee syphilis Study conducted 
by the US Public Health Service from 1932 to 1972 is a very specific example of 
unethical treatment of Black people throughout the history of the United States. Gmble 
(1997) writes that the legacy of Tuskegee symbolizes racism in medicine, misconduct in 
human research, the arrogance of physicians and government abuse of Black people. 
Gamble (1997) further asserts that this mistrust between African Americans and whites in 
fact predates Tuskegee and it is limiting to consider one event as the single cause of such 
complex attitudes (Gamble, 1997).   
Crawley (2001) details multiple dimensions of trust as they impact decision-
making for clinical trials to include 1) trusting in the fiduciary relationship 2) trust as 
confidence in competence; and 3) perceptions of trustworthiness. This consideration 
suggests how multifaceted attitudes towards clinical trials, which are rooted in racially 
based trust issues, truly are.  
Worry that Investigators Will Treat Poor or Black Patients Unfairly 
 
Some African Americans fear that clinical trials will leave them vulnerabl  to 
exploitation because of their status as a minority group or their lack of income.  This 
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vulnerability, in the context of research, refers to an inability on the part of study 
participants to protect their own interests (Grady et al., 2006). While this attitude can be 
linked to historical abuse, it also relates to the fact that minority patients are more likely 
to have lower incomes, be younger, less educated, and underinsured or uninsured 
(Macklin, 2003).  Community leaders and ethicists have expressed concern that 
regardless of the risks involved, those with limited access to health care will enrol  in 
research studies to obtain the basic health care services that would otherwise be 
unavailable to them (Grady et al., 2006).  Patients fear that they are then even more likely 
to be treated unfairly by researchers or healthcare workers if they are visible minorities 
(Kennedy et al., 2007). In the radiation oncology patients studied by Wood and 
Colleagues (2006), this attitude was pervasive whereby more non-White patients believed 
that they had been treated on clinical trials without their knowledge (Wood et al., 2006).  
Kennedy, Mathis, and Woods (2007) also confirm that there continues to be an 
underlying element of mistrust and fear of being treated unfairly between th poor 
populations and minority populations that may be subjects of research and the research 
establishment.   
Concern About the Ethical Conduct of Researchers 
 
Studies of patient populations and the public alike, reveal a concern that 
researchers and clinical research in general is not conducted in an ethical manner when it 
comes to African American participants (Gamble, 1997; Corbie-Smith, 1999; Comis et 
al., 2003).  Corbie-Smith and colleagues conducted focus group interviews of 33 African 
American patients in an urban public hospital outpatient setting in 1997. They reported 
participants expressed concern about unethical treatment of poor or minority patients. 
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This in turn fed into their general mistrust of the medical establishment.  One study 
showed only 28% of the African American women surveyed about perceptions of women 
in clinical trials felt that the research was ethical (Mouton et al., 1997).  
The unethical treatment of African Americans in the Tuskegee Syphilis study i  
thought to fuel continued concern about the present day ethical conduct of researcher. 
There are, however, polarized views as to whether or not there really are long lasting 
effects and differential knowledge about Tuskegee to the effect it has impact on 
enrollment in clinical trials or any other aspect of the patient experience. Shavers and 
Colleagues (2008) suggest that awareness of historical and ethical misconduct in 
biomedical research and the knowledge of Tuskegee must be taken into account when 
recruiting into clinical trials.  Differences in awareness of the study have been shown. 
Out of 179 African American and white Detroit residents, 88% of African Americans h d 
heard of the Tuskegee study, compared with 28% of whites.  Further, 51% of African 
Americans reported less trust of researchers due to knowledge of Tuskegee, compared 
with 34% of whites. 49% of African Americans stated they would not be willing to 
participate in a research study due to this knowledge, compared to 17% of whites.  Katz 
and colleagues (2008), however challenge this purview, reporting that the widely
acknowledged “legacy” was not statistically associated with the willingness to participate 
in biomedical studies (Katz et al., 2008b; Katz et al., 2007; Katz et al., 2009). They 
confirmed that their studies did not assess the broader question of whether and how 
historical events influence people’s willingness to participate in research (Katz et al., 
2008a).  
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Fear of Loss of Autonomy After Signing an Informed Consent Document 
 
 Several studies have reported on the general misunderstanding and lack of 
understanding of the research informed consent process (Corbie-Smith, 1999; Verheggen 
et al., 1998).  For example, Corbie-Smith reported that patients did not understand the 
goal of the consent process and instead saw signing the document as akin to relinquishing 
their rights (Corbie-Smith, 1999).  They further reported that participants understood an 
informed consent form to be a means of legal protection for physicians (Corbie-Smith, 
1999; Corbie-Smith et al., 1999). The extent of a research participant’s understanding of 
the informed consent process has been debated for general clinical research populations 
(Joffe et al., 2001) and this may pose an even greater barrier for African Americans. 
2.4 Racial Identity and Trial Participation 
As described previously, trust is a major impediment to the willingness of African 
Americans to enroll in clinical trials and has been linked to the legacy of Tuskegee 
(Tejeda et al., 1996; Braunstein et al., 2008)). Personal experiences with racism h ve also 
been found to foster a mistrust of the medical system. Terrell and Terrell (1981) define a 
construct known as cultural mistrust, which refers to African American’s mistrust of 
Whites and the White American establishment (e.g., government, law enforcement, 
schools). This is reactive to racism and mistreatment by mainstream society and is 
characterized by suspicion of the motives of others and a general lack of trust of Whi e 
Americans.  This construct has been examined in studies of educational and occupational 
expectations of Black adolescents (Terrell et al., 1993). Conceptually, this appears 
directly pertinent to how Blacks may view doctors, the healthcare establishment and 
subsequently clinical trials.  
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Considering the link between cultural mistrust and experiences with racism the 
range of factors that may influence African American’s mistrustful attitudes should be 
further explored. Given that African Americans are skeptical of clinical research due to 
the historical treatment of blacks, it is conceivable that feeling vulnerable and liable to be 
exploited depends on the extent to which they also identify as a part of the mistreated 
group.  According to Helms (1990) a person’s interpretation of information and their 
response to their environment is strongly influenced by their racial identity.  Sellers and 
colleagues (1998) define racial identity as the significance and qualitative meaning one 
attributes to being black in their conceptualizations of self. Thus one’s racial or ethnic 
identity can be examined in the context of decision-making for clinical trials.  Racial 
identity has rarely been studied in the context of attitudes towards clinical trials, but may 
be a relevant factor.  
Sellers and colleagues (1998) have done a considerable amount of work to 
identify the components of racial identity.  They propose four dimensions of racial 
identity: racial salience, the centrality of identity, the regard in which a person holds the 
group associated with the identity and the ideology associated with the identity (Sellers et 
al., 1998a).  Their work suggests  identities are situationally influenced, as well as being 
stable properties of the person. That is, racial identity in African Americans has both 
dynamic (susceptible to conceptual cues) and stable properties, which influence behavior 
accordingly at the level of the specific event (Sellers et al., 1998a). The current study 
focused only on centrality, which refers to the significance that an individual attaches to 
race in defining themselves and is thought to be relatively stable across situations (Sellers 
et al., 1998a).  Their work also suggests that an individual’s perception of their racial 
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identity is the most valid indicator of their identity. Individuals have a number of 
different identities, which are hierarchically ordered, thus focusing on the importance hat 
an individual places on race in their definition of self (Sellers et al., 1998a).   
Williams-Brown and colleagues (2008) proposed that more work should be done 
to establish how cultural and racial/ethnic profiles impacted individual health attitudes 
and behaviors. They conducted a series of individual interviews with U.S.-born and 
Jamaican-born Black men living in the metropolitan Atlanta area.  Participants were 
asked to talk about their sense of self, their ethnicity, their culture and their health-rel ted 
attitudes. The study found that both U.S-born and Jamaican-born Black men who 
conveyed a sense of strong ethnic identity were more likely to have positive health 
attitudes compared with men who did not convey a strong sense of ethnic identity. 
Overall ethnic identity was positively associated with health related atitudes.  Considered 
as a health-related behavior, the attitudes towards enrolling in a clinical trial may be 
similarly impacted by a level of racial or ethnic identity for African Americans. 
The concept of racial identity has not been extensively considered in the context 
of health decision-making, especially when it comes to clinical trials partici tion. There 
is literature that suggests racial/ethnic minority groups have shown that greater 
identification with one’s race/ethnicity or culture of origin may have a protective effect 
on health and may buffer the negative influence of unfair treatment and racial/ethnic 
discrimination (Chae et al., 2008).  Chae and colleagues found that high levels of ethnic 
identification were associated with lower odds of being a current smoker compared with 
low levels of identity.  Given that clinical trials decision-making has been linked with 
issues of trust and racial discrimination in the past, perhaps racial identity ought t  be 
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similarly explored for its potential buffering or enhancing effect on this decision for 
African Americans. In a separate study of 1216 African American men from the National 
Survey of American Life, a significant interaction was found between reported 
discrimination and internalized negative racial group attitudes (a related identity measure) 
in predicting cardiovascular disease (Chae et al., 2010).  Agreeing with negative beliefs 
about Blacks was positively associated with cardiovascular disease history and moderated 
the effect of racial discrimination.  This study suggested overall that a group identity was 
a moderating factor in assessing and predicting cardiovascular health among African 
American men. 
The psychological health and well-being of African Americans has also been 
linked to racial identity (Bediako et al., 2007; Sellers et al., 1998b; Carter et al., 1997; 
Rivas-Drake, 2010). Literature substantiates the claim that African Americans with a 
strong racial identity tend to have better mental health status than those who have less 
positive or weaker racial identity (Helms, 1990; Butler, 1975).  In a study of 555 youth 
(Sellers et al., 2003), racial identity and race-related stress accounted for more of the 
variance in mental health among African American college students than any other 
predictors.  Further, there is evidence of a direct relationship between racial centr lity and 
psychological distress (Sellers et al., 2003).  Of note, racial centrality w s found to be a 
risk factor for experiencing discrimination and a protective factor in buffering the 
negative impact of discrimination on psychological distress.  Centrality is thus likely to 
be relevant to the decision to participate in a clinical trial due to the fact that African 
Americans who define themselves more strongly as African Americans or Black are more 
likely to feel a sense of cultural commitment, which in turn may lead to an increased 
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willingness to participate in a clinical trial.  It is conceivable that those with stronger 
racial identity might be more willing to participate in clinical trials since they may feel a 
stronger connection to other African Americans and may recognize that their 
participation may have benefits for the larger group.  Thus, there may be an intr ction 
between racial identity and mistrust because of the history of African Americans and 
research in the United States.  
Other studies show that an African American’s strong self identity relates directly 
to health outcomes including stress management and dietary control (Bediako et al., 
2007); Chambers, 2000). Applied to his study on racial identity and sickle cell disease 
management, Bediako proposes a termed salutogenic, or health-enhancing effect, of 
racial identity in certain circumstances (Bediako et al., 2007). He suggests a 
generalizability to other health behaviors. 
Emerging research explores the role of a social identity, like racial nd ethnic 
identity in consumer behavior and health (Oyserman et al., 2007; Oyserman, 2008). 
Oyserman’s work focuses on how the self-concept, which includes racial identity, 
functions to influence judgment, decision-making and real world behavior (Oyserman t 
al., 2007).  Oyserman (2007) proposes a mechanism of identity-based motivation, 
whereby individuals make choices based on how they see themselves or identify as part 
of a group.  This work considers an individual’s membership as a particular racial or 
ethnic group, influential of beliefs about how the group fits into a broader society, what 
they should believe in, and how they should act in ways that are congruent with beliefs 
about group membership. This is thought to motivate the types of decisions individuals 
make and thus influence their health beliefs and health decisions.  Extending this 
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argument, perhaps individual decisions to enroll in clinical trials are influenced by 
whether one believes the choice to be congruent with their in-group’s (i.e., African 
Americans or other Blacks) choice.  
Oyserman and colleagues’ (2007) identity-based motivation model has been used 
to understand barriers to engaging in health promotion among racial-ethnic minorities 
and low-SES Americans; positing that they are more likely to perceive health promotion 
as an out-group characteristic rather than an in-group characteristic. Thus thinking of 
oneself as a minority in-group member dampens health promotion efficacy (i.e., “that is 
not a thing that we do”), and increases health fatalism (i.e., “there is nothing we can do 
about it”) (Altschul et al., 2006). They reported a significant moderating effect related to 
in-group identity.  
Oyserman and colleagues (2007) showed that white American and racial-ethnic 
minority group participants differ in their beliefs about health promotion and that raci l-
ethnic minority group participants are more likely to encode health promotion activities 
as middle class and White.  Thus it is conceivable that participating in a clinical trial is 
something that African Americans, particularly those with a strong racial identity, do not 
see as congruent with in-group behavior and thus their willingness to enroll may be 
modified by this perspective.  A 2007 study illustrates this point referencing a study in 
which women who self-identified as “African American” were more likely to seek 
mammography screening than those who self-identified as “Black” (Bowen et al., 1997a).  
The author’s rationale was that perhaps women who self identified as African American 
felt less at odds with the dominant culture than those who self-identified as Black ( owen 
et al., 1997b; Oyserman et al., 2007).  While the intricacies of differentiating between 
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Black and African American are not the focus of this dissertation, this finding does 
suggest a role for racial identity worthy of exploring in the context of clinical trials 
decision-making.  Further, it alludes to the need to establish whether a strong racial 
identity is more likely to promote enrollment, as consistent with the concept of altruism 
and doing something to benefit the group, as discussed earlier; or if it has the opposite 
effect whereby participating in clinical trials is not seen as in-group behavior for African 
Americans thus would dissuade one from participating. The latter would be consistent 
with Oyserman’s observations where minority focus group participants did not see health 
promotion as in-group defining but rather described behaviors such as exercising, eating 
salad and dieting as “White” behaviors (Oyserman et al., 2007).   
2.5 Religion and Trial Participation 
It is conceivable that racial differences in trial participation may also be 
attributable to cultural factors such as religion; however, the role of religion or religious 
beliefs in the intention to enroll in cancer clinical trial has rarely (if at all) been examined. 
Advani et al., (2003) found that a belief in God was a significant predictor of a decreased 
willingness to participate in research.  In this study, 95% of African-American patients 
(compared with 78% of white patients) reported strongly believing that God woul 
determine their prognosis and whether they would be cured or die from their disease.  
Interactions were not tested to determine potential moderating effects of covariates, 
however the overall results of this study are important to consider since religion, 
education, income were more important barriers to willingness to participate than race 
(Advani et al., 2003).  
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The connection between religion and health has been shown for decades. In a 
survey of community health center in Glasgow, the prevalence of symptoms was found to 
relate to religious allegiance (Hannay, 1980).  People who actively participated in their 
religion, rather than having a purely passive allegiance, had significantly fewer physical, 
mental or social symptoms. Greater religious observance was found among minority 
groups and acted as a stabilizing factor (Hannay, 1980).  
 The connection between religion and health has been further demonstrated by 
several, more recent studies (Levin et al., 2005; Blumenthal et al., 2007; Contrada et al., 
2004c; Hannay, 1980; Ellison & Levin, 1998c; Contrada et al., 2004b; Contrada et al., 
2004a; Holt et al., 2005; Ingersoll-Dayton et al., 2002; Johnson et al., 2005a). The extant 
literature, using various definitions of spirituality or religiosity, tends to focus on the role 
of religion in recovering from acute conditions such as myocardial infarctions 
(Blumenthal et al., 2007). Current studies have examined the positive effects of religi n 
and religious involvement (Blumenthal et al., 2007) both in general populations, as well 
as specifically African American populations (Levin et al., 2005) on health. These studi s 
find a direct relationship between religious involvement and having a belief in God, and 
better disease outcomes and increased rates of recovery.  An association has also been 
found with more frequent church attendance and better self-rated health (Krause, 2010).  
Further there are lower rates of morbidity and cause-specific mortality among those with 
religious affiliations that make strict behavioral demands compared to religions with 
more liberal guidelines (Levin et al., 2005).   
 In research on religious beliefs and general medical treatment, Matthews, 
Sellergren and Manfredi (2002) found various factors to affect medical informati n 
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seeking, treatment engagement and emotional adjustment among African American 
cancer patients. They cited religious beliefs among their focus group participan s, as a 
key cultural factor which played an important role in the behavior of African American 
cancer patients (Matthews et al., 2002). 
 The literature that does address religion and health decision-making among 
African Americans pertains mainly to screening decisions and health seeking b havior 
(Gullate, 2006; Figueroa et al., 2006; Dessio et al., 2004).  For example religiousness and 
self-directed problem solving were significantly associated with prostate cancer screening 
attitudes (Abernethy et al., 2009). Interviews with a convenience sample of 129 women 
between 30 and 84 who self-reported finding a breast symptom before their breast cancer 
diagnosis were conducted.  Women who reported talking to God only about their breast 
change were significantly more likely to delay seeking medical care than those who 
reported telling another person (Gullatte et al., 2010).  
However, not all studies have found an association between religion and health.  
For example, Blumenthal found little evidence that self-reported spirituality, frequency of 
church attendance and frequency of prayer were associated with cardiac morbidity  all 
cause mortality after an acute myocardial infarction (Blumenthal et al., 2007).  
The existing body of research does not adequately examine how specific religious 
beliefs may factor into complex health decision-making for African Americans and is 
worth exploring.  Linden and colleagues’ qualitative research revealed that participants 
expressed a mistrust in recruitment into clinical trials, and they believed that culturally 
sensitive recruitment efforts would be more effective in recruiting African American 
patients (Linden et al., 2007). Specifically participants in the study stated a higher 
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likelihood of participating if the church was somehow involved in their decision, stating 
they would feel more trusting and more likely view the clinical trial as more legitimate if 
someone from the church presented it. This suggests that where a negative attitud  
towards participation exists, religious factors may have a moderating effect. In this study, 
women also discussed the importance of ‘praying” over medical interventions and how in 
particular, Southern Blacks consider God the ultimate healer, and they did not go to 
doctors (Linden et al., 2007).  This again suggests there may be utility in further 
exploring how religious beliefs influence enrollment and exactly how they may modify 
prevalent attitudes towards clinical trials. 
2.6 Theoretical Considerations 
There is a paucity of research on clinical trial recruitment of minorities that is 
driven by a solid theoretical model. Several studies make mention of a theory used; 
however, they do not discuss the manner in which the theory was used nor do they 
directly connect any constructs to a theoretical basis. For example, Du and colleagues in 
their study of the impact of the NCI video on recruitment of lung cancer patients, state 
their hypothesis is based on Andersen’s health behavior model(Du et al., 2008). However 
they do not to elaborate beyond this nor do they mention how exactly the theory connects 
their aims and hypotheses.   
Also used in some research on clinical trial participation is the Theory of 
Reasoned Action (Azjen & Fishbein, 1980).  This model considers predisposing and 
enabling factors that differentially predict willingness to participate in a clinical treatment 
trial (Brown & Topcu, 2003). Considering race as one of the predisposing factors in the 
framework, the study posits that race will lead to a differential effect in willingness to 
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participate.  However the main criticism of the TRA is it does not account for behaviors 
that are under volitional control, and participation in clinical trials is behavior under 
volitional control.  
Yang et al. (2009) employ the Risk Information Seeking and Processing 
framework (RISP), which they suggest is an antecedent to the Theory of Planned 
Behavior. The RISP model (2009) proposes a way in which cancer patients deal with 
information about clinical trial enrollment. They postulate information processing tyles 
influence the attitudes toward clinical trials and in turn how this relates to behavioral 
intentions to participate (Janet Yang et al., 2010).  They also test how this works in terms 
of motivations for participation, under the premise that attitudes are formed relative to 
how information is processed.  The findings of this study point towards an overall role for 
information processing and attitudes toward clinical trials, however not to the intent to 
participate (Yang et al, 2009).  They are among the first to provide evidence in support of 
the TPB proposition that attitudes toward clinical trials will lead to intention to enroll in 
clinical trials.  Further, they provide strong justification that communication and 
justification about clinical trial enrollment should move beyond simply increasing 
awareness. That addressing and changing attitudes towards clinical trials is key. 
Specifically, the authors proposed finding means to cancer patients’ cognitive a d 
affective evaluations of potential risks involved in the research process (Yang et al., 
2010).   This highlights the fact that any theoretical basis should look more towards the 
intention to participate (as for example suggested by the TPB) and factors that have a 
direct theoretical link to the intention construct.   
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Use of the TPB may be particularly relevant when investigating clinical tr al 
participation since work has shown that intention to engage in a specific behavior does 
predict actual behavior, in this case enrollment (Andrykowski et al., 2006).  As 
articulated by the theory, intention is the cognitive representation of a person’s eadiness 
to perform a given behavior, and it is considered to be the immediate antecedent of 
behavior (Ajzen, 1985).  The TPB posits that intention to engage in a specific behavior is 
a strong proximal indicator of the subsequent and actual performance of said behavior 
(Andrykowski et al., 2006; Ajzen, 1985).  As stated by Godin and Kok (1996) the 
correlation between measures of intention and subsequent health behavior ranges from 
0.25 to 0.72 and on average is 0.47. In the context of the dissertation, the variables under 
study relate to each of the key cognitive variables that determine intention. That is 
attitudes regarding that behavior (attitudinal barriers towards clinical trial participation); 
subjective norms regarding the behavior (as determined by ones ethnic identity and how 
they define themselves or identify with other black people); and perceived behavioral 
control (the extent of an individual’s belief in God as a healer of their cancer). While the 
study variables are not exhaustive representations of the TPB constructs, the theory 
seems to be a reasonable guide for better understanding how these factors impact the 
intention to enroll.  
Du et al.’s assessment of impact of their educational video in lung cancer patients 
showed a significant impact on attitudes towards clinical trials and they found that the 
reported likelihood to enroll was correlated with actual trial enrollment (2008). The 
connection between attitudes, intention to enroll and actual enrollment is consistent with 
the TPB even though this study did not explicitly use this theoretical guidance. Studies 
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that have examined and applied the TPB to understanding of behavioral intentions have 
shown that the collection of TPB constructs accounted for up to 53% of variance in 
behavioral intentions beyond that which could be accounted for by clinical and 
demographic variables (Andrykowski et al., 2006) . Further, of these constructs in the 
TPB it was consistently behavioral attitude that was most consistently associ ted with 
behavioral intentions and subjective norms the least so (Andrykowski et al., 2006).  
Andrykowski and colleagues applied the TPB to a study of intentions to engage in 
physical and psychosocial health behaviors after cancer diagnosis(Andrykowski et al., 
2006). The TPB helped to facilitate understanding of how 130 adults with a cancer 
diagnosis were currently performing and their future intentions based on a collection of 
physical and psychosocial health behaviors. They found the TPB constructs explained an 
added 25% of the variance in intentions over and above that explained by demographic 
and clinical variables (Andrykowski et al., 2006).  Behavioral attitude was most 
consistently associated with intention. Andrykowski and colleagues (2006) affirm that 
TPB serves as a comprehensive model for understanding change in psychosocial and 
physical health behaviors alike following a cancer diagnosis. The TPB also would permit 
a consideration of variables which relate to ones normative beliefs and attitudes such as 
religious beliefs and racial identity, making it a good guiding theory for understanding 
factors affecting intention to enroll in clinical trials.   
Many models of racial identity are based on the explicit assumption that race is  
very central identity in a normally functioning African American(Sellers t al., 1998b). 
There are several theoretical models in racial identity literature, many of which are 
modeled on Cross’s Model of Racial Identity (Ponterotto & Pederson, 1993). These 
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models however were not specifically designed for use in a health decision-making 
context; however, they provide some context and guidance for health-based interventions.   
2.7 Summary 
In consideration of culturally competent interventions, integration of social and 
historical context of a population is essential (Kagawa-Singer et al., 2010). While there is 
no shortage of literature that details some of the barriers to participation in trials 
identified among African Americans, some critical constructs, such as raci l identity and 
religiosity, have rarely been examined.  Previous multidisciplinary work sugge ts these 
two constructs may moderate the attitudes of African American patients towards many 
health behaviors, thus understanding how they may impact clinical trial decision-making 
could prove especially valuable.   
There are further gaps in the literature in terms of methods to impact these 
barriers as most work has been atheoretical.  There appears to be no reason why the TPB 
cannot be used as a suitable framework to understand the relationship between these 
constructs and the intention to participate in clinical trials. Attitudes, norms and perceived 
behavior control are all characteristics of human behavior that are modifiable 
(Andrykowski et al., 2006). Thus the ability to understand and demonstrate the level of 
influence exerted by socio-cultural factors may provide better guidance than currently 
exists for designing interventions to impact the intention of African American cancer 
patients to participate in a clinical trial.  
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CHAPTER THREE: METHODS 
 
This chapter includes a description of the study sample, conceptual model, study 
design, measures and instrumentation. The data analysis plan is also presented.  
3.1 Study Overview 
In current health disparities research, a call to action for researchers suggests a 
focus on the impact of cultural variables shaping individual attitudes toward disease and 
treatment. There is, however, limited research examining these relationships among 
Black cancer patients and cultural factors surrounding their attitudes toward and 
intentions to enroll in clinical trials.  Subsequently there are few culturally targeted 
interventions, which are focused on impacting these attitudes in order to increase the 
likelihood of trial participation among African Americans with cancer. Therefore, this 
study specifically examines two cultural constructs recognized as important in Black 
culture, and their relationship with attitudinal barriers to trial participation. Findings may 
inform new areas of focus for targeting interventions and designing educational materials 
to address the underrepresentation of African Americans in therapeutic clinical trials.   
3.2 Study Site 
The Washington Hospital Center (WHC) is an acute care teaching and research 
hospital, the largest non-profit hospital in the District of Columbia (DC) metropolitan 
region. Washington Cancer Institute (WCI) at WHC sees African American patients of 
diverse backgrounds and is DC’s largest provider of cancer care, treating more of DC’s 
cancer patients than any other program.  Based on a 2007 annual report from the Cancer 
Institute, 38.7 percent of patients coming to WCI lived in the District of Columbia, 49.9 
percent in Maryland, 7.8 percent in Virginia and 3.6 percent were from other states and 
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countries. Further, 54.5 percent of the patients were female; 59.2 percent were African-
American, 34.3 percent non-Hispanic white, 3.0 percent Hispanic white and 3.7 percent 
had designated race as “other”.  WCI thus provided a diverse pool of patients from which 
to draw for this study.  The cancer institute was funded by the National Center on 
Minority Health and Health Disparities for a two-year project targeting African American 
cancer patients. The overall goal was to design and implement an intervention that will
help to increase minority participation in cancer clinical trials. This dis ertation made use 
of the same study population. 
3.3 Study Sample 
Sampling and Eligibility 
 
The sample for the dissertation study was a non-probability, purposive convenience 
sample of patients at WCI and dictated by the parent study described later in th  section. 
Eligible participants: 
 Self-identified as Black or African-American 
 Were age 21 years or older 
 Able to communicate verbally in English 
 Had a confirmed cancer diagnosis 
 Anticipated cancer treatment to be given at Washington Hospital Center 
Patients who met any of the following criteria were ineligible:  
 
 Had previously expressed an interest in participating in a clinical trial 
 Had ever participated in any research study (including those unrelated to cancer), 
as manifested by having ever signed a research informed consent 
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 Had apparent physical distress or altered mental status precluding ability to give 
informed consent and/or complete study procedures 
 
Recruitment 
Potentially eligible participants were identified by their medical oncologist or 
nurse navigator either during their consultation visit or the day prior through the 
electronic scheduling system.  This recruitment method initially resulted in an 
overrepresentation of female breast cancer patients as this was the main source of study 
referrals by physicians and staff.  A deliberate effort was then made to recruit participants 
from other specialty oncology clinics within the hospital center, which resulted in an 
increase in male participants and the diversity of primary cancer sites represented within 
the sample.   Ultimately, enrollments in the study were the result of a number of 
recruitment mechanisms which varied depending on the care provider they were referr d 
by and the manner in which the study was initially presented to them.  For instance ome 
patients were given an overview of the study by their provider, before being asked to 
participate.  Others were approached directly, while in the waiting room and w iting to 
see their provider, thus presented the study and asked to participate directly by me. 
Further, due to recruitment from several specialty clinics, participants were at various 
stages of treatment and at different points post-diagnosis. 
Sample Description 
 
The final study sample consisted of 111 participants; the majority of whom were 
female (76%).  The mean age was 60 with the youngest participant 31 years of age and 
the oldest 87 years of age.  Eighty-two percent of the participants were older than age 50. 
Patients self-identified as African-American (41%), Black (46%), African (4%), 
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Caribbean (4%) or Other (5%). The latter category included participants who were of 
mixed parentage/ethnicity or who considered themselves bi-racial.  Eighty-ei t percent 
of participants were US born nationals, while 12% were foreign-born/immigrants. More 
than half of the US-born sample were born on the East-Coast (58%), 29% were born in 
the Southern United States; 2% and 3% respectively, were born in the 
Midwestern/Central US and on the west coast.  Approximately one third of the sample 
(37%) had a total annual household income over $75,000.  Overall this was a relatively 
educated sample with fewer than 10% of participants having not completed high school.  
Seventy-one percent reported a family history of cancer, 42% were married and 82% had 
at least one child.  All but 3% of the sample reported being Christian; the majority self-
identified as Baptist (48%).  Forty-seven percent reported attending church at least once a 





Table 1: Summary Statistics: Socio-Demographic Variables 
 N= 111 Mean Range 
Age  60.1 (31-87) 
Gender 
 N Percent 
Female 84 76 






Black 51 46 
African Ancestry 4 4 
Caribbean or West Indian Ancestry 4 4 
Other 6 5 
Participant Born in 
US 
Yes 98 89 
No 13 12 




West Coast 3 3 
East Coast 64 58 
South 29 26 









< $8000 13 12 
$8000- $11999 3 3 
$12000 –$15999 7 6 
$16000 – $19999 3 3 
$20000 - $29999 6 5 
$30000 – $39999 9 8 
$40000 –$49999 8 7 
$50000 - $74999 
21 19 
>$ 75000 41 37 
Family History of 
Cancer 
No 32 29 






Never Married 26 23 
Married 47 42 
Marriage Equivalent 1 1 
Widowed 13 12 
Separated/Divorced 24 22 
Number of Children 
 
None 20 18 
1 or More 91 82 
 
Highest Level of 
Education 
 
< High School 11 10 
High School Graduate or GED 29 26 
Some college or technical school 33 30 




None 25 23 
1-3 Times 34 31 





Not at All 17 15 
Not Much 37 33 
Not Sure 15 14 
Somewhat 31 28 
Extremely 11 10 
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3.4 Study Design 
Data for this dissertation were collected from participants of the parent study 
aimed to assess the impact of a narrative based video on cultural attitudes towardsclinical 
trials among African American cancer patients. The dissertation was a non-experimental 
cross-sectional quantitative study testing a conceptual model that incorporated four of the 
attitudes from the parent study, with two cultural constructs measured solely for the 
dissertation work.  
The parent study evaluated whether a 15-minute video with targeted information 
for African American cancer patients impacted six dimensions of attitude and affected 
their willingness to enroll in therapeutic clinical trials. I conducted a thorough informed 
consent process and obtained signed consent from the participants prior to any study 
activities and data collection.  All key terms in both the consent form and items in the 
structured interview were explained to the participant as they appeared, to ensure a basic 
level of understanding.  For clarity, participants were also told that the terms clinical trial, 
clinical research study and therapeutic trial were used interchangeably throughout the 
study and these words were also clearly defined.  Participants completed a structured 
interview pre-test assessing their attitudes on six barriers, racial identity, religious belief 
and intention to enroll, immediately before viewing the intervention video for the parent 
study.  Participants completed the same items related to the six dimensions of attitude and 
a single item of self-reported likelihood of enrollment in a clinical trial, immediately 




I verbally administered each interview reading each question and all possible 
response options to the participant.  Responses were recorded on a paper version of the 
questionnaire and later double-keyed into a secure database.  The study design did not 
include a control group, thus all participants viewed the same video.  
3.4.1. Pilot Work and Video Description 
 
The parent study developed and tested the impact of a culturally targeted video on 
the six previously cited patient-level barriers to clinical trial participation among African 
Americans. Through the use of compelling patient, physician and ethicist narra ives, the 
video addressed each barrier in turn and showed how each patient went from a place of 
fear after receiving their diagnosis, to overcoming that aspect of their fear o  participating 
in a clinical trial. The physician and ethicists’ interviews served to provide factual context 
for each barrier. The 15-minute video made use of progress messaging via narrative 
communication, shown to be particularly effective with communicating disparity based 
information and impacting behavioral intention among the study population (Nicholson et 
al., 2008).  
A series of patient interviews were conducted to develop the content for the video. 
These interviews served also to inform potential areas of focus for the dissertat on study.  
I conducted 27 semi-structured interviews with cancer survivors, together with the 
producer of the patient education video. The patients were identified by research 
coordinators, nurse navigators and physicians in the Washington Cancer Institute. They 
had previously participated in a clinical trial, or consulted with an oncologist at WCI 
following their diagnosis. The patients discussed their experience from receiving their 
cancer diagnosis through considering their treatment options which included a clinic l 
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trial. They were asked directly about their experience as it pertained to each of the 
attitudinal study barriers.  Themes, quotes and key points from these interviews were 
used to identify further areas of inquiry for the dissertation study.  
3.4 Conceptual Framework/Model 
The framework (figure 1) depicts the explanatory variables studied in this 
dissertation investigating the impact of four dimensions of attitude along with rac al
identity and religious beliefs on the intention to enroll in a clinical trial.  
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3.5 Data Collection 
3.5.1 Data Time-points 
 
Demographic data were collected at pre-test.  To minimize issues of health
literacy the survey was verbally administered, which enabled participants to ask questions 
for clarification and ensured the completeness of the data. The pre-test consi ed of a 
two-page survey taking approximately 20 minutes or less to complete.  A post-test was 
administered in a similar fashion; however, the dissertation utilized data collected at pre-
test only. I personally conducted all interviews to ensure uniform delivery to all 
participants. 
3.5.2 Measures and Instrumentation 
 
Dependent Variable: Intention to Enroll in a Therapeutic Clinical Trial 
Participant’s intention to enroll in a clinical trial was the main study outcome.  A 
single item question on the survey was used to assess the participant’s hypothetical 
willingness to participate in a clinical trial on a likert-type response scale.  Scores on this 
item were 5 = Very likely; 4 = Somewhat likely; 3 = Not Sure; 2 = Somewhat unlikely; 
1= Very unlikely. A high score indicated a greater intention to enroll.  
To account for the proportion of the sample responding “Not Sure” (16.2%), the 
same question was asked of the study sample a second time, however only providing a 
‘Yes’ or ‘No’ response option.  This resulting binary intention variable was used a  the 
main study outcome/dependent variable. In some cases the analysis used the binary 
intention variable, and this was noted in each section as appropriate. Table 2 shows the 
distribution of responses to these two items in the sample.  
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At this moment, is it likely that you would sign up to 
participate in a therapeutic clinical trial 
18 (16.2%) 39 (35.1%) 18 (16.2%) 15 (13.5%) 21 (18.9%) 
 
Binary Assessment: Yes No 
At this moment, is it likely that you would sign up to 
participate in a therapeutic clinical trial 
50 (45%) 61 (55%) 
 
Independent Variables: Attitudinal Barriers 
Each of the independent variables represented attitudinal barriers to trial 
participation documented in the literature.  Six dimensions of attitude were measured for 
the parent study, four of which were used for the dissertation study and are detail d here.  
As there was no previously validated instrument to measure the exact attitudes identified 
for study a new one was developed for this purpose and was pilot tested and validated in 
this population for the dissertation study.  These items were all adapted from existing 
scales, which measured concepts similar, but not identical to those assessed in thi  study.  
Constructs were assessed using a 5-item scale with likert-type respons s scored 1 = 
Strongly Disagree; 2= Somewhat Disagree; 3 = Not sure/Neither; 4 = Somewhat Agree; 
5= Strongly Agree. The responses for each item were summed to produce a composite or 
total score for each attitude dimension with a possible range from 5 to 25.  Some items 
were reverse scored as required such that a high score indicated higher influence. 
The four attitudinal scales, items, and their response frequencies are shown in 
tables 3 through 6 followed by the two scales for the moderator variables and their items 






1. Fear and distrust of the medical establishment scale assessed fear and distrust of 
doctors, scientists and the government.  It included five statements.  Re ponses were 
given on a 5-point scale. For items 1 and 2, the lead in question was: “On a scale from 
‘very much’ to ‘not at all’, how much would each of the following affect your decision 
whether or not to participate in a clinical trial?”  For items 3 and 4, the lead in question 
asked, “How much do you ‘agree’ or ‘disagree’ with the following statement?” 
Table 3: Distribution of Responses on Fear and Distrust of the Medical Establishment Scale: Frequencies and 
Percents 
 Not at All Not Much Not Sure Somewhat Very Much 
 
1. Trust in the doctor who offers you the trial 6 (5.4%) 4 (3.6%) 5 (4.5%) 11 (9.9%) 85 (76.6%) 
 
2. The reputation of the treatment center 
where the trial is done 











3. I can not trust health care workers 50 (45.0%) 29 (26.1%) 4 (3.6%) 23 (20.7%) 5 (4.5%) 
 
4. I am suspicious of clinical trials 22 (19.8%) 19 (17.1%) 13 (11.7%) 43 (38.7%) 14 (12.6%) 
 
5. I am suspicious of information I receive 
from researchers 
21 (18.9%) 30 (27.0%) 13 (11.7%) 34 (30.6%) 13 (11.7%) 
 
2. Concern about the ethical conduct of investigators cale included five statements. 
The lead in questions for this scale were as follows: “How much do you ‘agree’ or 
‘disagree’ with the following statements” (items 6 - 9).  “From ‘very likely’ to very 





















6. Most clinical research is ethical 
 
27  (24.3%) 56(50.5%) 12 (10.8%) 9 (8.1%) 7 (6.3%) 
7. Researchers do not care about me or my well 
being 
32 (28.8%) 36 (32.4%) 12 (10.8%) 20 
(18.0%) 
11 (9.9%) 
8. My doctor would not ask me to participate in a 
clinical trial if he or she thought it would hurt me 
66 (59.5%) 25 (22.5%) 3 (2.7%) 10 (9.0%) 7 (6.3%) 
9. I am confident the group of people who approve 
clinical trials make sure all participants are 
treated fairly 












10. How likely do you think it is that you might be 
used as a guinea pig if you were in a clinical 
trial? 
 




3. Fear of losing one’s rights by signing a research informed consent document scale 
was a five item likert-type response set. The lead in question for all items was: “If I were 
to sign an informed consent for a clinical trial…” 
Table 5: Distribution of Responses on Fear of losing one’s rights by signing a research informed consent document 











11. I could still ask my doctors any questions that I 
want to 
94 (84.7%) 14(12.6%) 1 (0.9%) 2 (1.8%) 0 (0%) 
12. If doctors took my blood they could do tests on it 
they have not told me about 
19 (17.1%) 13 (11.7%) 9 (8.1%) 35 (31.5%) 35 (31.5%) 
13. I would only be agreeing to do what is explained 
to me in the consent form 
68 (61.3%) 32 (28.8%) 6 (5.4%) 1 (0.9%) 4 (3.6%) 
14. I could still change my mind about participating 
at any time 
84 (75.7%) 23 (20.7%) 1 (0.9%) 2 (1.8%) 1 (0.9%) 
15. The researchers would only do what is stated in 
the consent form 
42 (37.8%) 49 (44.1%) 5 (4.5%) 7 (6.3%) 8 (7.2%) 
 
 
4. Worry that investigators will treat poor or Black patients unfairly  
 
The lead in question for items 16 through 19 was: “How much do you ‘agree’ or 






Table 6: Distribution of Responses Worry That Investigators will treat poor or Black patients Unfairly Scale: 











16. Black people in clinical trials receive the same 
care from doctors and health care workers as 
people of other races and ethnicities 
16 (14.4%) 40(36.0%) 12 (10.8%) 21 (18.9%) 22(19.8%) 
17. If I were to enroll in a clinical trial my doctors 
would treat me with dignity and respect 
56 (50.5%) 39 (35.1%) 9 (8.1%) 7 (6.3%) 0 (0%) 
18. Compared with others, poor people are used 
more in research without their permission 
14 (12.6%) 17 (15.3%) 25 (22.5%) 25 (22.5%) 30 (27.0%) 
19. Black people are used more in research with their 
knowledge or permission than other races and 
ethnicities 
18 (16.2%) 15 (13.5%) 25 (22.5%) 27 (24.3%) 26 (23.4%) 





20. How often, if ever, do you think doctors 
prescribe medication as a way of experimenting 
on Black patients without their knowledge or 
permission 
12 (10.8%) 20 (18.0%) 38 (34.2%) 26 (23.4%) 15 (13.5%) 
 
Moderator Variable 1: Centrality  
 
Racial identity was measured using the Multidimensional Inventory of Black Identity, 8-
item Seller’s Centrality Scale (Sellers, Smith et al, 1998). The Centrality dimension in 
Seller’s Identity Scale (1997) has established construct validity and displayed moderate 
internal consistency when used in a study of African American students (Cronbach’s α  = 
0.78).  Rowley et al. (1998) reported similar measures of reliability with α  = 0.73 in a 
study of college students, and α  = 0.73 in a population of high school students. Mean 
scores were found to range from 5.20 (SD 1.14) for African American students at a 
predominantly white university, to 5.28 (SD =0.98) for African American students at an 
African American university. Items 1, 4 and 8 were modified slightly to create positively 
phrased statements rather than the reversed coded items in the original scale. Possible 
range for the composite score was 8 to 40.  The stem of the questions was: “To what 
















1. Overall, being Black has a lot to do with how I 
feel about myself. 
39 (35.1%) 8(7.2%) 6 (5.4%) 15 (13.5%) 43 (38.7%) 
 
2. God and only God can heal cancer 15 (13.5%) 6 (5.4%) 6 (5.4%) 16 (14.4%) 68 (61.3%) 
 
3. My destiny is tied to the destiny of other Black 
people. 
41 (36.9%) 16 (14.4%) 4 (3.6%) 19 (17.1%) 31 (27.9%) 
4. Being Black is important to my sense of what 
kind of person I am. 
22 (19.8%) 9 (8.1%) 9 (8.1%) 23 (20.7%) 48 (43.2%) 
5. I have a strong sense of belonging to Black 
people. 
11 (9.9%) 11 (9.9%) 8 (7.2%) 25 (22.5%) 56 (50.5%) 
6. I have a strong attachment to other Black people 7 (6.3%) 12 (10.8%) 8 (7.2%) 26 (23.4%) 58 (52.3%) 
7. Being Black is an important reflection of who I 
am 
56 (50.5%) 20 (18.0%) 5 (4.5%) 14 (12.6%) 16 (14.4%) 
8. Being Black is a major factor in my social 
relationships 
28 (25.2%) 17 (15.3%) 5 (4.5%) 20 (18.0%) 41 (36.9%) 
 
 
Moderator Variable 2:  Belief in God as Healer 
 
The aspect of religious beliefs measured was the perception of ‘God as a healer’ 
as measured by an established scale (Holt et al., 2009). This construct assessed an 
individual’s belief that God acts as a healer in the event they have cancer, either directly 
or indirectly through physicians. This is a two dimensional construct. The scale had hig  
internal reliability with Cronbach’s α  = 0.86 (Holt et al., 2009). Total score for the 
construct ranges from 9 to 45. The scale consists of 9-items as follows and Table 8 details 





















God works through the doctors to heal cancer 3 (2.7%) 3(2.7%) 5 (4.5%) 20 (18.0%) 80 (72.1%) 
 
God and only God can heal cancer 16 (14.4%) 18 (16.2%) 9 (8.1%) 9 (8.1%) 59 (53.2%) 
 
My experience with cancer has made me realize that 
God is the ultimate healer 
3 (2.7%) 6 (5.4%) 8 (7.2%) 10 (9.0%) 84 (75.7%) 
I believe that if one is healed of cancer, it is God’s 
will 
4 (3.6%) 7 (6.3%) 4 (3.6%) 16 (14.4%) 80 (72.1%) 
I believe that God gives the doctors/nurses the ability 
to heal cancer 
2 (1.8%) 7 (6.3%) 7 (6.3%) 16 (14.4%) 79 (71.2%) 
I believe that if you ask God for healing, He will heal 
you 
6 (5.4%) 7 (6.3%) 9 (8.1%) 23 (20.7%) 66 (59.5%) 
I believe that having a close relationship with God 
will lead to cancer recovery 
7 (6.3%) 7 (6.3%) 5 (4.5%) 30 (27.0%) 62 (55.9%) 
Healing can only occur from God, not from medicine 
or doctors 
28 (25.2%) 28 (25.2%) 8 (7.2%) 12 (10.8%) 35 (31.5%) 
Doctors give the cancer treatment, but God does the 
actual healing 




To assess the influence of various other characteristics, several contextual 
variables were assessed directly or by proxy measure.  These are described below and 
shown in Table 1. 
Acculturation: On the demographic survey, country of birth (United States versus other) 
was assessed.  For foreign-born respondents (n = 13), the length of time they have been 
living in the U.S. was assessed.  Also, generation was assessed by asking whether or not 
their parents were born in the United States.  The primary language spoken at home was 
also assessed. These responses were translated to a proxy measure of high (46.2%), 
medium (38.0%), and low acculturation (15.8%) based on generation, length of time in 






Experiences of racism were thought to be important in considering responses to questions 
about racial centrality and potentially any questions related to an intention to enroll in a 
clinical trial.  As such the decision was made to assess whether personal experiences with 
racism may relate to the individual attitudes under study. Due to limited time and space 
on the demographic questionnaire a single item was added to assess study participant’s 
personal experience with racism. This asked: “Overall, during your lifetime, how much 
have you personally experience racism?” Response options and corresponding scores 
were: 1= Not at all (15.3%); 2= Not much (33.3%); 3 = Not sure (13.5%); 4 = Somewhat 
(27.9%); 5 = Very Much (9.9%). 
Socioeconomic Status was measured by average household income, and split into 
categories as High, medium and low 
Dichotomous Variables 
 
Dichotomous versions of the independent variables were created and also tested in 
separate models in addition to the likert-type variables.  For each variable a mean split 
was used to classify each participant as either ‘high’ or  ‘low’ for that category depending 
upon their total score being above or below the mean. 
God as Healer: The mean score on this scale was 37.29 and anyone scoring above this 
(59.5% of the sample) was considered High, and below this (40.5% of the sample) was 
considered low belief.  Due to the distribution of responses on this scale, only the 





Centrality: The mean score was 24.86 and participants were categorized as having high 
centrality if their scores were greater than this (56.8% of the sample) and low centrality 
below this (43.2%). Due to the distribution of responses on this scale, only the continuous 
version of this variable was entered into the multivariate models. 
Distrust of the medical establishment: The mean score was 8.09 and anyone scoring 
above this (54.1% of the sample) was considered High on the distrust scale, and below 
this (45.9% of the sample) was considered low on the distrust scale.
Concern about ethical conduct of investigators: The mean score on this scale was 11.71 
and anyone scoring above this (46.8% of the sample) was considered High, and below 
this (53.2% of the sample) was considered low belief. 
Fear of losing rights after signing research informed consent: The mean score was 9.58 
and anyone scoring above this (45.0% of the sample) was considered high belief, and 
below this (55.0% of the sample) was considered low belief. 
Worry about being treated unfairly: The mean score on this scale was 14.36 and anyone 
scoring above this (49.5% of the sample) was considered High, and below this (50.5% of 
the sample) was considered low belief 
 
3.6 Data Analysis Plan 
 
SPSS v. 18.0 was used for all analyses.  First, the reliability and validity of scales 
were examined.  Next, bivariate associations were assessed.  Finally multivariate 
associations and interactions were estimated.  An alpha level of .05 was assumed for all 
analyses.  




A principal components analysis for the items for each of the four attitudinal 
scales was performed using SPSS to establish the basic psychometric properties.  
Principle components analysis, using PROMAX oblique rotation explored the factor 
structure of these four scales.  In addition, the two validated scales used for Racial 
Identity and Belief in God as Healer were assessed for internal reliability in this study 
population. 
3.6.2 Bivariate Analysis 
 
Correlation analyses examined the relationships between the attitude scales and 
the likert outcome of the dependent variable. Chi-square analyses were the primary
technique to assess relationships with the binary dependent variable.  Bivariate 
associations using analyses of variance assessed relationships between all scales (i.e., the 
attitudinal scales, the moderators and the dependent variable likert scale) with 
demographic variables. The latter are included for reference as Appendix I. 
3.6.3. Regression Analyses 
 
 Logistic regression analysis was chosen as the primary multivariate n lytic method 
based on the binary main study outcome variable (Intention to enroll: Yes/No).   Due to 
the exploratory nature of this study, a forced entry method was used as it doe not r ly on 
some level of ‘a priori’ theoretical knowledge of the basic relationships between th  
variables.  There is very scant literature to date that has looked at either racial centrality 
or belief in God as a healer in this context, thus there was otherwise limited theoretical 
guidance for this decision.   
A baseline regression model was established to determine necessary covariates to 
include. There were no statistically significant differences in intention to eroll based on 
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different levels of the socio-demographic variables in the sample, as such four covariates 
were retained due to their conceptual relevance to clinical trial partici tion.  Age, 
gender, marital status and experience of racism were all controlled for in each model.  
Unadjusted models for each of the attitudes and the moderators were first tested, followed 
by adjusted models for each.  Next, each interaction was tested: attitude 1 by cntrality; 
attitude 2 by centrality; attitude 3 by centrality; and attitude 4 by centrality. This was then 
repeated with the corresponding interactions using the belief in God as healer variable. 
Finally racial centrality and religious belief were stratified to explore whether the 
predictive value of these models was modified at different levels of the proposed 
moderator variables. As described earlier, the mean split in each variable was used to 
classify participants as either high or low for each of centrality and level of religious 
belief. 
3.6.4 Missing Data 
 
As the survey instruments was interviewer administered, this ensured that 
complete answers for each survey item were obtained. Thus, no missing data occurred.   
 
3.6.5 Power Analysis 
 
Based on analysis of the study hypotheses and assuming a 5% attrition rate, and 
80% power, recruitment of 114 participants was the target of the parent study. WCI 
planned to recruit this sample of 114 African American cancer patients potentially 
eligible for therapeutic trials over an 11-month period.  Three patients were ultimate y 
ineligible thus the final sample size was 111. 
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Since the dissertation used data from the parent study, a final power analysis ws 
conducted using G*Power, (Faul et al., 2009) to determine the actual power achieved for 
these analyses.  Based on a sample size of 111, alpha of 0.05 and the set of predictors 
selected for the final multivariate models and their distribution, the actual power achieved 
for this study and the primary outcomes was 68%. 
3.7 Human Subjects Concerns 
 
This proposal was submitted and approved by the University of Maryland, 
College Park Institutional Review Board (IRB) and the Georgetown University/Medstar 
Health IRB through a joint agreement (See Appendix B). 
Prior to administration of any study instruments or viewing of the video, I 
executed a thorough informed consent with each study participant (See Appendix C for 
consent form).  After completing the pre-test, watching the video and completing the 
post-test, all participants received a $25 gift card to Target as acknowledgment for their 
participation and appreciation of their time. Since the study site required all visitors and 
patients to pay for parking, those who drove to the site were given a parking voucher to 
cover the cost of their parking.  
An additional consent form was also signed for those participants agreeing to do a 
qualitative follow-up study via telephone interview, which is beyond the scope of this 
dissertation (Appendix D). They were all provided a copy of their consent forms. 
Participants were informed there were no major risks to participating in thestudy; 
however, that there was a possibility that they may feel uncomfortable discussing some of 
the study topics, particularly surrounding race, their religious beliefs and cancer.  Further, 
there was a possibility that some participants would feel distress discuss ng treatment 
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options, especially if they were unsure at the time of their course of action. Caution was 
taken to administer each interview with compassion to minimize distress and allow the 
participant to stop or take a break as needed.  In the instance where participants expressed 
a desire to further discuss participating in a clinical trial, they were referred to speak with 
their oncologist about trials for which they may be eligible.  If they expressed any other 
issues, they were referred to the patient liaison in WCI’s patient support service  center to 
help them identify resources and provide guidance.  The patient support services is a 
resource for patients and their families, providing access to licensed social w rkers, 




CHAPTER FOUR: RESULTS 
4.1 Introduction 
This chapter describes the results of the current study of the role of racial identity 
and religious beliefs in the attitudes of African American cancer patients’ intention to 
enroll in therapeutic clinical trials. These results describe how the proposed moderators 
relate to four attitudinal barriers and subsequently to trial participation inte t on among 
the study population.  Also described is the relative contribution of the attitudinal barriers 
and demographic characteristics to the intention to enroll in a clinical trial among the 
study population. The chapter concludes with a summary of the overall findings. 
4.2 Independent Variables: Attitudinal Barrier  
The first step in the analysis was to examine and establish the independent variables, 
the four attitudinal barriers.  Thus, a correlation matrix of all items was examined.  Next 
reliability coefficients for each of the four scales were examined.  Finally, factor analyses 
were conducted.    
4.2.1 Reliability Analysis of Scales 
Cronbach’s alpha was established for the four attitudinal scales.  This statistic 
measures how well the items in a scale correlate with the sum of the other items, 
measuring the consistency between these individual items. Cronbach’s alpha, item means 
and standard deviations, as well as total scale means and variances are summarized in 
Table 9. For general interpretation of the Cronbach’s alpha for each scale, the following 
rules of thumb provided by George and Mallery (2003) were used.  Greater than 0.9 is 
considered excellent, greater than 0.8 is considered good, greater than 0.7 is acceptable, 
greater than 0.6 is questionable, greater than 0.5 is Poor, and below 0.5 is unacceptable. 
 
 72 
1. Fear & Distrust of Medical Establishment 
 
The Cronbach’s alpha for the fear and distrust of the medical establishment scal  
was 0.586 for the original 5-items, which is considered relatively low, or ‘questionable’. 
The removal of two items increased the alpha to 0.746 which is considered “good” per 
George and Mallery (2003). The resulting final scale had 3 items, with a total scale mean 
of 8.10 (possible range 5 to 15) and variance of 10.73.  These 3 items included: “I can not 
trust health care workers”, “I am suspicious of clinical trials” and  “I am suspicious of 
information I receive from researchers” 
2. Concern about Ethical Conduct of Investigators 
 
The original alpha for the concern about ethical conduct of investigators scale of 
five items was low at 0.528 (considered ‘poor’) and an analysis of the item-total statistics 
did not suggest any improvement with the removal of items from this scale. The final 
scale mean was 11.71 (in a possible range of 5 through 25). Standard deviation was 
3.607. 
3. Fear of Losing Rights by Signing Informed Consent 
 
Cronbach’s alpha was 0.602 for the five-item scale measuring the extent to which 
participants were fearful of losing their rights after signing an informed consent form for 
a clinical trial. This represents an acceptable alpha for this scale, so all 5 items were 
retained and the mean score on this scale was 9.58 where 5 was the minimum and 25 the 





4. Worry About Being Treated Unfairly (Poor/Minority) 
 
Cronbach’s alpha was 0.636 for the full five-item scale of worry about being 
treated unfairly, which again was considered acceptable and no items were removed. The 
mean score on this scale was 14.36 where 5 was the minimum and 25 the maximum. 
 













Variance Scale sd 
Fear and Distrust 
(original) 0.59 5 3.43 1.54 17.13 14.49 3.81 
        
Fear and Distrust 
(Final) 0.75 3 2.70 1.80 8.10 10.73 3.23 
        
Ethical Conduct 0.53 5 2.34 1.50 11.71 13.01 3.61 
        
Fear of Losing 
Rights 0.60 5 1.92 1.02 9.58 9.81 3.13 
        
Worry about Being 
Treated Unfairly 0.64 5 2.87 1.70 14.36 15.96 4.00 
        
Centrality (original) 0.68 8 3.39 0.42 27.09 47.06 6.86 
        
Centrality (Final) 0.84 7 3.55 2.42 24.86 60.61 7.79 
        











4.2.2 Correlation of Individual Items on Attitudes Scales 
Pearson product-moment correlation coefficients were calculated to assess the 
strength of association between each individual item on the attitudes scales. Corr lation 
of the items with each other and with the single response item to the intention to enroll 
outcome were examined.  The correlation matrix in table 10 shows the relationship 
between the twenty items comprising the attitudes scales. The individual items as listed in 
the matrix by number are:  
1. Trust in the doctor who offers you the trial 
2. The reputation of the treatment center where the trial is done 
3. I can not trust health care workers 
4. I am suspicious of clinical trials 
5. I am suspicious of information I receive from researchers 
6. Most clinical research is ethical 
7. Researchers do not care about me or my well being 
8. My doctor would not ask me to participate in a clinical trial if he or she thought it would 
hurt me 
9. I am confident the group of people who approve clinical trials make sure all participan s 
are treated fairly 
10. How likely do you think it is that you might be used as a guinea pig if you were in a 
clinical trial? 
11. I could still ask my doctors any questions that I want to 
12. If doctors took my blood they could do tests on it they have not told me about 
13. I would only be agreeing to do what is explained to me in the consent form 
14. I could still change my mind about participating at any time 
15. The researchers would only do what is stated in the consent form 
16. Black people in clinical trials receive the same care from doctors and health care workers 
as people of other races or ethnicities on clinical trials 
17. If I were to enroll in a clinical trial my doctors would treat me with dignity and respect 
18. Compared with others, poor people are used more in research without their permission 
19. How often, if ever, do you think doctors prescribe medication as a way of experimenting 
on Black patients without their knowledge or permission? 
20. Black people are used more in research without their knowledge or permission than 
others races and ethnicities 




Seven of the 20 attitude items were significantly correlated with the intention item. At 
the p = 0.01 level, significant correlations with the intention item were found for item 4 (r 
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= - 0.29); item 5 (r = - 0.34); item 18 (r = - 0.353); and item 19 (r = - 0.22).  At the p = 
0.05 level, item 7 (r = - 0.196); item 19 (r = - 0.234); and item 20 (r = 0.223) were 
correlated with the intention item.  As depicted in table 10 many of the individual items 
were significantly correlated with each other. For example item 4: “I am suspicious of 
clinical trials” was strongly correlated with 12 of the other items. Item 7: “Researchers do 
not care about me or my well being”, was significantly correlated with 10 of the ther 
items. Items 1 and 2 were the only items having significant correlations only with each 
other and no other items on the attitudes scales.  These two items asked “How much 
would the following affect your decision whether or not to participate in a trial”: Item 1: 
“Trust in the doctor who offered you the trial”, and item 2: “The reputation of the 
treatment center where the trial is done” (r = 0.623)
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Table 10: Pearsons Correlation of Individual Items on Attitudes Scale and Intention Item 
** Correlation is significant at the 0.01 level (2-tailed).                             *Correlation is significant at the 0.05 level (2-tailed). 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Y 
1 1 .623** .017 -.011 .048 -.133 .007 -.015 .023 -.106 -.011 -.097 -.122 .085 -.039 -.027 -.066 .034 .050 .008 -.011 
2   1 .079 -.079 -.042 -.032 .009 -.064 .019 -.053 -.047 -.143 -.076 .027 -.019 .011 -.002 -.023 .144 -.013 .053 
3     1 .431** .380** .194* .351** .152 .171 .242* .207* .140 .071 .198* .077 .114 .091 .314** .126 .302** -.129 
4       1 .668** .117 .457** .149 .261** .179 .216* .304** .198* .232* .368** .223* .294** .441** .227* .456** -.292** 
5         1 .194* .453** -.008 .275** .260** .219* .243* .065 .219* .252** .264** .104 .409** .254** .376** -.335** 
6 
          1 .207* .005 .131 .091 .158 -.038 -.024 .091 -.059 .182 .201* .112 .143 .137 -.132 
7             1 .206* .261** .307** .133 .199* .220* .164 .349** .299** .107 .368** .220* .375** -.196* 
8               1 .142 .121 .266** .119 .172 .109 .129 .146 .106 .140 .096 .205* -.088 
9 
                1 .335** .201* .151 .201* -.044 .372** .293** .174 .353** .283** .341** -.180 
10 
                  1 .058 .210* .049 -.100 .165 .230* .096 .262** .190* .245** -.234* 
11                     1 .084 .451** .379** .320** .175 -.009 .101 .182 .152 -.106 
12                       1 .224* .174 .217* .224* .079 .302** .237* .417** -.161 
13                         1 .280** .533** .142 .031 .162 .094 .165 .070 
14 
                          1 .195* .196* -.102 .123 .128 .167 .062 
15 
                            1 .221* .202* .304** .126 .345** -.035 
16 
                              1 .270** .267** .121 .202* -.147 
17 
                                1 .068 -.039 .093 -.127 
18 
                                  1 .367** .622** -.353** 
19                                     1 .446** -.292** 
20 
                                      1 -.223* 
Y 




4.2.3 Principle Components Analysis 
A factor analysis was conducted in order to determine if the underlying structure of the 
attitudinal measures analytically corresponded to the conceptual scales.  As this was the first use 
of the attitudinal items, a principle components analysis (PCA) was conducted for an 
examination of the full set of 20 items used to measure the four attitudinal constru ts.  
As there was known correlation between some of the attitudinal variables (see Table 12), 
an oblique rotation  (PROMAX) of the correlation matrices was selected. The resulting Kaiser-
Meyer-Olkin (KMO) statistic measuring sampling adequacy was .753, indicating PCA was 
appropriate for these data. The Bartlett’s test of sphericity was also c lculated to test the null 
hypothesis that the variables were uncorrelated.  It was found to be statistically ignificant (Chi-
square= 606.60; 190 df; p <0.01). This also suggested the appropriateness of a factor analysis for 
these data (Field et al., 2003).  
Conducting an exploratory factor analysis, results suggested a six factor solu ion for the 
20 items assessing attitudes.  This was determined by examination of the scree plot, Eigen 
values, and factor loadings.  Items loading with at least .55 were considered. For the fear and 
distrust of the medical establishment scale, two components were extracted. Similarly for the 
worry of being treated unfairly scale, two factors were extracted. Concern of ethical conduct and 
fear of losing rights scales both had one factor each extracted.  
Next, the PCA was conducted forcing a 4-factor solution to determine how these item  
loaded on each factor. With a forced 4-factor solution, the solution resulted in a 48.1% total item 
variance explained (compared with 60.2% of total item with the 6 factor solution).  There was 
some overlap in how the items loaded on the four factors (See Appendix H), yet the decision was 
made to maintain the original four scales for conceptual reasons.  
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4.3 Moderator Variables 
4.3.1 Racial Identity: Seller’s Centrality Scale 
 
Initially, the 8-item Seller’s Centrality Scale was examined. With all original items 
retained, the internal consistency was lower than previously reported values in th  literature 
(alpha = 0.675).  An examination of item-statistics suggested the removal of one item: “Being 
black is an important reflection of who I am.”  Removal of this item resulted in the 7-item final 
scale which was used for the study, raising the overall alpha to 0.841 which is considered good 
reliability and is higher than that reported for previous uses of this scale in other populations (see 
Table 9).  PCA of the centrality scale in this population revealed a uni-dimensional tructure with 
all items loading on just one factor. Table 10 shows these factor loadings for the cen rality scale.  
Table 11: Factor Loadings for Centrality Scale 
 
4.3.2 Belief in God as Healer 
 
Table 9 includes the descriptive statistics associated with the God as Healer scale which 
assessed levels of the proposed moderator variable among the study population. Mean scores and 
variances were computed for each item in the scale and all summary statistic  re presented. 
Being Black is important to my sense of what kind of person I am. 0.811 
Being Black is a major factor in my social relationships. 0.775 
I have a strong sense of belonging to Black people. 0.738 
 I have a strong attachment to other Black people. 0.715 
 In general, being Black is an important part of my self-image. 0.708 
My destiny is tied to the destiny of other Black peo le. 0.670 
Overall, being Black has a lot to do with how I feel about myself. 0.619 
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The reliability for the God as Healer scale was good with an alpha of 0.837 in this
population. This is consistent with the Cronbach’s alpha previously reported by the researchers 
who developed and validated this scale (0.86) (Holt et. al, 2009). 
Factor loadings for the God as Healer scale (shown in Table 12) revealed two distinct
dimensions for the scale, which is also consistent with previous use in the literature (Holt et. al, 
2009). Seven items loaded onto the first dimension, God as direct healer, and the remaining two 
items loaded onto the second dimension for God as indirect healer through medicine and doctors. 
Table 12: Factor Loadings for God as Healer Scale 
Factor 1: God as Healer- Directly 
 God and only God can heal cancer 0.831 
 Doctors give the cancer treatment, but God does the actual healing 0.804 
 Healing can only occur from God, not from medicine or doctors  0.751 
 I believe that if one is healed of cancer, it is God’s will 0.740 
 I believe that if you ask God for healing, He will heal you 0.736 
 My experience with cancer has made me realize that God is the ultimate healer  0.651 
 I believe that having a close relationship with God will lead to cancer recovery 0.649 
Factor 2: God as Healer through Medicine, and Doctors 
 God works through the doctors to heal cancer 0.781 
 I believe that God gives the doctors/nurses the ability to heal cancer 0.778 
 
4.7 Correlation Analysis 
Pearson product-moment correlation coefficients were calculated to assess the strength of 
association between the composite score variables on each of the four attitudinal scales, the two 
moderator scales and the Likert form of the intention to enroll variable (See Table 13).  The 
correlation between the two proposed moderators God as healer and racial centrality was 0.23 
and was significant at the 0.05 level (2-tailed).  Total belief in God as healer w s also 
significantly correlated with distrust at 0.05 level (r =0.21).  Eleven of the remaining correlations 
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were significant at the 0.01 level. Specifically, concern about the ethical condu t of investigators 
was positively and significantly correlated with distrust of the medical est blishment scale (r = 
0.49) and worry of being treated unfairly due to being poor or minority scale (r = 0.58).  It was
also significantly negatively correlated with intention to enroll (r = -0.28). Distrust of the medical 
establishment scale was significantly correlated with a fear of losing one’s rights by signing a 
research informed consent scale (r =0.38) and worry of being treated unfairly due to being poor 
or minority scale ( r =0.53).  Finally it had a statistically significantly negative correlation with 
intention to enroll (r = -0.31). Worry of being treated unfairly due to being poor or minority was 
significantly associated with a concern about losing one’s rights after signing a consent form (r = 
0.47); and statistically significantly negatively associated with intention to enroll ( r = -0.36). A 
fear of losing one’s rights after signing a consent form was significantly ssociated with a belief 
in God as healer (r =0.25), worry of being treated unfairly (r =0.47) and concern about ethical 
conduct of investigators (r =0.35).  
 
Correlational Research Questions 
 
Examination of these correlations provides some evidence of the support of the first two 
study hypotheses.  Hypotheses 1 and 2 investigate the relationship between racial identity and 
intention to enroll, and belief in God as healer and intention to enroll, respectively. Power 
analysis using G*Power revealed that with the sample size of n=111, and alpha set to 0.05 ( wo-
tailed bi-directional test), a correlation coefficient of 0.30 or larger would be significant in either 
a positive or negative direction Power (1- β) = 0.907. 
Hypothesis 1 suggests that participants with higher levels of racial identity will be more 
likely to express intention to enroll in a therapeutic clinical trial: proposing a positive correlation 
between the two. Table 12 reveals this relationship is not statistically significant (r = -0.05, 
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p=.592).  The direction of the correlation is negative implying a higher level of racial identity 
correlates with a decreased intention to enroll in a clinical trial, yet itis close to zero and not 
statistically significant.  Thus there is no evidence to support hypothesis 1 through correlation 
analysis. 
Hypothesis 2  proposes that participants with stronger belief in the notion of God as 
healer will be less likely to express an intention to enroll in a therapeutic clinical trial, suggestive 
of a negative correlation between the two variables.   Although the association is in the 
hypothesized direction, showing that the stronger the belief in God as healer the less likely a 
participant has intention to enroll, the correlation is weak and not statistically significant (r = -
0.027, p =0.78). Thus the correlational analyses do not support Hypothesis 2.   
 
Table 13:  Pearson Correlations of Attitudes, Moderators and Intention Variables 
 
Distrust Ethics Rights Worry  Centrality 
God as 
Healer Intention 
Distrust 1 0.49**  0.38**  0.53**  0.11 0.21* - 0.31**  
Ethics  1 0.35**  0.58**  0.03 0.10 - 0.28**  
Rights   1 0.47**  -0.07 0.25**  - 0.07 
Worry     1 0.03 0.06 - 0.36**  
Centrality     1 0.23**  -0.05 
God as Healer 
     1 - 0.03 
Intention 
      1 
**Correlation is significant at the 0.01 level (2-tailed). 




4.8 Binary Dependent Variable Analyses 
Next, the binary version of the dependent variable was considered.  Overall 
intention to enroll in a clinical trial (yes versus no/not sure) was examined to first identify 
if there were any differences in intention based on the distribution of demographic 
variables within the sample. Chi-square tests of independence were performed t  examine 
the relationship between this binary intention to enroll variable and all background 
variables shown in Table 14. 
While there were some differences in the percentage of each group expressing 
intention to enroll, none of these were statistically significant at α = 0.05. For instance, 
within this sample a greater proportion of men (55.6%) expressed intention to enroll than 
did women (41.7%) at baseline. Similarly a greater proportion of foreign-born 
participants (53.8%) expressed intention to enroll than did the corresponding proportion 
for US-born nationals (43.9%).  It should be noted however that the limited sample size 





Table 14: Proportion of Intention to enroll by Demographic Variable 
  Intention To Enroll N (%) 
  Yes Chi-Sq p-value 
Gender Male 15 (55.6%) 
1.591 0.207  Female 35 (41.7%) 
Age 30-39 4 (57.1%) 
1.807 0.771 
 40-49 5 (41.7%) 
 50-59 18 (50.0%) 
 60-69 15 (45.5%) 
 70-89 8 (34.8%) 
Marital Status Married or Equivalent 19 (39.6%) 
1.019 0.313  Not Married 31(49.2%) 
US vs Foreign Born US Born 43 (43.9%) 
0.461 0.497  Foreign Born 7 (53.8%) 
SES Low 16 (50.0%) 
0.822 0.663 
 Middle 15 (39.5%) 
 High 19 (46.3%) 
Education Level < High School 3 (27.3%) 
2.961 0.398 
 High School grad or GED 15 (51.7%) 
 
Some College or Technical 
School 17 (51.5%) 
 College Graduate 15 (39.5%) 
Number of Children None 12 (60.0%) 
2.204 0.138  1 or more 38 (41.8%) 
Experience of Racism Not At All 8 (47.1%) 
1.026 0.906 
 Not Much 15 (40.5%) 
 Not Sure 6 (40.0%) 
 Somewhat 15 (48.4%) 
 Very Much 6 (54.5%) 
Number of Times 
Attending Church per 
month 
None 14 (56.0%) 
1.575 0.455 
1-3 Times 14 (41.2%) 
4 or more 22 (42.3%) 
Family History of 
Cancer 
Yes 34 (43.0%) 
0.446 0.534 No 16 (50.0) 
Belief in God as 
Healer High 26 (39.4%) 
2.100 0.147  Low 24 (53.3%) 
Racial Centrality High 28 (44.4%) 




4.10 Regression Analysis 
Multivariate logistic regression was conducted to assess the role of each predictor 
in the study population’s intention to enroll in a clinical trial. These relationships are 
summarized beginning with model 1 in Table 15. 
Model 1  
 Model 1 assessed Hypothesis 1 by regressing the intention to enroll variable on 
the centrality scale.  In an unadjusted model, using the continuous form of the centrality 
variable (model 1a), the relationship was not statistically significant (OR = 1.002, p = 
0.926).  Regressing intention to enroll on the binary form of the centrality variable 
(model 1b) the relationship was also not statistically significant (OR = 1.058, p = .884). 
Thus, again Hypothesis 1 seems unsupported. 
Table 15: Unadjusted Regression Model: Racial Centrality 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
1a Racial Centrality (Likert) 1.002 0.955 1.052 .926 
1b Racial Centrality (Binary) 1.058 0.884 2.249  .497 
 
Model 2 
Model 2 assessed Hypothesis 2 (Table 16). Three unadjusted models (2a, 2b and 
2c) were used to test the direct ability of a belief in God as healer to predict a 
participant’s intention to enroll, using the binary version of the intention variable. As 
noted in Chapter 3, the two dimensions of the God as healer scale were parsed out and 
therefore model 2a tested the full scale (OR = 0.972, p = 0.277), model 2b tested God as 
direct healer subscale (OR = 0.962, p = 0.752) and model 2c tested subscale God as 
healer through doctors and medicine (OR = 0.969, p = 0.269). None of these models 




 The unadjusted model (2b) was run a second time using the binary measure of 
belief in God as healer (full scale), and this also was not found to be statistically 
significant (OR = 0.569. p =0.149) 
Table 16: Unadjusted Regression Model: God as Healer 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
2a God as healer (full scale- Likert) 0.972 0.922 1.023 .277 
2b God as direct healer dimension 0.962 0.752 1.230 .758 
2c God as indirect healer dimension 0.969 0.916 1.025 .269 
 2d God as healer (full scale- Binary) 0.569 0.264 1.223 .149 
 
Model 3 
In order to inform interaction analyses, the relationships between the attitudinal 
scales and the intention outcome variable were next assessed.  Table 17 shows unadjusted 
models assessing the predictive ability of each of the four attitudinal barriers showed that 
concern about the ethical conduct of investigators scale (OR = 0.840, p = 0.004), distrust 
of the medical establishment scale (OR = 0.834, p = 0.004), and worry about unfair 
treatment scale (OR = 0.873, p = 0.009) (Models 3a, 3b and 3c respectively) were 
significant predictors of intention to enroll when entered into separate models. 
Specifically, the higher a participant scored on these scales, the less likely they were to 
express intention to participate in a trial. A concern about loss of rights or autonomy after 
signing a consent form, fell short of significance in the unadjusted model (Model 3d, OR 





Table 17: Unadjusted Regression Models by Individual Attitude 
      95% CI for exp b 
Model Variable OR Lower Upper p-value 
3a Ethics 0.840 0.746 0.945 .004 
3b Distrust 0.834 0.736 0.945 .004 
3c Worry 0.873 0.788 0.966 .009 
3d Rights 0.941 0.83 1.07 .337 
 
Model 4 
The four attitudinal barriers scale were entered into Model 4 together without any 
other covariates using a forced entry method.  As shown in Table 18 each of the 
predictors fell short of statistical significance in this model. There was no adjustment for 
demographic variables in this model and no moderators entered, suggesting that these 
four variables together in the absence of covariates do not sufficiently predict intention to 
enroll in a clinical trial.  This raised concerns of collinearity because of the significant 
and moderate correlation between scales (see Table 13), thus all subsequent models were 
also run separately for each scale.  Each model testing hypotheses 3 and 4 was fitted fir t 
entering all four attitudinal constructs together in one adjusted model, followed by each 
attitude separately within each adjusted model to examine how this impacted the 
predictive value of the variables in each model.  
 
Table 18: Unadjusted Regression Models With all Four Attitudes 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
4 Ethics 0.898 0.779 1.034 .135 
 Distrust 0.893 0.769 1.038 .141 
  Worry 0.942 0.822 1.079 .385 






Demographic variables identified as potentially influential from the bivariate 
analyses or determined to be theoretically important were entered into Model 5.  These
analyses adjust for the effects of SES, gender, age, marital status and having ever 
experienced racism.  Age was entered into all models as a continuous variable; SES 
(high, medium, low), gender, marital status (married, not married) and experience with 
racism (some/very much versus not much/none) were all entered as categoricl variables 
(shown in Table 19). Reference categories in each case are indicated by ‘1’ values.
Demographic variables among the study population were entered in the second 
block following the four attitudinal barriers entered in block 1. Results showed that 
ethical conduct of investigators was the only statistically significant attitudinal variable in 
this adjusted model.  Participants with greater concern about ethical conduct were less 
likely to express intention to enroll (OR = 0.85; p =0.04) in the multivariate model. 
Each attitudinal variable was then tested separately.  Model 5a t sted concern 
about the ethical conduct of investigators scale in a model with the demographic 
covariates.  Again an increase in concern about ethical conduct scale was significantly 
associated with a decreased likelihood of enrollment (OR = 0.810, p = .01).  Model 5b 
tested only distrust of the medical establishment scale in the adjusted model. An increase 
in distrust was a significant predictor of a decreased intention to enroll (OR = 0.822, p = 
0.04).  Model 5c included the scale, Worry of being treated unfairly due to being poor or 
minority, and this was a significant predictor of a decreased odds of intention to enroll 
(OR = 0.877, p = 0.02).  Model 5d included the concern about losing rights scale, which 




Table 19: Adjusted Regression Model for All Four Attitudes 
      95% CI for exp b 
Model Variable OR Lower Upper p-value 
5 Ethics 0.850 0.726 0.995 .043 
 Distrust 0.889 0.758 1.043 .150 
 Worry 0.976 0.844 1.129 .744 
 With all 4  Rights 0.889 0.758 1.043 .451 
 attitudes Age 0.970 0.934 1.008 .126 
 Male (reference) 1    
  Female 0.481 0.174 1.329 .158 
  Married or Equivalent  (reference) 1    
 Not Married 0.561 0.210 1.495 .248 
  High SES  (reference) 1    
 Middle SES 0.781 0.261 2.334 .658 
  Low SES 1.318 0.372 4.662 .669 
 
Racism (some to very much) 
(reference) 1    
 Racism (not much to none) 1.011 0.411 2.483 .982 
 
Table 20: Adjusted Regression Models for Individual Attitudes 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
5a Ethics 0.810 0.713 0.920 .001 
Only Ethics  Age 0.972 0.936 1.008 .127 
 Male  1    
  Female 0.419 0.157 1.124 .084 
 Married or Equivalent (reference) 1    
 Not Married 0.528 0.206 1.350 .182 
  High SES (reference) 1    
 Middle SES 0.681 0.243 1.907 .464 
  Low SES 1.112 0.342 3.617 .860 
 Racism (some to very much, ref)  1    
 Racism (not much to none) 1.060 0.447 2.516 .895 
5b Distrust 0.822 0.720 0.939 .004 
Only 
Distrust Age 0.974 0.939 1.011 .164 
 Male 1    
 Female 0.603 0.233 1.558 .296 
 Married or Equivalent 1    
 Not Married 0.680 0.268 1.728 .418 
  High SES 1    
 Middle SES 0.890 0.310 2.554 .829 
  Low SES 1.583 0.472 5.313 .457 
 Racism (some to very much)  1    
 Racism (not much to none) 0.855 0.365 2.003 .719 
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     95% CI for exp b 
Model Variable OR Lower Upper p-value 
5c Worry 0.877 0.789 0.975 .015 
Only Worry Age 0.984 0.950 1.019 .371 
 Male 1    
  Female 0.591 0.271 1.509 .271 
 Married or Equivalent 1    
 Not Married 0.627 0.252 1.560 .316 
  High SES 1    
 Middle SES 0.762 .274 2.115 .601 
  Low SES 1.154 0.360 3.695 .810 
 Racism (some to very much)  1    
 Racism (not much to none) 0.862 0.372 1.997 .728 
5d Rights 0.944 0.829 1.075 .384 
Only Rights Age 0.981 0.947 1.016 .276 
 Male 1    
  Female 0.553 0.223 1.372 .223 
 Married or Equivalent 1    
 Not Married 0.646 0.264 1.581 .339 
  High SES 1    
 Middle SES 0.688 0.249 1.900 .470 
  Low SES 1.121 0.356 3.536 .845 
 Racism (some to very much)  1    
 Racism (not much to none) 0.878 0.372 1.994 .755 
 
4.10.1 Moderation Effects 
 
Model 6: Racial Centrality as a Moderator 
The first proposed moderation model had each of the four attitudinal barrier scales 
entered simultaneously, and racial centrality entered as an interaction term wi h each of 
the four attitudes.  None of the interaction terms were statistically significant in this 
adjusted model nor were the main effects, when all four attitudes were entered io the 







Table 21: Centrality Interaction Models with All Four Attitudes 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
6 Ethics 0.737 0.399 1.359 .328 
 Distrust 0.809 0.390 1.681 .571 
  Worry 0.890 0.513 1.546 .680 
  Rights 1.237 0.662 2.309 .505 
 Centrality 0.947 0.735 1.220 .673 
  Age 0.967 0.929 1.007 .101 
 Male (reference) 1    
  Female 0.477 0.170 1.338 .159 
  Married or Equivalent (reference) 1    
 Not Married 0.595 0.218 1.626 .312 
 High SES (reference) 1    
 Middle SES .817 0.268 2.494 .723 
 Low SES 1.587 0.422 5.972 .494 
 Racism (some to very much) (ref) 1    
 Racism (not much to none) 0.955 0.363 2.508 .925 
  Centrality*Distrust 1.003 0.978 1.029 .806 
  Centrality*Ethics 1.005 0.984 1.027 .628 
  Centrality*Rights 0.994 0.969 1.019 .633 




Again, due to concerns of multicollinearity each moderation model was then fit 
with only one attitudinal barrier at a time.  Model 6a first tested a moderation model as in 
Model 6, however it focused only on the ethics scale interaction with racial centrality.  
There were no significant interactions between centrality and the attitudinal barrier, nor 
were there any significant main effects, as shown in Table 22.  
Table 22: Centrality Interaction Model for Ethics 
    95% CI for exp b  
Model Variable OR Lower Upper p-value 
6a Ethics 0.679 0.427 1.082 .103 
  Centrality 0.941 0.793 1.116 .483 
 Age 0.969 0.932 1.007 .104 
 Male (reference) 1    
 Ethics Female 0.409 0.152 1.102 .137 
  Married or Equivalent (reference) 1    
 Not Married 0.549 0.213 1.418 .223 
 High SES (reference) 1    
 Middle SES 0.704 0.249 1.987 .507 
 Low SES 1.248 0.369 4.219 .721 
 Racism (some to very much)  (ref) 1    
 Racism (not much to none) 0.861 0.348 2.128 .916 
  Centrality*Ethics 1.007 0.990 1.023 .434 
 
Model 6b included the distrust scale, and this main effect was not a significant 
predictor of intention to enroll and none of the interaction effects were statistically 
significant.  Similarly, Model 6c and 6d tested the worry scale and the rights scale, 
respectively.  As shown in table 23 none of the main nor interaction effects were 
statistically significant. 
When initially examining each of the models involving centrality, an interaction 
term for centrality*racism was also tested. Despite its apparent conceptual relevance, this 
interaction was never found to be significant thus was left out of these models for the
sake of parsimony.  
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Table 23: Centrality Interaction Models by Individual Attitudes 
    95% CI for exp b  
Model Variable OR Lower Upper p-value 
  Distrust 0.775 0.488 1.231 .280 
6b Centrality 0.997 0.859 1.157 .966 
 Age 0.974 0.938 1.011 .162 
  Male 1    
  Female 0.600 0.232 1.553 .292 
 Distrust Married or Equivalent 1    
  Not Married 0.690 0.269 1.766 .439 
 High SES 1    
 Middle SES 0.911 0.316 2.627 .863 
 Low SES 1.643 0.483 5.584 .426 
 Racism (some to very much) (ref) 1    
 Racism (not much to none) 1.187 0.501 2.812 .698 
 Centrality*Distrust 1.002 0.985 1.020 .810 
  Worry 0.758 0.504 1.139 .182 
6c  Centrality 0.927 0.743 1.156 .499 
 Age 0.983 0.948 1.019 .350 
 Worry Male 1    
 Female 0.577 0.224 1.490 .256 
  Married or Equivalent 1    
 Not Married 0.634 0.255 1.581 .329 
 High SES 1    
 Middle SES 0.759 0.273 2.112 .598 
 Low SES 1.227 0.378 3.988 .733 
 Racism (some to very much)  1    
 Racism (not much to none) 1.102 0.466 2.607 .826 
  Centrality*Worry 1.006 0.991 1.021 .463 
6d Rights 1.019 0.640 1.621 .938 
  Centrality 1.031 0.860 1.235 .744 
 Age 0.981 0.947 1.016 .285 
 Rights Male 1    
 Female 0.559 0.225 1.390 .211 
  Married or Equivalent 1    
 Not Married 0.645 0.263 1.578 .336 
 High SES 1    
 Middle SES 0.685 0.247 1.900 .468 
 Low SES 1.119 0.355 3.527 .848 
 Racism (some to very much)  1    
 Racism (not much to none) 1.175 0.507 2.724 .707 
  Centrality*Rights 0.997 0.979 1.015 .739 







Model 7 Belief in God as Healer as a Moderator 
To test hypothesis 4 the full model included all of the attitudinal variables with 
religious belief in God as a healer entered in an interaction with each of the atti udinal 
barriers.  Table 24 shows there were no statistically significant interaction effects seen 
with all the individual attitudes together in the adjusted model, nor were there any 
statistically significant main effects.  
Table 24:  God as Healer Interaction Model with all Four Attitudes 
     95% CI for exp b 
Model Variable OR Lower Upper p-value 
7 Ethics 1.287 0.501 3.308 .601 
 Distrust 1.692 0.534 5.356 .371 
  Worry 0.687 0.315 1.498 .346 
  Rights 0.773 0.309 1.930 .581 
 Religious Belief 1.052 0.824 1.344 .684 
  Age 0.968 0.931 1.008 .112 
 Male (reference) 1    
  Female 0.539 0.186 1.558 .254 
  Married or Equivalent (reference) 1    
 Not Married 0.483 0.177 1.317 .155 
 High SES (reference) 1    
 Middle SES 0.779 0.258 2.348 .657 
 Low SES 1.348 0.365 4.982 .654 
 Racism (some to very much)  1    
 Racism (not much to none) 0.903 0.358 2.275 .829 
  Religious Belief*Distrust 0.983 0.955 1.013 .263 
  Religious Belief*Ethics 0.988 0.963 1.014 .358 
  Religious Belief*Rights 1.009 0.986 1.033 .457 





When the attitudinal barriers were entered into this model individually, there were 
similarly no significant main effects or interaction effects detected (Table 25). 
Specifically, Model 7a tested the ethics scale by itself in an interaction with belief in God 
as healer. There were no significant interaction or main effects. Model 7b t sted distrust 
of the medical establishment as an interaction with belief in God as a healer.  None of 
these effects reached statistical significance.  
Table 25: God as Healer Interaction Models for Ethics and Distrust 
   95% CI for exp b  
Model Variable OR Lower Upper p-value 
7a Ethics 1.114 0.605 2.051 .730 
  Religious Belief 1.094 0.897 1.336 .375 
 Age 0.971 0.935 1.008 .122 
 Male (reference) 1    
 Ethics Female 0.429 0.157 1.168 .098 
  Married or Equivalent (reference) 1    
 Not Married 0.496 0.192 1.281 .147 
 High SES (reference) 1    
 Middle SES 0.663 0.235 1.871 .437 
 Low SES 1.050 0.319 3.458 .936 
 Racism (some to very much)  (ref) 1    
 Racism (not much to none) 0.925 0.387 2.212 .861 
  Religious Belief*Ethics 0.991 0.974 1.008 .305 
7b Distrust 1.026 0.507 2.075 .943 
  Religious Belief 1.044 0.893 1.220 .591 
 Age 0.974 0.939 1.011 .168 
 Male (reference) 1    
Distrust Female 0.629 0.239 1.656 .347 
  Married or Equivalent (reference) 1    
 Not Married 0.644 0.249 1.666 .364 
 High SES (reference) 1    
 Middle SES 0.866 0.300 2.505 .791 
 Low SES 1.543 0.459 5.192 .483 
 Racism (some to very much)  (ref) 1    
 Racism (not much to none) 1.160 0.495 2.722 .733 
  Religious Belief*Distrust 0.994 0.976 1.013 .535 





In Table 26,  Model 7c entered the worry about being treated unfairly scale into 
the model while Model 7d tested the concern about losing rights scale and found neither 
of them reached statistical significance with interaction or main effects. 
Table 26: God as Healer Interaction Models for Worry and Rights 
   95% CI for exp b  
Model Variable OR Lower Upper p-value 
7c Worry 0.831 0.491 1.404 .488 
  Religious Belief 0.961 0.778 1.186 .709 
 Age 0.984 0.950 1.020 .378 
 Male (reference) 1    
 Worry Female 0.624 0.241 1.621 .333 
  Married or Equivalent (reference) 1    
 Not Married 0.645 0.257 1.623 .352 
 High SES (reference) 1    
 Middle SES 0.795 0.283 2.233 .664 
 Low SES 1.178 0.363 3.820 .785 
 Racism (some to very much)  (ref) 1    
 Racism (not much to none) 1.162 0.501 2.695 .727 
  Religious Belief*Worry 1.001 0.988 1.016 .835 
7d Rights 0.880 0.823 1.142 .710 
  Religious Belief 0.969 0.429 1.802 .726 
 Age 0.981 0.947 1.016 .287 
 Male (reference) 1    
Rights Female 0.570 0.225 1.446 .237 
  Married or Equivalent (reference) 1    
 Not Married 0.654 0.266 1.606 .354 
 High SES (reference) 1    
 Middle SES 0.704 0.253 1.959 .501 
 Low SES 1.130 0.355 3.599 .837 
 Racism (some to very much)  (ref) 1    
 Racism (not much to none) 1.126 0.494 2.563 .778 
  Religious Belief*Rights 1.002 0.984 1.020 .826 
 
 
4.10.2 Stratified Analysis 
 
Finally, as a means to further explore the moderation hypotheses given the 
concern about collinearity between the attitudinal variables, a stratified analysis was 
conducted to explore the effects on different levels of the proposed moderator variables, 
racial centrality and religious belief.  Cases were split based on the mean to create high 
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and low levels of centrality and belief in God as a healer. Adjusted regression models 
were then fit using these levels of stratification. 
These results are shown in Table 27 as a presentation of model 8 (which includes 
all four attitudinal variables with covariates), followed by models 8a through 8d 
(individual attitudinal variables one at a time, with covariates).  This is displayed first for 
the low centrality stratum followed by the corresponding models for the high centrality 
stratum (models 9 and 9a through 9h).  
 
Model 8: Low Centrality  Model 8 shows for participants with low centrality there were 
no statistically significant predictors in an adjusted model of all four attitudinal variables  
Table 27: Stratified Analysis Low Centrality- Full Model 
 Low Centrality   95% CI for exp b  
Model Variable OR Lower Upper p-value 
 Ethics 0.918 0.710 1.186 .512 
 Distrust 0.869 0.672 1.123 .283 
  Worry 0.870 0.664 1.140 .312 
8  Rights 1.156 0.929 1.438 .193 
 Age 0.989 0.935 1.046 .693 
 Male 1    
  Female 1.109 0.314 7.433 .693 
Low 
centrality  Married or Equivalent 1    
 Not Married 1.109 0.232 5.295 .897 
 High SES 1    
 Middle SES 0.581 0.111 3.023 .518 
 Low SES 2.234 0.277 18.046 .441 
 Racism (some to very much)  1    










Similarly when each adjusted model was fit with one attitudinal variable at a time in 
Table 28 (Models 8a through 8d)  
 
Table 28: Stratified Analysis Low Centrality- Ethics and Distrust 
 Low Centrality   95% CI for exp b  
Model Variable OR Lower Upper p-value 
8a Ethics 0.834 0.678 1.026 .087 
 Age 0.989 0.939 1.042 .680 
 Male 1    
  Female 1.068 0.265 4.305 .927 
Low 
centrality Married or Equivalent 1    
 Not Married 0.9240 0.228 3.743 .912 
 High SES 1    
 Middle SES 0.505 0.105 2.418 .392 
 Low SES 1.375 0.226 8.361 .729 
 Racism (some to very much)  1    
 Racism (not much to none) 0.753 0.187 3.023 .228 
8b Distrust 0.827 0.664 1.028 .087 
 Age 0.989 0.938 1.042 .669 
 Male 1    
  Female 1.653 0.405 6.743 .483 
Low 
centrality Married or Equivalent 1    
 Not Married 1.368 0.319 5.860 .673 
 High SES 1    
 Middle SES 0.24 0.127 3.062 .561 
 Low SES 2.154 0.308 15.073 .439 
 Racism (some to very much)  1    


















Table 29: Stratified Analysis Low Centrality- Worry and Rights 
 
 
 Low Centrality   95% CI for exp b  
Model Variable OR Lower Upper p-value 
8c Worry 0.842 0.689 1.029 .092 
 Age 0.997 0.947 1.050 .917 
 Male 1    
  Female 1.509 0.358 6.355 .575 
low 
centrality Married or Equivalent 1    
 Not Married 1.178 0.291 4.775 .818 
 High SES 1    
 Middle SES 0.526 0.110 2.523 .422 
 Low SES 2.003 0.295 13.622 .477 
 Racism (some to very much)  1    
 Racism (not much to none) 0.506 .133 1.920 .317 
8d Rights 1.040 0.860 1.259 .684 
 Age 1.0030 0.955 1.053 .915 
 Male 1    
  Female 1.287 0.338 4.899 .712 
 Married or Equivalent 1    
low 
centrality Not Married 0.895 0.227 3.534 .874 
 High SES 1    
 Middle SES 0.375 0.078 1.806 .222 
 Low SES 0.982 0.163 5.932 .984 
 Racism (some to very much)  1    
 Racism (not much to none) 0.469 0.129 1.708 .251 
 
 
Model 9: High Centrality :  
In Table 30, Model 9 shows an adjusted model of all four attitudinal variables 
entered simultaneously. Gender was found to be a statistically significant predictor of 
intention to enroll in high centrality models.  Females with high centrality were
significantly less likely to express intention to enroll compared with their male 
counterparts in this full model (OR = 0.125, p = 0.019). This gender effect was seen in 
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each of Models 8a (OR = 0.134, p = 0.016), 8b (OR = 0.163, p = 0.026) and 8c (OR = 
0.190, p = 0.029) and 8d (OR = 0.125, p = 0.043). 
Table 30: Stratified Analysis High Centrality- Full  Model 
 High Centrality   95% CI for exp b  
Model Variable OR Lower Upper p-value 
 Ethics 0.842 0.668 1.060 .143 
 Distrust 0.836 0.655 1.067 .151 
  Worry 1.041 0.848 1.277 .701 
  Rights 0.975 0.722 1.316 .867 
 Age 0.935 0.868 1.006 .071 
High 
centrality Male 1    
9  Female 0.125 0.022 0.715 .019 
  Married or Equivalent 1    
 Not Married 0.251 .056 1.128 .071 
 High SES 1    
 Middle SES 0.787 0.148 4.181 .779 
 Low SES 1.603 0.257 9.981 .613 
 Racism (some to very much)  1    
 Racism (not much to none) 1.642 0.399 6.751 .492 
 
Two marginally significant main effects were seen for marital statu  nd age 
among participants with high centrality, although falling short of the 0.05 significa ce 
level. The corresponding variables in the low centrality subset of the sample did notreach 
statistical significance and had odds ratios in the opposite direction. This is further 
suggestive of a moderation effect of centrality, however on the demographic variables 
rather than the attitudinal variables.  The ethics scale was significant in Model 9a; 
however, the coefficient and direction for the ethics scale were quite similar for Model 8a 







Table31: Stratified Analysis High Centrality- Ethics, Distrust, Rights, Worry 
 High Centrality   95% CI for exp b  
Model Variable OR Lower Upper p-value 
9a   Ethics 0.797 0.663 0.959 .016 
 Age 0.942 0.882 1.006 .075 
High 
centrality Male 1    
 Female 0.134 0.026 0.688 .016 
  Married or Equivalent 1    
 Not Married 0.259 .062 1.084 .075 
 High SES 1    
 Middle SES 0.636 0.138 2.930 .562 
 Low SES 1.121 0.212 5.925 .893 
 Racism (some to very much)  1    
 Racism (not much to none) 1.698 0.456 6.317 .430 
  Distrust 0.784 0.644 0.955 .015 
 Age 0.943 0.882 1.007 .081 
9b  Male 1    
  Female 0.163 0.033 0.803 .026 
High 
centrality Married or Equivalent 1    
 Not Married 0.283 .068 1.178 .083 
 High SES 1    
 Middle SES 0.818 0.171 3.926 .802 
 Low SES 1.616 0.292 8.932 .582 
 Racism (some to very much)  1    
 Racism (not much to none) 1.633 0.432 6.170 .469 
  Rights 0.854 0.671 1.086 .198 
 Age 0.953 0.896 1.013 .122 
 Male 1    
  Female 0.190 0.043 0.844 .029 
9c  Married or Equivalent 1    
High 
centrality Not Married 0.362 .091 1.444 .071 
 High SES 1    
 Middle SES 0.777 0.159 3.786 .754 
 Low SES 1.248 0.241 6.470 .792 
 Racism (some to very much)  1    
 Racism (not much to none) 1.451 0.386 5.454 .582 
  Worry 0.887 0.771 1.020 .093 
 Age 0.960 0.903 1.020 .190 
9d Male 1    
  Female 0.125 0.022 0.715 .043 
High 
centrality  Married or Equivalent 1    
 Not Married 0.313 .079 1.237 .098 
 High SES 1    
 Middle SES 0.741 0.160 4.879 .702 
 Low SES 0.949 0.185 4.879 .950 
 Racism (some to very much)  1    




Model 10: Low Belief in God as Healer 
In Table 32, Model 10 examines the predictive value of all four attitudinal 
variables entered together with covariates, followed by models 10a through 10d 
(individual attitudinal variables analyzed one at a time, with covariates) for the low belief 
in God as a healer stratum.  
Model 10 was an adjusted model including all four attitudinal variables for those 
with a low level of belief in God as a healer.  In this full model, ethics was a statistically 
significant predictor of decreased intention to enroll (OR = 0.743, p = 0.026) but none of 
the other three attitudes were significant.   
 
Table 32: Stratified Analysis Low Belief in God as Healer- Full Model 
 Low Belief in God as Healer  95% CI for exp b  
Model Variable OR Lower Upper p-value 
10 Ethics 0.743 0.573 0.965 .026 
 Distrust 0.873 0.704 1.082 .215 
Low 
Belief  Worry 0.971 0.792 1.190 .774 
  Rights 1.210 0.973 1.505 .087 
 Age 1.008 0.954 1.065 .765 
 Male 1    
  Female 0.530 0.113 2.493 .421 
  Married or Equivalent 1    
 Not Married 0.322 0.077 1.350 .121 
 High SES 1    
 Middle SES 0.509 0.121 2.138 .356 
 Low SES 0.375 0.057 2.482 .309 
 Racism (some to very much)  1    
 Racism (not much to none) 1.454 0.387 5.459 .579 
 
 
Separate models were run with each of the attitudinal barriers at a time.  These 
models suggest that at low level of belief in God as healer, it was demographic factors, 
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which proved to be significant predictors of enrollment intention (Models 10a through 
10d). Specifically, (Model 10a) when ethics was the only attitude in the model, it was no 
longer significant as a main effect (OR = 0.849, p = 0.085), however age was a 
significant predictor of decreased odds of intended enrollment. Specifically, with 
increasing age, there was decreased likelihood of intention to enroll, for those with low 
belief in God as a healer (OR = 0.901, p = 0. 009).  
Table 33: Stratified Analysis Low Belief in God as Healer- Ethics 
 Low Belief in God as Healer  95% CI for exp b  
Model Variable OR Lower Upper p-value 
 Ethics 0.849 0.7051 1.023 .085 
10a Age 0.901 0.833 0.975 .009 
Low 
Belief Male 1    
  Female 0.470 0.090 2.450 .370 
  Married or Equivalent 1    
  Not Married 0.716 0.154 3.334 .671 
 High SES 1    
 Middle SES 1.887 0.275 12.962 .519 
 Low SES 6.811 0.787 58.934 .081 
 Racism (some to very much)  1    
 Racism (not much to none) 1.104 0.244 4.987 .898 
 
When distrust was the only attitudinal variable included in the adjusted model, 
age and SES became significant predictors of intention.  With increasing age, participants 
were significantly less likely to express intention to enroll (OR = 0.893, p = 0.010).  
Participants of low SES were significantly more likely to express intention to enroll (OR 







Table 34: Stratified Analysis Low Belief in God as Healer- Distrust 
 
 Low Belief in God as Healer  95% CI for exp b  
Model Variable OR Lower Upper p-value 
10b Distrust 0.795 0.609 1.038 .092 
 Age 0.893 0.820 0.973 .010 
 Male 1    
Low 
Belief  Female 0.487 0.090 2.642 .404 
  Married or Equivalent 1    
 Not Married 0.879 0.177 4.376 .875 
 High SES 1    
 Middle SES 2.251 0.294 17.253 .435 
 Low SES 10.157 1.011 102.061 .049 
 Racism (some to very much)  1    
 Racism (not much to none) 0.901 0.192 4.220 .895 
 
When worry of being treated unfairly was the only attitude introduced into the 
adjusted model (10c), age again was a significant predictor of intention to enroll such that 
increasing age was associated with a decreased likelihood of intention to enroll (OR = 
0.909, p = 0.016). The same age effect was seen for model 10d with fear of losing one’s 












Table 35: Stratified Analysis Low Belief in God as Healer- Worry and Rights 
 
 Low Belief in God as Healer  95% CI for exp b  
Model Variable OR Lower Upper p-value 
10c Worry 0.845 0.703 1.016 .073 
 Age 0.909 0.842 0.982 .016 
Low 
Belief Male 1    
  Female 0.654 0.124 3.460 .617 
  Married or Equivalent 1    
 Not Married 0.824 0.170 3.994 .810 
 High SES 1    
 Middle SES 2.346 0.332 16.595 .393 
 Low SES 9.231 0.962 88.534 .054 
 Racism (some to very much)  1    
 Racism (not much to none) 0.792 0.174 3.614 .763 
      
 Rights 0.876 0.667 1.151 .342 
 Age 0.907 0.839 0.980 .013 
10d  Male 1    
  Female 0.483 0.096 2.436 .378 
 Low 
belief Married or Equivalent 1    
 Not Married 0.708 0.151 3.322 .662 
 High SES 1    
 Middle SES 1.882 0.276 12.804 .518 
 Low SES 7.236 0.785 66.723 .081 
 Racism (some to very much)  1    
 Racism (not much to none) 0.946 0.217 4.136 .942 
 
Model 11: High Belief in God as Healer 
For those with a high level of belief in God as healer, a full adjusted model 
including all four attitudinal variables, suggested that age (OR = 0.895, p = 0.015) was 
significant predictor of decreased odds of intention to enroll. Being in a low SES group 
compared with the high SES group was predictive of a greater odds of enrolling (OR = 
11.06, p = 0.052).  
 In models 11a and 11b, a high belief in God as healer revealed a statistically 
significant reduction in odds of intention to enroll for those who had high concern about 
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ethics and high levels of distrust of medicine and doctors. Specifically in Model 11a 
where ethics was the only attitudinal barrier entered there was a significant decrease in 
odds of intention to enroll (OR = 0.762, p = 0.011) with increased concern.  In Model 11b 
where distrust was the only attitudinal barrier entered, increasing distrust was associated 




Table 36: Stratified Analysis High Belief in God as Healer- Full Model, Ethics and Distrust 
 High Belief in God as Healer     
Model Variable OR Lower Upper p-value 
11 Ethics 0.916 0.729 1.150 .449 
High belief Distrust 0.909 0.633 1.305 .603 
  Worry 0.942 0.714 1.242 .670 
  Rights 0.940 0.690 1.282 .698 
 Age 0.895 0.818 0.978 .015 
 Male 1    
  Female 0.497 0.082 3.005 .447 
  Married or Equivalent 1    
 Not Married 0.937 0.183 4.809 .938 
 High SES 1    
 Middle SES 2.540 0.316 20.401 .381 
 Low SES 11.063 0.979 125.075 .052 
 Racism (some to very much)  1    
 Racism (not much to none) 0.961 0.196 4.719 .961 
 Ethics 0.762 0.618 0.939 .011 
11a Age 1.009 0.958 1.063 .735 
 Male 1    
 Female 0.535 0.119 2.396 .414 
  Married or Equivalent 1    
 Not Married 0.413 0.108 1.582 .197 
High 
belief  High SES 1    
 Middle SES 0.514 0.134 1.966 .331 
 Low SES 0.393 0.072 2.150 .281 
 Racism (some to very much)  1    
 Racism (not much to none) 1.193 0.351 4.058 .778 
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 High Belief in God as Healer     
Model Variable OR Lower Upper p-value 
 Distrust 0.832 0.695 0.994 .043 
 Age 1.016 0.966 1.069 .530 
11b  Male 1    
  Female 0.921 0.225 3.776 .130 
High belief Married or Equivalent 1    
 Not Married 0.640 0.183 2.233 .484 
 High SES 1    
 Middle SES 0.661 0.172 2.537 .547 
 Low SES 0.560 0.106 2.964 .495 
 Racism (some to very much)  1    
 Racism (not much to none) 0.894 0.281 2.850 .850 
 
Models 11c and 11d suggested no statistically significant predictors of intention to enroll 
for participants with a high belief in God as healer. 
 
Table 37:  Stratified Analysis High Belief in God as Healer- Worry and Rights 
 High Belief in God as Healer     
Model Variable OR Lower Upper p-value 
 Worry 0.884 0.762 1.026 .105 
 Age 1.027 0.978 1.080 .286 
High belief Male 1    
11c  Female 0.909 0.225 3.673 .893 
  Married or Equivalent 1    
 Not Married 0.592 0.169 2.078 .413 
 High SES 1    
 Middle SES 0.568 0.153 2.107 .398 
 Low SES 0.369 0.072 1.885 .231 
 Racism (some to very much)  1    
 Racism (not much to none) 0.956 0.305 2.999 .938 
 Rights 0.997 0.846 1.151 .970 
11d Age 1.025 0.976 1.076 .330 
 Male 1    
 Female 0.940 0.246 3.584 .928 
 Married or Equivalent 1    
 Not Married 0.695 0.205 2.357 .559 
High belief  High SES 1    
 Middle SES 0.492 0.133 1,821 .288 
 Low SES 0.365 0.071 1.868 .227 
 Racism (some to very much)  1    






4.12 Summary Findings 
The analyses in this chapter yielded no significant findings based on the original 
study hypotheses 1 and 2. They did however partially support hypotheses 3 and 4. Table 
18 summarizes the findings. 
 
Table 38: Summary Findings and Decisions 
 Decision Findings 
Hypothesis 1 
 
Participants with higher levels of 
racial identity will be more likely to 
express intention to enroll once 
attitudinal barriers and demographic 












- Correlation analysis: Direction of 
association is consistent with 
hypothesis.  The correlation is 
negative implying a higher level of 
racial identity correlates with a 
decreased odds of intention to 
enroll in a clinical trials  
- Correlation is weak and not 
statistically significant 
- Unadjusted regression model 
shows no significant relationship 




Participants with stronger belief in the 
notion of God as healer will be less 
likely to express an intention to enroll 
in a therapeutic clinical trial once 
attitudinal barriers and demographic 













- Correlation analysis: Direction of 
association is consistent with 
hypothesis.  Correlation is negative 
implying stronger belief in God as 
healer correlates with decreased 
odds of intention to enroll 
- Correlation is not statistically 
significant 
- Unadjusted regression models 
show no significant relationship 










The attitudinal barriers will be 
moderated by racial identity 
(centrality) such that there will be less 
influence on the intention to enroll for 















- No moderation effect on attitudinal 
barriers 
- Potential moderation effect of 
racial centrality on gender and 
intention to participate.   Males 
with high centrality have 
significantly increased likelihood 
of intending to enroll in clinical 







The attitudinal barriers will be 
moderated by belief in God as healer 
such that there will be less influence 
on the intention to enroll for those 

















- Participants with low levels of 
belief in God as a healer increasing 
age significantly lowers the 
likelihood of intending to 
participate (but not for those with 
high levels of belief) 
-  
- Belief in God as a Healer 
moderates the effect of a ‘Concern 
about ethical conduct of 
investigators’ scale as a predictor 
of intention to enroll as well as the 
distrust of medical establishment 
scale 
- For participants with low levels of 
belief, being in the low SES group 
significantly increased the odds of 
intention to enroll compared with 


















CHAPTER FIVE: DISCUSSION 
5.1 Introduction 
This chapter is a summary and discussion of the results of the study as presented 
by the findings for each study hypothesis.  These findings are discussed in the co text of 
the study population and with respect to the larger population of African American 
cancer patients and the place of this research in the existing literature.  It also includes a 
discussion of the inevitable limitations of the study, as well as implications for theory, 
practice and future interventions and research. 
5.2 Study Findings 
The dissertation study was part of a larger intervention aimed to assess the 
effectiveness of a culturally targeted video.  The video was designed to specifically 
address the attitudinal barriers, which serve as independent variables in this dissertation 
study. The four specific attitudinal barriers considered were, 1) fear and distrust of the 
medical establishment (doctors, scientists and the government); 2) concern about the 
ethical conduct of investigators; 3) fear of losing one’s rights by signing a research 
informed consent; and 4) worry that investigators will treat poor Black patients, in 
particular, unfairly (e.g. the patient becomes a guinea pig because of their race or SES).  
In this study population three of the four attitudes were related to intention to enroll. The 
attitudinal barrier, fear of losing one’s rights by signing a consent form, did not prove to 
be significantly associated with intention. Of the three attitudes that were relat d to 
intention, concern about ethical conduct of investigators appeared to be most important in 
the study population as evidenced by its significant relationship with the intention 
outcome in both adjusted and unadjusted models.  
  
 110
The ethical misconduct of scientists and researchers especially relative to African 
American populations in the US appears to resonate and be particularly salient to this 
study population.  The US Public Health Services Study is not the only example of 
ethical misconduct and exploitation of African Americans in biomedical research. There 
is, however, discourse surrounding how relevant it still is to African Americans today, 
and the role it plays in their attitudes towards participation in clinical research. These data 
suggest that occurrences such as the Tuskegee study are still highly relevant, particularly 
for this population. Further, these data implore a full consideration of the role this and 
other such incidents may still play in the decision of African Americans cancer pati nts to 
consider a therapeutic clinical trial. Where the tendency today may be for some pr viders 
to want to avoid bringing up Tuskegee and other historical abuses of human subjects, 
these data suggest that it is in fact a subject that needs to be broached.   For African 
American patients in particular, fostering an environment where such issuescan be 
openly addressed may prove beneficial. 
While each of the four attitudinal scales were proposed as distinctly related to 
intention to enroll, this study revealed that the associations were not clear cut.  All of the 
items were highly correlated, causing some overlap in the scales. While each scale 
measured different dimensions of attitude and addressed different elements of a patients 
concern, some of the differences in the constructs were subtle. The initial correlation 
analysis revealed significant correlations between the scales such that one might caution 
against their use analytically in this manner.   However it should be noted that the 
exploratory nature of this study necessitated such an examination.  In the absence of a 
literature base to otherwise establish an acceptable level of correlation between these 
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variables, the nature of their interrelationships was important to understand in order to 
guide further study. 
 
5.2.1 Relationship between attitudinal barriers and intention to enroll 
 
Hypothesis 1 suggested that participants with higher levels of racial identity are mor
likely to express intention to enroll once attitudinal barriers and demographic controls are 
taken into account.  In the unadjusted logistic model racial centrality was not significant, 
thus the first hypothesis was unsupported.  
 
Hypothesis 2 suggested that participants with stronger belief in the notion of God as 
healer will be less likely to express an intention to enroll in a therapeutic clinical trial 
once attitudinal barriers and demographic controls are taken into account. Results did not 
support this second hypothesis.   
Two scales were central to Hypotheses 1 and 2. While they did not seem to be 
important predictors of intention to enroll in a therapeutic clinical trial in this sample, this 
study was able to validate the centrality scale and the God as healer scale for the first 
time in this study population. This is important because it shows the distribution of these 
scales in a sample of newly diagnosed urban African American cancer patients, providing 
information on the utility of these instruments with diverse populations. 
The data collected on religious denominations represented by the participants and 
their frequency of church attendance demonstrated the high religiosity of the sample. 
Thus, it is possible that there may not have been enough variability in the measure for 
religious belief to significantly detect an association with intention to enrll i  a 
therapeutic trial with the sample size of 111.  In Holt and colleagues’ (2006) original 
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scale validation and development study, the population consisted of cancer patients along 
the “Bible belt”, with past cancer diagnoses. The current study population consisted of 
relatively recently diagnosed patients, mostly in active treatment. Item m ans for the 
dissertation study population were higher on each of the 8 items on the instrument, when 
compared with the original population.  Further, the overall mean score on the God as 
healer scale was relatively high for the study population: 37.29 (7.27) and certainly 
higher than the original population with 32.23 (3.96).  Thus, if religiosity and belief in 
God as healer is high among all study participants, it may not be useful in distinguish  
between those who were willing to enroll in a clinical trial and those who were not.   
Similarly, responses on the Seller’s centrality scale resulted in partici nts who 
were either highly central, or who had low centrality and not as many participants n 
between or with neutral responses. The total mean score was 52.83 (7.27) in this study 
population, which was in the range of previous studies. What resulted in this case was a 
population with a somewhat bimodal distribution on this variable and means, which 
clustered at the midpoint of the scales for several items.  The item mean score was 3.39 
(0.42), compared with estimates in other populations ranging from 5.20 (1.14) for African 
American students at a predominantly white university, to 5.28 (0.98) for African 
American students at an African American university. There is value in validating such a 
scale in a population of African American cancer patients as ethnic identity variables 
such as centrality have been shown for example to buffer certain protective risk factors, 
while enhancing protective factors to drug use (Brook & Pahl, 2005).  Perhaps there may 
be value in exploring ways in which centrality might similarly work in such a unique 
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population as the cancer patients in this study relative to their attitudes and behavior 
towards clinical trials.  
It is plausible that centrality could have an enhancement effect on intention in 
cancer patients who are highly central: in such a way as to enhance the altruistic appeal of 
trial participation.  Alternately it may actually have a buffering effect, whereby 
participants who are more highly central may have more anti-establishment views and 
increasing levels of distrust research as they may identify more with experi nces of 
racism and historical  mistreatment of African Americans. This would result in a 
decreased intention to enroll.  The responses on the centrality scale within this population 
suggest there could conceivably be two types of centrality operating within this 
population. Perhaps one of which deals with the connectedness participants feel to other 
Blacks (which is potentially more likely to lead to an enhancing effect on intetion to 
enroll). Conversely there may be the dimension of centrality which addresses the xtent 
to which being Black is a part of how they view themselves- and perhaps this dimension 
may be more related to a decreased intention to enroll or a buffering effect.  
5.2.2 Moderation Effect 
 
According to Cohen, Cohen and Aiken (2003) an interaction is thought of as an 
interplay among predictors that produces an effect on the outcome that is different from 
the sum of the effects of the individual predictors.  As such when two predictors interact 
with one another, the regression of Y on one of the predictors is conditional on the value 
of the other predictor (Aiken and Aiken, 2003).  This study hypothesized a role for racial 
identity (specifically racial centrality) and a specific belief in God as a healer, in the 
patient’s expressed intention to enroll in a therapeutic clinical trial.  It further 
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hypothesized a conditional relationship between the outcome variable of intention to 
enroll in a therapeutic clinical trial, and four attitudinal barriers to participation. The 
relationship between these independent variables and the outcome was proposed as 
conditional on two contextual variables, racial centrality and a belief in God as a healer. 
This conditional relationship referred specifically to a moderation effect, whereby the 
strength and direction of the relationship between the independent variable and dependent 
variable may be reduced as the value of the moderating variable increases, or vice ve sa. 
According to Baron and Kenny (1986) a moderator effect may also be said to occur 
where the direction of the correlation changes in the presence of another variable (Baron 
and Kenny, 1986).  
Hypothesis 3 proposed that the attitudinal barriers will be moderated by racial identity 
such that there will be less influence on the intention to enroll for those with higher levels 
of racial identity.  This hypothesis was only partially supported.  There was a potential 
moderation effect of racial centrality on gender and intention to participate but no 
moderation effect on the attitudinal barriers as hypothesized.  Females with high 
centrality had significantly lower odds of intention to enroll in clinical trials than did 
males. This was a surprising finding as the literature shows women are more likely to 
participate in clinical trials than men under most conditions.  In this case it could be that 
the altruism factor actually does play a role for Black men of high centrality, s 
previously note.  Whereas females with high racial centrality could perhaps be more 
impacted by the fear of exploitation that may come with clinical trials participation.  
An anecdotal qualitative response by one male study participant stated “ There is 
such a thing as machismo for Black men too, you know….maybe even more so than for 
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Hispanics even though everyone thinks that it’s more important for them. I’d argue it’s 
more important for Black men…we have to do things to preserve the race….”  
Hypothesis 4 suggested that attitudinal barriers will be moderated by belief in God as 
healer such that there will be less influence on the intention to enroll for those with higher 
levels of belief. This hypothesis was partially supported. A clear and direct moderati n 
effect was not seen as hypothesized however the stratified analyses and the significance 
of interaction terms in the adjusted models suggested there is some level of effect 
modification occurring. This effect however was difficult to isolate potentially due to the 
correlation between the four attitudinal variables. 
A belief in God as a Healer appeared to consistently moderate the effect of  
‘Concern about ethical conduct of investigators’ as a predictor of intention to enroll but 
no other attitudinal barriers. Specifically, for those with a stronger belief in God as 
healer, lower scores on the ethics scale predicted a greater intention to enroll tha  those 
with higher scores on the ethics scale. The relationship was weaker for those with less 
strong belief in God as healer, but still remained in the same direction. It may be that if 
one believes that God is ultimately the healer and has strong concerns about investigators 
conducting their research in an ethical manner, there may be no impetus to enroll in a 
trial or to consider something experimental.  
In the stratified analyses, among participants with low levels of belief in God as a 
healer there was evidence that increasing age lowered the odds of intention to enroll in a 
clinical trial. This may be a true age effect, consistent with the literature that shows that 
on the average, clinical trial participants tend to be younger.   Within the dissertation 
study population, clinical trial participation may decrease in likelihood with age due to 
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the distrust of clinical research that is consistent with older participants h ving more fears 
and concerns of trials for historical reasons. 
   Further, low levels of belief in God as a healer also showed that being in the low 
SES group significantly increased the odds of intention to enroll compared with the high 
SES group by over 10-fold, though this association was marginal due to large confidence 
intervals. This would be consistent with a theory of disenfranchisement for those of lower 
SES.  It could be argued, for instance, that individuals in a higher SES may feel more 
empowered in their health decision-making and are more apt to make decisions of their 
own volition, where members of a lower SES  group may make that same decision out of 
a feeling of vulnerability. That is, compared with those in a high SES, the lower SES 
group may include individuals who feel they have less control over their health outcomes 
and therefore be more likely to ‘subject themselves’ to research, or “the system” if they 
feel they have no choice. This also could be consistent with study findings that show that 
lower income populations are more likely to participate in research due to a lack ofother 
treatment options.  These individuals elect to enroll in clinical trials to access th  basic 
health care they lack. 
5.3 Implications of Findings 
Both religious belief in God as healer and racial centrality represent two variables 
which may help to capture variability among African American populations that can then 
be the focus for affecting health outcomes, in this case intentions to enroll in clinical 
trials. 
There is limited research examining the relationships of socio-cultural factors among 
Black cancer patients and factors surrounding their attitudes toward and inte tio s to 
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enroll in clinical trials.  Subsequently there are few culturally targeed interventions, 
which are focused on impacting these attitudes in order to increase the likelihood of trial 
participation for this subgroup. 
 While studies have certainly found positive associations with factors of religious 
involvement acting as mediators and moderators of health outcomes, the literature is lso 
replete with negative or null associations. The Belief in God as healer scale and 
measuring this aspect of religious influence on health outcome looks at an aspect of th  
religion-health connection which arguably stands separate from that usually associated 
with social support (Holt et. al, 2009). Where proposed mechanisms for the religion-
health connection tend to address intrapersonal factors (e.g. coping mechanisms) d 
interpersonal factors (e.g. social support and social influence), this concept seems to 
address what are referred to as faith based factors (Holt, Lewellyn et al, 2005). That is, 
factors that enable individuals to attach meaning to their illness and most important in 
this context, factors related to their spiritual health locus of control (Holt, Lewellyn et al, 
2005). 
A belief in God as healer may be consistent with a cancer patient feeling they are 
“giving the problem to God” (Holt and McClure, 2006).  The findings of this study 
perhaps highlight this aspect of coping with cancer and suggest the role of an individual’s 
control beliefs in the clinical trials decision-making process; one which is perhaps 
mediated by a belief in God as a healer. It could be that the extent to which a patient 
believes they are in control of their disease directly relates to their likelihood to 
participate in a trial. 
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In the US, the focus on eliminating health disparities has translated into an 
increased focus of research on race-specific or targeted messaging. Funding cont nues to 
be channeled and earmarked for ‘culturally appropriate and specific’ interveions.  Thus 
issues of race, and racial identity are inextricably linked to the approach taken in 
designing and even evaluating such interventions. Race, gender and SES represent un-
modifiable variables that are related to trial participation in this study.  
What this dissertation study and others have suggested is that given the relativ
importance of un-modifiable demographic factors such as gender perhaps an alternative 
approach to intervention is a focus on variables which are, at least conceptually related to 
these.  The two constructs - belief in God as healer and racial centrality - have been 
shown to moderate the relationship between gender, race and income (SES) and their 
ability to influence the intention to enroll. This may posit an alternative target for 
intervention and an indirect way to impact the demographic factors which make a 
difference in outcome.  
Consideration of moderators in intervention design 
 Linden and colleagues’ qualitative research revealed that participants in their 
study expressed a mistrust in recruitment into clinical trials, and they beli ved that 
culturally sensitive recruitment efforts would be more effective in recruiting African 
American patients (Linden, Hannah M. M. et al., 2007a). Participants in the study stated a 
higher likelihood of participating if the church was somehow involved in their decision, 
affirming they would feel more trusting and more likely view the clinical tri as more 
legitimate if someone from the church presented it. This suggests that where a negative 
attitude towards participation exists, religious factors may have a moderating effect. 
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Intervention designs tend to focus on a set of changeable characteristics in the 
target population and administer a treatment, the effect of which is intended to shift he 
target characteristic in the same direction for everyone. However this dissertation shows 
that the impact may differ for different subgroups based on different levels of fact rs 
such as religion or racial identity. That is, to establish a moderation of intervetion 
response-determining characteristics of those who respond and those who do not.  It als  
implies that targeting interventions for trial accrual based on two chara teristics or social 
constructs which are thought to be particularly salient for African American populations 
may not be as cost effective unless a measure of the strength of belief or str ngth of 
identity can first be established.  Further, together with the literatur, this seems to make 
the case that down the line it is more efficient to focus on religious belief through use of
the church or religious figures as a way to impact race and income based differences.  
 Studies across disciplines recognize that oftentimes when health interventions fail 
to show a significant impact on an individual level or community level, this can be 
attributed to a failure to acknowledge cultural norms and a lack of cultural specificity. 
Understanding the key cultural constructs and the manner in which they operate within a 
population and a focus on cultural congruency are both essential in designing cost-
effective interventions. 
5.5 Implications for theory 
 
The Theory of Planned Behavior was used to inform the theoretical framework 
for this study.  As postulated by the theory, behavior is mediated directly by intention, 
and indirectly through normative beliefs and attitudes, which impact intention (Azjen & 
Fishbein, 1975). The cross-sectional nature of this study renders it impossible to assess 
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whether an intention to enroll in a trial ever translates into actual trial enrol ment, thus 
utility of the theoretical framework in this context is limited.  It is through the TPB that a 
sense of directionality in the proposed relationships between the constructs was inferred 
such that attitudes preceded the intention, which hypothetically leads to engaging in the 
desired behavior, enrolling in a therapeutic trial. It should be noted that among this study 
population, intentions may be less tied to behavior (actual trial enrollment) due to the 
serious nature of the illness, which may make it difficult to make decisions.   This study 
also highlights a need for further theory development, with a focus on culturally relevant 
health behavior theory that accounts for important moderating variables among 
population subgroups. 
5.6 Limitations 
One limitation of this study is the selection bias inherent in the study population 
and the sampling methodology.  Potential participants were targeted in a purposive 
manner and the study sample consisted of patients who self-selected to participate in this 
study.  This represents a somewhat biased sample given these individuals were likely 
overall less resistant to research as indicated by their willingness to participate in this 
study.  Thus the true relationship between the attitudes, the mediators and the intention to 
enroll may be obscured by the biased sample. 
 Further, all of the participants in this study were cancer patients; therefor , it is 
likely their attitudes towards therapeutic trials were somewhat skewed giv n the nature of 
their illness.  Individuals faced with a terminal illness have more fatalistic attitudes or are 
more aware of their own mortality and consequently their responses to the questions 
about religion may represent a very skewed sample. Asking people who are already sick 
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how they feel about what is essentially another treatment option makes it challenging to 
tease out the true nature of the relationships between these attitudes and intention.  
Another limitation in this study was the validity of the instrument used to assess 
attitudes. While each of the scales by definition had at a minimum, an ‘acceptable’ alpha 
reliability, the instrument could certainly be more refined.  It may be that these alphas 
were in fact too low and contribute in part to the muted effect size in the study.  However, 
the argument can be made that for newly emerging constructs such as those under study, 
alphas upward of .8 may be unrealistic.  The items are brief and tested with a unique 
population.  Further, the concepts are emergent and still under development; they 
measure concepts that are not as concrete as some psychological constructs which may 
more appropriately be held to these rigorous standards of scale reliability. 
When the final regression models are considered, the study was only able to 
achieve moderate power (68%).  For this reason it is possible that some of the analys s 
were underpowered and thus the conclusions drawn citing a lack of relationship between 
hypothesized variables should be considered in light of this constraint (i.e Type 2 Error).  
 Also worth noting is the questionable validity of the item assessing the attitudinal 
barrier that is the concern about losing one’s autonomy after signing a consent form.  
Assessing issues related to consent problems, when one has to actually consent the 
participants in order to ask them about consent presents a unique challenge.  Responses to 
the items on the concern about losing autonomy after signing a research consent, scale 
ought to be interpreted with caution.  Prior to administering the study questionnaire, I 
conducted a full informed consent process for the study, as required.  As these questions 
were administered, it was not uncommon for participants to preface their response with 
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“well, I now know coz [sic] you said earlier, that I can stop at any time I want to”. Thus it 
is difficult to know the extent to which these responses were actually due to their level of 
knowledge versus what they understood from the study consent process. 
 
5.7 Threats to Validity 
Being a non-experimental design, this dissertation uses cross-sectional data which 
limits the ability to determine the direction of the relationships hypothesized. Those seen 
in this sample can only determine that there is an association.  It is difficult to determine 
whether intention to enroll influences attitudes, racial identity, and religious beliefs or 
whether the predictor variables affect intention to enroll.  However the results can 
provide support for potential causal associations and direct future research. 
There are likely multiple other factors that play into the formation of attitudes 
towards clinical trials that cannot be measured, but may become evident in qualitative 
interviews. There is the potential that other plausible or alternative explanations exist, 
presenting a threat to the internal validity of this study.  In the absence of an experimental 
design for this study, the results of this study have to be interpreted with caution nd with 
an understanding that they may simply inform future research. Further, it is expect d that 
there was a level of measurement error in assessing the study variables within the 
population particularly on the newly developed scales.  
It is also important to note that these results may not be generalizeable to African 
American populations in other locales within the United States based on the unique 
diversity among African Americans in the District of Columbia metro area.  These results 
may generalize to metropolitan areas with similar diversity among the Black population 
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however, the unique demographic of the area in which this study was conducted should 
be noted. 
In addition, patients enrolled were at various stages of treatment and yet this study 
asked questions dealing specifically with the intention to enroll on a therapeutic trial.  It 
is therefore important to note that results and attitudes might vary depending on the type 
of clinical trial in question. 
Given the nature of the questions asked in the structured interview, there may be a 
social desirability bias which may result in the participant not fully disclosing their true 
feelings on a response, or alternately may exaggerate it.  Finally, as noted by Rajakumar 
(2009), a challenge of studying trust and attitudes surrounding mistrust, is that those with 
high levels of distrust may not participate (Rajakumar, 2009), rendering the range of trust 
assessed, potentially more limited than in the general population (Rajakumar, 2009). 
When the final collection of variables in the regression models were considered, 
the relationships may not have been strong enough to detect the originally calculated 
effect sizes in such a small population.  The result of this would be an actual power that 
was lower than that originally calculated.    
 Finally, in assessing the role of racial identity among this population, there are 
additional items that would have added some valuable data to for context .  For instance, 
more data should have been collected on the survey instrument to assess the extent to 
which individuals had experienced racism or perceived racism. 
5.8 Future Research Directions 
The most obvious and immediate direction for future research is to address the 
limitations outlined in the previous section. A refinement of the instruments to be used to 
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assess the attitudinal barriers will be the first step as an accurate measurement will allow 
for more sound conclusions to be drawn from the study. This may in effect be easily 
achieved by adding more items to the existing instruments as their brevity impacts the 
reliability. The ability to further pilot test the instrument and then take the ass ssments in 
a separate but similar population would aid in refining the initial findings from this 
population.  
 Further, it would seem that this line of inquiry could benefit from further 
qualitative analysis and the exploration of a traditional mixed methods approach to this 
study. Either using the quantitative findings to inform further qualitative inquiry or using 
qualitative findings to inform additional quantitative methodology. For this study, I 
followed up with qualitative interviews on n= 38 participants.  My first step will be to 
analyze the transcripts from interviews that were conducted with participnts of this 
dissertation study. It is likely this might add context to some of the findings and help with 
further hypothesis development.  
The literature does identify other attitudinal barriers thought to affect the 
willingness of minority patients to participate in research. An assessment of these other 
attitudes among this population would help to establish their relative importance. It could 
be that there are some attitudes which are more salient for this population due to its 
unique make-up.  Of note is the lack of an assessment of the role that knowledge and 
awareness of clinical trials; which was not related to the study hypotheses and so was not 
considered.  It may be informative to assess this and then attempt to adjust for it in an 
explanatory model.  
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This research provides additional guidance for future inquiry attempting to better 
characterize minority accrual to clinical trials and development of targeted interventions 
based on religion and other potentially race-specific constructs. The literature is replete 
with guidance on how to use or incorporate religion and the push towards cultural 
competency. What this dissertation suggests is that these social constructs which are 
frequently the source of focus for many culturally-based interventions should be first 
characterized fully within the target population.  
5.9 Summary 
The aim of this study was to understand the relationship between attitudinal 
factors that present barriers to clinical trial participation and the subsequent intention to 
enroll in therapeutic clinical trials; and to understand the contribution of racialidentity 
and religious belief to the intention to enroll in therapeutic clinical trials. Data collected 
from this study population suggested that all of the attitudinal barriers cited in he clinical 
trials accrual literature may not necessarily apply to this population, rather demographic 
factors ultimately make more of a difference. The data suggested that the concern about 
ethical conduct of investigators was the only attitude of the four proposed, which was 
consistently a significant predictor of intention to enroll in both adjusted and unadjusted 
models.  African American populations in particular have deep-rooted historical reasons 
that need to be accounted for in the development of any intervention, educational or 
otherwise (Gamble, V. N., 1997a; Heintzelman, C. A., 2003a). This study seems to 
suggest that we still need to focus on the role that historical abuses play in influeci g the 
way African American patients feel about clinical research and the extent to which it may 
influence their attitudes. 
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Appendix A Flow Chart of Study Activities: Patient Recruitment for Parent 
Study and Dissertation Study 
 









































WCI study recruiter works with 
research coordinators to identify 
patients scheduled for consultation 
with WCI oncologist  
 
Passive consent 
letter sent from 
Physician to 
scheduled patients to 




WCI recruiter contacts potentially 
eligible patients by phone and explains 
study - extending invitation to 
participate to eligible patients* 
PATIENT 
INELIGIBLE* OR  
DECLINES 
Declining patients asked 
to respond to brief 
refusal questionnaire  
WCI recruiter verbally consents participant 
and schedules study visit for patient to 
come to WCI and view video/complete 
survey 
Patient comes to WCI- signs written consent; 
completes baseline and demographics; views 
video and completes post test 
 
Patient given opportunity to 
consent to contact for follow-
up/qualitative study for further 
information 
*Patient eligible for consent if: 
Age > 18; Self-identifies as 
AA/Black; scheduled for visit with 
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Appendix C Quantitative Study Consent 
Informed Consent for Clinical Research 
MedStar Research Institute/Georgetown University Medical Center 




You are invited to consider participating in this study. The study is called “Today’s Truth: 
Research Brings Hope”.   Please take whatever time you need to discuss the study with 
your family and friends, or anyone else you wish to.  It is important that you read and 
understand several things that apply to all who take part in our studies: 
 
(a) Taking part in the study is entirely voluntary; the decision to participate, or not 
to participate, is yours. 
 
(b) Personal benefit to you may or may not result from taking part in the study, but 
we hope you will benefit from the information it will provide. Knowledge may be 
gained from your participation that will benefit others. 
 
(c) You may decline to participate or you may withdraw from the study at any time 
without loss of any benefits to which you are entitled and without jeopardizing 
your access to care, treatment and health services unrelated to the research. 
 
The purpose and nature of the study, possible benefits, risks, and discomforts, other 
options, your rights as a participant, and other information about the study are 
discussed below. Any new information discovered, at any time during the research, 
which might affect your decision to participate or remain in the study will be provided 
to you. You are urged to ask any questions you have about this study with the staff 
members who explain it to you. You are urged to take whatever time you need to 
discuss the study with your physician, hospital personnel and your family and friends.  
The decision to participate or not is yours.  If you decide to participate, please sign and 
date where indicated at the end of this form.  The investigator (person in charge of this 
research study) is Sandra M. Swain, MD. 
 
The research is being sponsored by the National Institute of Health.  The National 
Institute of Health is called the sponsor and the MedStar Research Institute, is being 
paid by the National Institute of Health, to conduct this study with Sandra M. Swain, MD 
as the primary investigator. 
 




You are being asked to participate in this study because we would like to learn how you feel 
about African Americans taking part in cancer treatment research studies, also known as 
clinical trials.  
 
The purpose of this study is to provide information to African American cancer patients, 
which may increase their likelihood to participate in a treatment trial. The video designed 
for use in this study may be shared with other cancer researchers, including National Cancer 
Institute (NCI) cooperative groups.  
This research is being done because there are not enough African Americans who take part 
in cancer clinical trials. It is important that enough African Americans participate in cancer 
trials to allow discovery of possible differences of treatment effect by race/ethnicity based 
on biological, social or cultural factors related to race.  
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
People in the study are referred to as participants. 
 
About 125participants will be in this study at the Washington Cancer Institute, 
Washington Hospital Center only. 
 
WHAT IS INVOLVED IN THE STUDY? 
 
If you agree (consent) to participate in this study, a study interviewer will ask you several 
questions about your attitude about taking part in a clinical trial. Next, you will view a video 
that was made just for this study, and then the interviewer will ask you the same questions 
again.  
 
HOW LONG WILL I BE IN THE STUDY? 
 
We think that you will be in the study for about one hour or less. You can stop taking part at 
any time. 
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CONSENT T0  PARTICIPATE IN A 
CLINICAL 
RESEARCH STUDY 








Version May 2nd, 2010 
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There should not be any physical risks as this is not a treatment study; however, talking 
about attitudes toward clinical research may cause some anxiety for certain people. If you 
have questions about the study call the investigator at 202-877-8839.  
 
ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
 
If you agree to take part in this study, there may or may not be direct benefit to you. 
 
We cannot promise that you will experience benefits from participating in this study. 
We do hope that you will benefit from receipt of information in this study. We also hope 
the information learned from this study will benefit others in the future. 
 
WHAT OTHER OPTIONS ARE THERE? 
 
Instead of being in this study, you have the option not to participate. 
 
WHAT ABOUT CONFIDENTIALITY? 
 
You will not be identified in any reports or publications resulting from this study. In addition 
to the researchers and research institution(s) conducting this study, organizations that may 
request to inspect and/or copy your research records for quality assurance, data analysis 
and other research related and operational or administrative purposes, include groups such 
as:  
 
The National Institute of Health, MedStar Health Research Institute, MedStar Health 
Research Institute-Georgetown University Oncology Institutional Review Board (IRB), 




Information about your participation in this study is stored in a research computer that is 
protected from unauthorized disclosure, tampering, or damage. All data will be stored in a 
password protected computer that is kept locked. The only individuals allowed to access 
any data are the investigators associated with this study.  
 





GU IRB Ver 03/31/2010 
CONSENT T0  PARTICIPATE IN A 
CLINICAL 
RESEARCH STUDY 








Version May 2nd, 2010 
  
 131
There will be no cost to take part in this study.  
 
PAYMENT FOR PARTICIPATION 
 
Study participants who complete the study will receive a $25 gift card as thanks for their 
time and participation. They may also receive a pass to cover the cost of parking when they 
come to the Washington Cancer Institute.   
 
You should not expect anyone to pay you for pain, worry, lost income, or non-medical care 
costs that occur from taking part in this research study.  
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
 
Taking part in this study is voluntary. You may choose not to take part in or leave the 
study at any time.  
 
We will tell you about new information that may affect your health, welfare, or 
participation in this study. 
 




Throughout the study, we will tell you about new information we receive about 
treatments that may be appropriate for you, about the experimental treatments under 
investigation in this study, and any information that may affect your interest in 
remaining in the study.  
 
WHOM  DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
 
For questions about the study or a research-related injury, any problems, unexpected 
physical or psychological discomforts, or if you think that something unusual or 
unexpected is happening, call Sandra M. Swain, MD at 202-877-8839 or the Oncology 
fellow on-call at 202-877-6751.  Be sure to inform the physician of your participation in 
this study. 
 
For questions about your rights as a research participant, contact the MedStar Health 
Research Institute-Georgetown University Oncology Institutional Review Board at: 
 
 
Address: Georgetown University Medical Center Telephone:  (202) 687-1506 
  3900 Reservoir Road, N.W. 
  SW104  Med-Dent 




Withdrawal by investigator, physician, or sponsor 
 
The investigators, physicians or sponsors may stop the study or take you out of the 
study at any time should they judge that it is in your best interest to do so, if you 
experience a study-related injury, or if you do not comply with the study plan. They may 
remove you from the study for various other administrative reasons. They can do this 





After you have completed the study questions, the investigators participate or you 
may withdraw from the study at any time without loss of any benefits to which you 
are entitled and without jeopardizing your access to care, treatment and health 
services unrelated to the research. 
 
The purpose and nature of the study, possible benefits, risks, and discomforts, other 
options, your rights as a participant, and other information about the study are 
discussed below. Any new information discovered, at any time during the research, 
which might affect your decision to participate or remain in the study will be provided 
to you. You are urged to ask any questions you have about this study with the staff 
members who explain it to you. You are urged to take whatever time you need to 
discuss the study with your physician, hospital personnel and your family and friends.  
The decision to participate or not is yours.  If you decide to participate, please sign and 
date where indicated at the end of this form.  The investigator (person in charge of this 
research study) is Sandra M. Swain, MD. 
 
The research is being sponsored by the National Institute of Health.  The National 
Institute of Health is called the sponsor and the MedStar Research Institute, is being 
paid by the National Institute of Health, to conduct this study with Sandra M. Swain, MD 
as the primary investigator. 
 
WHY IS THE STUDY BEING DONE?  
 
You are being asked to participate in this study because we would like to learn how you feel 
about African Americans taking part in cancer treatment research studies, also known as 
clinical trials.  
 
The purpose of this study is to provide information to African American cancer patients, 
which may increase their likelihood to participate in a treatment trial. The video designed 
for use in this study may be shared with other cancer researchers, including National Cancer 
Institute (NCI) cooperative groups.  
This research is being done because there are not enough African Americans who take part 
in cancer clinical trials. It is important that enough African Americans participate in cancer 
trials to allow discovery of possible differences of treatment effect by race/ethnicity based 
on biological, social or cultural factors related to race.  
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
People in the study are referred to as participants. 
 
About 125participants will be in this study at the Washington Cancer Institute, 
Washington Hospital Center only. 
 




If you agree (consent) to participate in this study, a study interviewer will ask you several 
questions about your attitude about taking part in a clinical trial. Next, you will view a video 
that was made just for this study, and then the interviewer will ask you the same questions 
again.  
 
HOW LONG WILL I BE IN THE STUDY? 
 
We think that you will be in the study for about one hour or less. You can stop taking part at 
any time. 
 
WHAT ARE THE RISKS OF THE STUDY? 
 
There should not be any physical risks as this is not a treatment study; however, talking 
about attitudes toward clinical research may cause some anxiety for certain people. If you 
have questions about the study call the investigator at 202-877-8839.  
 
ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
 
If you agree to take part in this study, there may or may not be direct benefit to you. 
 
We cannot promise that you will experience benefits from participating in this study. 
We do hope that you will benefit from receipt of information in this study. We also hope 
the information learned from this study will benefit others in the future. 
 
WHAT OTHER OPTIONS ARE THERE? 
 
Instead of being in this study, you have the option not to participate. 
 
WHAT ABOUT CONFIDENTIALITY? 
 
You will not be identified in any reports or publications resulting from this study. In addition 
to the researchers and research institution(s) conducting this study, organizations that may 
request to inspect and/or copy your research records for quality assurance, data analysis 
and other research related and operational or administrative purposes, include groups such 
as:  
 
The National Institute of Health, MedStar Health Research Institute, MedStar Health 
Research Institute-Georgetown University Oncology Institutional Review Board (IRB), 




Information about your participation in this study is stored in a research computer that is 
protected from unauthorized disclosure, tampering, or damage. All data will be stored in a 
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password protected computer that is kept locked. The only individuals allowed to access 
any data are the investigators associated with this study.  
 
WHAT ARE THE COSTS? 
 
There will be no cost to take part in this study.  
 
PAYMENT FOR PARTICIPATION 
 
Study participants who complete the study will receive a $25 gift card as thanks for their 
time and participation. They may also receive a pass to cover the cost of parking when they 
come to the Washington Cancer Institute.   
 
You should not expect anyone to pay you for pain, worry, lost income, or non-medical care 
costs that occur from taking part in this research study.  
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
 
Taking part in this study is voluntary. You may choose not to take part in or leave the 
study at any time.  
 
We will tell you about new information that may affect your health, welfare, or 
participation in this study. 
 




Throughout the study, we will tell you about new information we receive about 
treatments that may be appropriate for you, about the experimental treatments under 
investigation in this study, and any information that may affect your interest in 
remaining in the study.  
 
WHOM  DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
 
For questions about the study or a research-related injury, any problems, unexpected 
physical or psychological discomforts, or if you think that something unusual or 
unexpected is happening, call Sandra M. Swain, MD at 202-877-8839 or the Oncology 
fellow on-call at 202-877-6751.  Be sure to inform the physician of your participation in 
this study. 
 
For questions about your rights as a research participant, contact the MedStar Health 





Address: Georgetown University Medical Center Telephone:  (202) 687-1506 
  3900 Reservoir Road, N.W. 
  SW104  Med-Dent 
  Washington, D.C.  20057 
 
Withdrawal by investigator, physician, or sponsor 
 
The investigators, physicians or sponsors may stop the study or take you out of the 
study at any time should they judge that it is in your best interest to do so, if you 
experience a study-related injury, or if you do not comply with the study plan. They may 
remove you from the study for various other administrative reasons. They can do this 
without your consent. 
 
After you have completed the study questions, the investigators want to give you an 
opportunity to provide them with more information about your thoughts and 
attitudes towards clinical trials. This will give you a chance to talk in more detail, in a 
follow-up telephone interview other thoughts that came to mind from the questions 
you were asked for this study. It will also give the investigators a chance to find out if 
there is anything additional you want them to know about how African Americans feel 
about participating in clinical trials.   
No matter what you decide to do about this follow-up interview, it will not affect your 
care or your participation in any other study including this main study. If you have any 
questions, please talk to the interviewer or investigator, or call the Institutional 
Review Board at 202-687-1506. 
 
I willingly consent to allow the investigators to contact me for a follow-up study to 
discuss in more detail the way African Americans think and feel about clinical trials.  





I have fully explained this study to the subject.  As a representative of this study, I have 
explained the purpose, the procedures, the benefits and risks that are involved in this 
research study. Any questions that have been raised have been answered to the 
individual’s satisfaction. 
 
_________________________________  _________________  ______ 
Signature of person obtaining the consent  Print Name of Person  Date 
 
I, the undersigned, have been informed about this study’s purpose, procedures, possible 
benefits and risks, and I have received a copy of this consent. I have been given the 





questions at any time. I voluntarily agree to participate in this study. I am free to 
withdraw from the study at any time without need to justify my decision. This 
withdrawal will not in any way affect my future treatment or medical management and I 
will not lose any benefits to which I am otherwise entitled. I agree to cooperate with 
Sandra M. Swain, MD and the research staff and to inform them immediately if I 
experience any unexpected or unusual symptoms. 
 
_________________________________  _________________ 
 ________ 












Appendix D Qualitative Study Consent 
Informed Consent for Clinical Research 
MedStar Research Institute/Georgetown University Medical Center 
INSTITUTION:    Washington Cancer Institute at Washington Hospital Center 
 
INTRODUCTION 
You are invited to consider participating in this follow-up interview for the study called 
“Today’s Truth: Research Brings Hope”.   Please take whatever time you need to discuss 
the study with your family and friends, or anyone else you wish to.  It is important that 
you read and understand several things that apply to all who take part in our studies: 
 
(a) Taking part in the study is entirely voluntary; the decision to participate, or not 
to participate, is yours. 
 
(b) Personal benefit to you may or may not result from taking part in the study, but 
we hope you will benefit from the information it will provide. Knowledge may be 
gained from your participation that will benefit others. 
 
(c) You may decline to participate or you may withdraw from the study at any time 
without loss of any benefits to which you are entitled and without jeopardizing 
your access to care, treatment and health services unrelated to the research. 
 
The purpose and nature of the study, possible benefits, risks, and discomforts, other 
options, your rights as a participant, and other information about the study are 
discussed below. Any new information discovered, at any time during the research, 
which might affect your decision to participate or remain in the study will be provided 
to you. You are urged to ask any questions you have about this study with the staff 
members who explain it to you. You are urged to take whatever time you need to 
discuss the study with your physician, hospital personnel and your family and friends.  
The decision to participate or not is yours.  If you decide to participate, please sign and 
date where indicated at the end of this form.  The investigator (person in charge of this 
research study) is Sandra M. Swain, MD. 
 
The research is being sponsored by the National Institute of Health.  The National 
Institute of Health is called the sponsor and the MedStar Research Institute, is being 
paid by the National Institute of Health, to conduct this study with Sandra M. Swain, MD 








WHY IS THE STUDY BEING DONE?  
You are being asked to participate in this follow up study because we would like to learn 
how you feel about African Americans taking part in cancer treatment research studies, also 
known as clinical trials, now that you have viewed our video about clinical trials.  
 
The purpose of this study is to see how your attitudes toward clinical trials have been 
affected after watching the video.  We also want to know what you think about the role of 
race, racial identity, and religion in making decisions about cancer treatment. The questions 
designed for use in this study may be shared with other cancer researchers, including 
National Cancer Institute (NCI) cooperative groups. None of the information shared along 
with this will identify you as an individual. This research is being done because there are not 
enough African Americans who take part in cancer clinical trials. It is important to know 
other factors that influence the decision to participate or not.  
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
People in the study are referred to as participants. 
 
About 125participants will be in this study at the Washington Cancer Institute, 
Washington Hospital Center only. 
 
WHAT IS INVOLVED IN THE STUDY? 
If you agree (consent) to participate in this study, a study interviewer will call you at the 
time you request and ask you several questions about your attitude now about taking part 
in a clinical trial. Next, you will be asked some questions about how you think race, racial 
identity, and religion may or may not influence your treatment decisions and those of other 
African Americans.  
 
HOW LONG WILL I BE IN THE STUDY? 
We think that this follow-up study will take about one hour or less. You can talk to the 
interviewer about your answers for as much time or as little time as you would like. You can 
stop taking part at any time. 
 
WHAT ARE THE RISKS OF THE STUDY? 
 
There should not be any physical risks as this is not a treatment study; however, talking 
about attitudes toward clinical research may cause some anxiety for certain people. If you 
have questions about the study call the investigator at 202-877-8839.  
 
ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
 
If you agree to take part in this follow-up interview, there may or may not be direct 
benefit to you. 
 
We cannot promise that you will experience benefits from participating in this 
interview. We do hope that you will benefit from receipt of information and sharing 
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your thoughts. We also hope the information learned from this study will benefit others 
in the future. 
 
WHAT OTHER OPTIONS ARE THERE? 
 
Instead of being in this study and completing this interview, you have the option not to 
participate. 
 
WHAT ABOUT CONFIDENTIALITY? 
 
You will not be identified in any reports or publications resulting from this study. In addition 
to the researchers and research institution(s) conducting this study, organizations that may 
request to inspect and/or copy your research records for quality assurance, data analysis 
and other research related and operational or administrative purposes, include groups such 
as:  
 
The National Institute of Health, MedStar Health Research Institute, MedStar Health 
Research Institute-Georgetown University Oncology Institutional Review Board (IRB), 
federal research oversight agencies. 
 
DATA SECURITY 
Information about your participation in this study is stored in a research computer that is 
protected from unauthorized disclosure, tampering, or damage. All data will be stored in a 
password protected computer that is kept locked. The only individuals allowed to access 
any data are the investigators associated with this study.  
 
 
WHAT ARE THE COSTS? 
There will be no cost to take part in this study.  
 
PAYMENT FOR PARTICIPATION 
There will be no payment for participation in this study.  
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Taking part in this study and completing the interview is voluntary. You may choose not 
to take part in or stop the interview at any time.  
We will tell you about new information that may affect your health, welfare, or 
participation in this study. 
By signing this form you do not lose any of your legal rights. 
 
NEW FINDINGS 
Throughout the study, we will tell you about new information we receive about 
treatments that may be appropriate for you, about the experimental treatments under 
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investigation in this study, and any information that may affect your interest in 
remaining in the study.  
 
WHOM  DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study or a research-related injury, any problems, unexpected 
physical or psychological discomforts, or if you think that something unusual or 
unexpected is happening, call Sandra M. Swain, MD at 202-877-8839 or the Oncology 
fellow on-call at 202-877-6751.  Be sure to inform the physician of your participation in 
this study. 
 
For questions about your rights as a research participant, contact the MedStar Health 
Research Institute-Georgetown University Oncology Institutional Review Board at: 
Address: Georgetown University Medical Center Telephone:  (202) 687-1506 
  3900 Reservoir Road, N.W. 
  SW104  Med-Dent 
  Washington, D.C.  20057 
 
Withdrawal by investigator, physician, or sponsor 
The investigators, physicians or sponsors may stop the study or take you out of the 
study at any time should they judge that it is in your best interest to do so, if you 
experience a study-related injury, or if you do not comply with the study plan. They may 
remove you from the study for various other administrative reasons. They can do this 




I have fully explained this study to the subject.  As a representative of this study, I have 
explained the purpose, the procedures, the benefits and risks that are involved in this 
research study. Any questions that have been raised have been answered to the 
individual’s satisfaction. 
 
_________________________________  _________________  ______ 
Signature of person obtaining the consent  Print Name of Person  Date 
 
I, the undersigned, have been informed about this study’s purpose, procedures, possible 
benefits and risks, and I have received a copy of this consent. I have been given the 
opportunity to ask questions before I sign, and I have been told that I can ask other 
questions at any time. I voluntarily agree to participate in this study. I am free to 
withdraw from the study at any time without need to justify my decision. This 
withdrawal will not in any way affect my future treatment or medical management and I 
will not lose any benefits to which I am otherwise entitled. I agree to cooperate with 
Sandra M. Swain, MD and the research staff and to inform them immediately if I 




_________________________________  _________________ 
 ________ 















Last Name: ___________________ 
 
First Name: __________________ 
 
Middle Initial (if pt doesn't have a MI, then a dash): ____ 
 
DOB:  _ _/ _ _/ _ _ _ _ 
 
Self Identified racial/ethnic background? 
 
1 =  African American     
2 =  Black       
3 =  African Ancestry     
4 =  Caribbean or West Indian Ancestry   
5 =  Other: _____________________                 
 997 = REF       
           998 = DK 
 
Were you born in the United States? 
1 = YES  
  
If U.S. Region of country at birth:  
• West Coast 





2 = NO        
 




If Non-US, length of time lived in US? ______ 
 
Were your parents born in the United States?  
1 = YES  
  
If U.S. Region of country at birth:  
• West Coast 







2 = NO        
 








• Never Married 
• Married 




Number of Children 
• None 
• 1 or more  
 
Education 
• < High School 
• GED 
• High school graduate 
• Some college or technical school 
• College graduate 
 
Religious Faith 
• Baptist/Freewill Baptist 
• Catholic  
• Episcopalian 






• Seventh Day Adventist 
• Other? 
 
About how many times a month do you usually attend religious services? 
 













• $8,000 - $11,999 
• $12,000 - $15,999 
• $16,000 - $19,999 
• $20,000 - $29,999 
• $30,000 - $39,999 




Family history of any cancer? Y/N
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Appendix F Survey of attitudes about clinical trial participation 
 
Barriers and Subscales 
1. Fear and distrust of the medical establishment: Questions 1-5 
2. Concern about the ethical conduct of investigators:  Questions6-10 
3. Fear of losing one’s rights by signing a research informed consent document Questions 
11-15 
4. Worry that investigators will treat poor or minority patients unfairly Questions 16- 20 
5. Loss of privacy Questions  21-25 
6. Lack of knowledge and awareness of clinical trials Questions 26-30 
7. Racial Identity Seller’s Centrality Scale Questions 31-38 




1. Fear and distrust of the medical establishment (doctors, scientists and the government).  
 
On a scale from ‘very much’ to ‘not at all’, how much would each of the following affect your 
decision whether or not to participate in a clinical trial? 
 
1. Trust in the doctor who offers you the trial 
Very much, somewhat, not sure, not much, not at all 
2. The reputation of the treatment center where the clinical trial is done 
Very much, somewhat, not sure, not much, not at all 
 
How much do you agree or disagree with these statements 
3. I can not trust health care workers  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
4. I am suspicious of clinical trials 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
5. I am suspicious of information I receive from researchers 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
2. Concern about the ethical conduct of investigators–  
How much do you agree or disagree with these statements 
6. Most clinical research is ethical  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
7. Researchers do not care about me or my well being 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
8.  My doctor would not ask me to participate in a clinical trial if he or she thought it would 
hurt me 




9. I am confident the group of people who approve clinical trials make sure all participants 
are treated fairly 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
10. How likely do you think it is that you might be used as a guinea pig if you were in a 
clinical trial?  
Very likely, Somewhat likely, Not Sure, Somewhat unlikely, Not at all likely, not at all likely 
 
3. Fear of losing one’s rights by signing a research informed consent document 
How much do you agree or disagree with these statements 
 
If I were to sign an informed consent form to participate in a clinical trial: 
11. I could still ask my doctors any questions that I want to 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
12. If doctors took my blood  they could do tests on it they have not told me about  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
13. I would only be agreeing to do what is explained to me in the consent form.  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
14. I could still change my mind about participating at any time  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
15. The researchers would only do what is stated in the consent form 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
4. Worry that investigators will treat poor or minority patients unfairly 
How much do you agree or disagree with the following statements 
 
16. Black people in clinical trials receive the same care from doctors and health care 
workers as people of other races or ethnicities on clinical trials 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
17. If I were to enroll in a clinical trial my doctors would treat me with dignity and respect 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
18. Compared with others, poor people are used more in research without their permission 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
19. How often, if ever, do you think doctors prescribe medication as a way of experimenting 
on Black patients without their knowledge or permission? 
very often, fairly often, do not know, rarely, never 
 
20. Black people are used more in research without their knowledge or permission than 
others races and ethnicities 




5. Loss of privacy 
How much do you agree or disagree with the following statements 
 
I believe that if I enroll in a clinical trial: 
21. People can access my medical records without my approval.  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
22. My medical records are kept private.  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
23. My privacy is a major concern for the researchers involved  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
24. Personal information like my name, address and phone number will remain confidential  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
25. Any center doing clinical trials has set rules to make sure my records are kept safe 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
 
6. Lack of knowledge and awareness of clinical trials(e.g., what would be done, what would be 
expected from them and what are the expected risks and benefits of the research presented at 
participant’s comprehension level).  
How much do you agree or disagree with the following statements 
 
26. There are always serious side effects related to clinical trials  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
27. If my doctor wanted me to participate in a clinical trial, he or she would fully explain to 
me everything that is involved 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
28. I can talk to my doctors to find out about participating in clinical trials 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
29. There may be benefits for me if I participate in a clinical trial   
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
30. There may be benefits for other people like me if I participate in a clinical trial 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
31. At this moment, is it likely that you would sign up to participate in a therapeutic clinical 
trial 
  Very likely, Somewhat  likely, Not sure, Somewhat unlikely, Very unlikely 
 
 If you were offered a clinical trial right now would you participate? 
    YES   NO 




Racial Identity (pre-test only)  
How much do you agree or disagree with the following statements 
32.  Overall, being Black has a lot to do with how I feel about myself.  
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
33.  In general, being Black is an important part of my self-image. 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
34. My destiny is tied to the destiny of other Black people. 
Strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, very 
 much disagree 
35. Being Black is important to my sense of what kind of person I am.   
Strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, very 
 much disagree 
36. I have a strong sense of belonging to Black people. 
Strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, very 
much disagree 
37.   I have a strong attachment to other Black people. 
Strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, very 
much disagree 
38.  Being Black is an important reflection of who I am. 
Strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, very 
 much disagree 
39.  Being Black is a major factor in my social relationships.   
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very 
much disagree 
Religious Beliefs: ‘God As Healer’ (pre-test only) 
How much do you agree or disagree with the following statements-  
 
40. God works through the doctors to heal cancer 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
41. God and only God can heal cancer 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
42. My experience with cancer has made me realize that God is the ultimate healer 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
43. I believe that if one is healed of cancer, it is God’s will 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
44. I believe that God gives the doctors/nurses the ability to heal cancer 




45. I believe that if you ask God for healing, He will heal you 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
46. I believe that having a close relationship with God will lead to cancer recovery 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 
47. Healing can only occur from God, not from medicine or doctors 
Strongly agree, somewhat agree, neither agree or disagree, somewhat disagree, very much 
disagree 





Appendix G Qualitative Study Interview Guide 
 
Date _________ 




Introduce yourself  
Discuss the purpose of the study  
Reaffirm informed consent  
Overview structure of the interview (audio recording, taking notes, and use of 
pseudonym)  
Ask if they have any questions  
Ensure audio recording equipment is working and remind them they are being taped 
 
ICE BREAKER 
Thank you again for participating in the informational study when you came to WCI a 
few weeks ago. Have you had a chance to think any further about some of the things you 
saw in the video related to African Americans and clinical trials? 
I wanted to just start out by asking you what types of thoughts or words or images now 
come to mind for you when you hear the term clinical trial? 
Would you describe your view as generally positive or generally negative when it comes 
toward clinical trials?  
 
I am interested in hearing more detail about what you think about some particular topics 
we want to learn more about in this study. I have four main groups of questions I would 
like you to share your thoughts on.  
I. QUESTIONS ABOUT CLINICAL TRIALS AND RELIGIOUS BELIEFS 
1. Do you believe in God or consider yourself a spiritual person? 
2. Do you think that religion and a belief in God is more or less important for Black 
people than others? 
a. Why do you think that? 
3. How do you think religion or spirituality relate to health? 
a. Why do you think that? 
4. What role does religion play when it comes to clinical trials for treating ca cer? 
5. Do you think religion affects whether people who have cancer get better or not? 
a. Can you give some examples? 
6. For people diagnosed with cancer, do you believe there is hope of finding a better 
treatment for them through clinical trials if they also believe in God? 
 
 
II. QUESTIONS ABOUT CLINICAL TRIALS AND RACE/RACIAL IDENTITY 
1. Do you think this is a different experience for Black people vs. other? 
a. Why do you think you feel like that? 
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b. What sort of things would need to happen to change this? 
2. What advice would you give other Black people who may have to make the 
decision to participate on a clinical trial? 
a. Why would you say this? 
3. Where would you say most of your ideas about clinical trials come from? 
4. Where do you think most Black people get their ideas about clinical trials? 
a. Do you think these are accurate? 
5. Do you think more black people would participate in clinical trials if they 
understood how important it is for others like them? 
a. How would that influence your decision to participate? 
b. What do you think is the most important thing for Black people to 
understand about this? 
 
III. QUESTIONS ABOUT RACE AND CANCER TREATMENT 
1. Think of any instances you know of where African Americans have been treated 
unfairly 
a. Can you describe what happened? 
b. Has this experience influenced how you view clinical trials? 
2. Can you think of any instances where you have experienced racism? 
a. Can you describe what happened? 
b. Has this experience influenced how you view clinical trials? 
3. How do you think racism influences African American cancer patients? 
a. What does your family think? 
b. How does your family/friends affect how you feel? 
4. Do you know any friends/family who have been on a clinical trial? 
a. Do you know what their experience was like? 
b. How does this affect how you feel about clinical trials? 
5. Who do you think clinical trials are supposed to benefit? 
a. Why do you think this is? 
b. Do you believe there is a benefit for African Americans? Why/Why not? 
c. What would be most important for you, personally in deciding whether to 
participate in a clinical trial? 
 
IV. CONCLUDING QUESTIONS AND STATEMENTS? 
1. Is there anything else you would like to add or share about this topic that you 
think is important for me to know? 




Thank them for their participation  
Ask if they would like to see a copy of the results once the study is completed 




Appendix H: Contact notification recruitment letter  
 
 





Dear Mr./Ms. «Last_Name_»: 
 
I am sending this letter to let you know of a patient education study that the 
Washington Cancer Institute at Washington Hospital Center is doing as part of our 
commitment to serving the needs of our patients.  The purpose of this patient education 
study is to learn more about the attitudes African Americans have toward clinical trials.  
We want to find better ways to provide information that patients need.  I thought you 
might want to know more about this study and I want to give you a chance to take part 
if you like.   
 
You will receive a telephone call from a study representative who will explain the study 
to you.  They will call you so you can ask any questions you have and invite you 
personally to be part of the study.   
 
The study will take about one hour of your time.  Patients who complete the study will 
receive a $25 gift card as we truly appreciate your time.  We will also be happy to cover 
your parking cost for this visit.  
 
Being a part of this study is your choice.  This is a patient education study, and is not 
related to your treatment, nor will it affect the care you receive from your doctor.   
 
If for any reason you do not wish to be part of the study, please call 202.877.8448 and 
ask that we do not contact you.  
 







Sandra M. Swain, MD 




APPENDIX I:  Exploratory Factor Analysis Results 
Factor Loadings for Attitudes Scales Including Forced 4 Factor Solution. 
 
1. Exploratory FA for 20 items comprising Attitudes Scale 
 
Total Variance Explained 
Comp
onent 
Initial Eigen values Rotation Sums of Squared Loadings 
Total 
% of 
Variance Cumulative % Total 
% of 
Variance Cumulative % 
1 4.832 24.159 24.159 2.900 14.501 14.501 
2 1.782 8.911 33.069 2.380 11.899 26.401 
3 1.681 8.404 41.473 2.136 10.679 37.079 
4 1.333 6.664 48.137 1.721 8.607 45.686 
5 1.306 6.528 54.664 1.628 8.138 53.825 
6 1.111 5.555 60.219 1.279 6.394 60.219 
7 .988 4.939 65.157    
8 .961 4.803 69.960    
9 .867 4.336 74.296    
10 .719 3.595 77.891    
11 .699 3.494 81.386    
12 .636 3.178 84.563    
13 .538 2.688 87.251    
14 .506 2.532 89.783    
15 .477 2.386 92.169    
16 .389 1.944 94.113    
17 .350 1.752 95.866    
18 .307 1.536 97.402    
19 .274 1.371 98.773    
20 .245 1.227 100.000    




2. Factor loadings for 6 factor solution 
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1 2 3 4 5 6 
4. I am suspicious of clinical trials .811 .120 .104  .230 -.123 
5. I am suspicious of information I receive from researchers .798 .169   .112  
3. I can not trust health care workers .605 .131    .291 
7. Researchers do not care about me or my well being .535 .286 .162  .254  
19. How often, if ever, do you think doctors prescribe medication as a way of 
experimenting on Black patients without their knowledge or permission? 
.153 .690 .145 .148 -.213 .110 
20. Black people are used more in research without their knowledge or 
permission than others races and ethnicities 
.464 .641 .107   -.133 
18. Compared with others, poor people are used more in research without their 
permission 
.479 .594    -.124 
9.  I am confident the group of people who approve clinical trials make sure all 
participants are treated fairly 
 .577 .172  .448  
10. How likely do you think it is that you might be used as a guinea pig if you 
were in a clinical trial? 
 .562  -.137 .299 .103 
12. If doctors took my blood  they could do tests on it they have not told me 
about 
.336 .381  -.242  -.351 
11. I could still ask my doctors any questions that I want to .128  .803   .158 
13. I would only be agreeing to do what is explained to me in the consent form   .727 -.119 .143 -.349 
14. I could still change my mind about participating at any time .416 -.153 .599  -.288  
8. My doctor would not ask me to participate in a clinical trial if he or she thought 
it would hurt me 
 .277 .425  .131 .117 
2. The reputation of the treatment center where the trial is done    .891   
1. Trust in the doctor who offers you the trial    .882   
17. If I were to enroll in a clinical trial my doctors would treat me with dignity and 
respect 
.164    .775  
16. Black people in clinical trials receive the same care from doctors and health 
care workers as people of other races or ethnicities on clinical trials 
.205 .207 .233  .484 .127 
6. Most clinical research is ethical .197  .114 -.106 .185 .749 
15. The researchers would only do what is stated in the consent form 




Forced 4 Factor Solution: 
 
 
Total Variance Explained 
Compo
nent 
Initial Eigen values Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % Total % of Variance Cumulative % 
1 4.832 24.159 24.159 3.236 16.180 16.180 
2 1.782 8.911 33.069 2.358 11.792 27.973 
3 1.681 8.404 41.473 2.281 11.407 39.380 
4 1.333 6.664 48.137 1.751 8.757 48.137 
5 1.306 6.528 54.664    
6 1.111 5.555 60.219    
7 .988 4.939 65.157    
8 .961 4.803 69.960    
9 .867 4.336 74.296    
10 .719 3.595 77.891    
11 .699 3.494 81.386    
12 .636 3.178 84.563    
13 .538 2.688 87.251    
14 .506 2.532 89.783    
15 .477 2.386 92.169    
16 .389 1.944 94.113    
17 .350 1.752 95.866    
18 .307 1.536 97.402    
19 .274 1.371 98.773    











Factor loadings for forced 4 factor solution 
 




1 2 3 4 
20. Black people are used more in research without their knowledge or permission than 
others races and ethnicities 
.708 .241 .150  
18. Compared with others, poor people are used more in research without their permission .687 .269   
9.  I am confident the group of people who approve clinical trials make sure all participants 
are treated fairly 
.629    
10. How likely do you think it is that you might be used as a guinea pig if you were in a 
clinical trial? 
.550 .171 -.145 -.174 
12. If doctors took my blood  they could do tests on it they have not told me about .524  .202 -.158 
19. How often, if ever, do you think doctors prescribe medication as a way of 
experimenting on Black patients without their knowledge or permission? 
.522 .108  .248 
5. I am suspicious of information I receive from researchers .376 .650 .117  
6. Most clinical research is ethical  .644  -.131 
3. I can not trust health care workers .173 .639 .107 .121 
4. I am suspicious of clinical trials .428 .589 .240  
7. Researchers do not care about me or my well being .435 .477 .190  
16. Black people in clinical trials receive the same care from doctors and health care 
workers as people of other races or ethnicities on clinical trials 
.312 .323 .181  
17. If I were to enroll in a clinical trial my doctors would treat me with dignity and respect .163 .311  -.225 
13. I would only be agreeing to do what is explained to me in the consent form .214 -.133 .770 -.134 
11. I could still ask my doctors any questions that I want to  .205 .745  
14. I could still change my mind about participating at any time 
-.133 .305 .657 .207 
15. The researchers would only do what is stated in the consent form 
.490  .563  
8. My doctor would not ask me to participate in a clinical trial if he or she thought it would 
hurt me 
.196  .335  
1. Trust in the doctor who offers you the trial    .865 




APPENDIX J:  ANOVA Results 
 
This was done to examine if any of the covariates related to the attitudinal barriers 
or to the proposed moderators. A one-way analysis of variance was used to test for 
differences in mean scores on each of the four attitudinal barriers scaleby age category, 
gender, family history of cancer, US/foreign born, SES, marital status, experi nce with 
racism, and whether or not they had children. A one-way analysis of variance was also 
used to test for differences in mean scores on the proposed moderator variables by each 
of these covariates.  These findings are summarized below 
 
Association of Gender and Six Study Scales 
Comparing mean scores between males and females in the sample on each of the 
four constructs representing attitudinal barriers revealed no significant difference. 
Similarly there was no significant difference found on scores of racial centrality. The 
only significant gender effect was seen in mean scores on the God as healer scale 
(F(1,109) = 3.74, p < 0.05), where on the average females had a significantly higher 
mean score than males in the sample. 
 
Association of Age and Six Study Scales 
There was no significant difference in mean scores on any of the attitudinal scales 
or the proposed moderators by age groups. 
Association of Marriage and Six Study Scales Marital Status 
There was no significant difference in mean scores on any of the independent 
variables or proposed moderators by marital status. 
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Association of Income and Six Study Scales 
Income was significantly related to the total distrust scale (F (8,102) = 3.79, p = 
.001). Post hoc analyses using Tukey’s test revealed significant mean differences in 
distrust scores for participants such that those making  <$8,000 had lower distrust scores 
than those with incomes of $8,000- $11,9999. Similarly those in $8, 0000 - $11,999 had 
significantly higher distrust scores compared with those in the ($20,000- $29,999) 
income category and higher still than those in the ($50,000- $74,999) category. Finally 
those in the >$75,000 had the lowest mean distrust scores and these were significantly 
different from participants in the ($8,000- $11,999) and ($30,000-$39,999) respectively.   
An income effect was also found for participant’s worry about being treated unfairly,  
F(8,102) = 2.08, p = .04; and for concern about losing one’s rights F (8,102) = 2.85, p = 
.01  Post hoc analyses with Tukey’s test showed significant mean difference for groups 
with incomes in the ($8,000- $11,999) who had higher worry scores than those in the 
($12000-$15,999) and compared with those with incomes > $75,000.  
This evidence suggests that income or some proxy measure of socioeconomic 
status is likely a key covariate in a model predicting the relative importance of factors 
which predict intention to enroll in a clinical trial.  
 
Association of Place of Birth and Six Study Scales 
A comparison of mean scores revealed no significant difference for most of the 
study variables based on differences in country of birth. There was, however, a 
significant difference in mean scores on the racial centrality scale betw en participants 
who were US born and those who were born outside of the country (F (1, 109) = 5.06, p 
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= 0.027). Specifically, US born study participants had a statistically significa t higher 
mean centrality score compared with their foreign born counterparts.  
 
Association of SES and Six Study Scales 
A SES variable was created using the income data within the sample to create 
groupings of low, middle and high SES. The resulting analysis of variance testing the 
differences in mean  
scores for each of the independent and moderator variables revealed significant 
difference for two attitudinal scales. There was a significant difference in mean scores on 
the fear of losing one’s rights after signing an informed consent (F(2,108) = 3.48 , p = 
.03).  Post hoc analyses using Tukey’s test revealed a statistically significant mean 
difference between those classified as mid-SES compared with those of high-SES, such 
that the latter group had lower mean scores than the former (higher SES groups had le s 
concern of loss of their rights). There was also a significant difference by SES on the 
trust score (F (2,108) = 3.68, p = .03) and post hoc analyses showing significant mean 
difference between high and mid SES. Again the relationship was  such that there was a 
lower mean distrust score for the higher of the two income groups.  
 
Association of Education and Six Study Scales  
There was a significant education effect between groups on mean scores for total
distrust scores (F (3,107) = 2.90, p = .04).   Post hoc analysis using Tukey’s criterion for 
significance indicated there was a significant difference between partici nts with less 




Association of Number of Children and Six Study Scales 
There was no significant difference in mean scores on any of the independent 
variables or proposed moderators for participants who had no children compared with 
those having one or more child. 
 
Association of Experiences of Racism Effect and Six Study Scales 
There was no significant difference in mean scores on any of the independent 
variables or proposed moderators by experience of racism. Post hoc analyses revealed a 
significant mean difference between participants who reported experiencing ‘very much’ 
racism in their lifetime compared with those reporting ‘not much’. There was also a 
significant difference for those reporting ‘very much’ compared with those responding 
‘don’t know’ 
 
Association of Family History and Six Study Scales 
There was no significant difference in mean scores on any of the independent 
variables or proposed moderators between participants with a family history of cancer 









One-way ANOVA Results for Comparison of Means, by Demographic Characteristics 
   ANOVA Statistics 
Demographic variable and predictor 
variable df MSE F  p-value 
Gender Distrust 1 10.79 0.34 0.560 
  Ethics 1 12.97 1.33 0.25 
  Worry 1 16.03 0.5 0.483 
  Rights 1 9.9 0.29 0.865 
  Racial Centrality 1 61.07 0.17 0.690 
  Belief in God as Healer 1 51.54 3.73 0.056 
  Intention to Enroll (Likert ) 1 1.874 1.52 0.221 
Age Distrust 4 11.07 0.15 0.961 
  Ethics 4 13.26 0.48 0.747 
  Worry 4 15.87 1.16 0.332 
  Rights 4 10.14 0.11 0.977 
  Racial Centrality 4 59.96 1.3 0.275 
  Belief in God as Healer 4 54.42 0.2 0.94 
  Intention to Enroll (Likert ) 4 1.883 0.995 0.413 
Marital Status Distrust 4 10.48 1.66 0.165 
  Ethics 4 13.38 0.23 0.920 
  Worry 4 15.55 1.73 0.148 
  Rights 4 9.45 2.06 0.091 
  Racial Centrality 4 62.33 0.24 0.915 
  Belief in God as Healer 4 52.82 1 0.410 
  Intention to Enroll (Likert ) 4 1.808 2.141 0.081 
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Demographic variable and predictor 
variable df MSE F  p-value 
Income Distrust 8 8.92 3.79* 0.001 
  Ethics 8 12.54 1.52 0.169 
  Worry  8 14.8 2.08* 0.045 
  Rights 8 8.65 2.85* 0.007 
  Racial Centrality 8 62.16 0.66 0.727 
  Belief in God as Healer 8 51.36 1.39 0.209 
  Intention to Enroll (Likert ) 8 1.965 0.42 0.905 
US Born vs 
Immigrant Distrust 1 10.66 1.67 0.199 
  Ethics 1 13.07 0.51 0.477 
  Worry 1 16.1 0.04 0.844 
  Rights 1 9.9 0.02 0.888 
  Racial Centrality 1 58.45 5.06* 0.027 
  Belief in God as Healer 1 53.23 0.16 0.694 
  Intention to Enroll (Likert ) 1 1.893 0.385 0.536 
      
SES Distrust 2 10.23 3.675* 0.029 
  Ethics 2 13.13 0.48 0.618 
  Worry 2 15.68 1.97 0.144 
  Rights 2 9.39 3.480* 0.034 
  Racial Centrality 2 61.02 0.63 0.535 
  Belief in God as Healer 2 53.27 0.55 0.582 
  Intention to Enroll (Likert ) 2 1.908 0.27 0.766 
Education 
Level Distrust 3 10.2 2.9* 0.038 
  Ethics 3 12.54 2.38 0.074 
  Worry 3 15.8 1.37 0.257 
  Rights 3 9.83 0.93 0.429 
  Racial Centrality 3 61.68 0.36 0.781 
  Belief in God as Healer 3 51.18 2.18 0.095 
  Intention to Enroll (Likert ) 3 1.921 0.27 0.847 
Number of 
Children Distrust 1 10.82 0.006 0.939 
  Ethics 1 13.12 0.07 0.798 
  Worry 1 16.08 0.18 0.677 
  Rights 1 9.9 0.001 0.971 
  Racial Centrality 1 59.37 3.3 0.072 
  Belief in God as Healer 1 53.28 0.07 0.793 
  Intention to Enroll (Likert ) 1 1.867 1.97 0.164 
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Demographic variable and predictor 
variable df MSE F  p-value 
Experience of 
Racism Distrust 4 10.92 0.5 0.733 
  Ethics 4 12.77 1.51 0.205 
  Worry 4 15.91 1.08 0.368 
  Rights 4 9.64 1.49 0.210 
  Racial Centrality 4 57.96 2.68* 0.048 
  Belief in God as Healer 4 53.72 0.54 0.505 
  Intention to Enroll (Likert ) 4 1.832 1.75 0.143 
Family 
History of 
Cancer Distrust 1 10.81 0.14 0.711 
  Ethics 1 13.12 0.04 0.852 
  Worry 1 16.01 0.66 0.420 
  Rights 1 0.01 0.001 0.971 
  Racial Centrality 1 60.99 0.31 0.580 
  Belief in God as Healer 1 53.17 0.59 0.591 
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